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Abstract    
Background: The Australian healthcare system is complex. Assessing the quality of the 
care provided in the management of acute coronary syndromes (ACS) is problematic 
because of disparate systems that constrain an integrated reporting approach. Registry 
data reported within a comparative effectiveness research (CER) framework establishes 
the case for clinical process indicators to measure and report hospital performance.   
Objectives: To aggregate data from The Global Registry of Acute Coronary Events 
(GRACE) and the Cooperative National Registry of Acute Coronary Care Guideline 
Adherence and Clinical Events (CONCORDANCE) to describe temporal trends in the 
management of ACS and associations with in-hospital events, hospital readmission and 
six month mortality; to develop a composite score of hospital performance quality; to 
determine associations between adherence to the quality composite score and in-hospital 
events, hospital readmission and six month mortality and develop a benchmarked 
stakeholder hospital performance report.  
Methods: A single case study embedding three units of analysis was used to explore 
and explain how data reported in a CER framework measures hospital performance in 
the management of ACS.  
Analysis: Descriptive analyses of prospectively collected data on the management and 
outcomes of over 7000 patients admitted to 46 hospitals from 1999 to 2016. 
Findings: The first Unit of Analysis reports temporal trends in the management of ACS 
across 11 hospitals in the GRACE registry from 2000 to 2007 which informed the 
design of the CONCORDANCE registry; The second Unit of Analysis combines both  
GRACE and CONCORDANCE registries and reports on the management of ST-
elevation acute myocardial infarction (STEMI ) from 1999 to 2016 revealing gains in 
pre-hospital care and fewer in-hospital clinical events, and readmission for urgent 
revascularisation without a significant reduction in in-hospital or six month mortality. 
The third Unit of Analysis reports the observed and risk-adjusted association between 
adherence to the quality composite score and reduced in-hospital events, and increased 
survival at hospital discharge and at six months post discharge.  
Conclusion: Case-study analysis of CER in the context of ACS registries provides 
evidence on adherence to evidence-based care and a quality composite measure of 
hospital performance in the management of ACS.  
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1 Introduction  
Cardiovascular disease was the leading cause of death in Australia in 2012–20141 and 
was responsible for 13% of all hospitalisations in 2012–2013.2 Ischaemic heart disease 
manifests as an acute coronary syndrome (ACS) and is predominantly treated in tertiary 
referral public hospitals. Notwithstanding comprehensive clinical guidelines from 
decades of clinical studies, hospital-based care for patients admitted with an ACS varies 
widely in Australia. There are limited ways to systematically assess or report quality of 
care and using risk-adjusted mortality alone is problematic as a quality measure. While 
the provision of evidence-based treatment is effective in reducing death and in-hospital 
morbidity, clinicians frequently struggle to apply clinical trial results to routine clinical 
practice (Steg et al. 2007; Fox et al. 2003; Chew et al. 2008; Walters et al. 2008; Chew 
et al. 2009). Robust clinical registries have provided useful and effective guidance (Fox 
et al. 2007; Cameron et al. 2005; Graves et al. 2004) and feedback to clinicians on 
adherence to guideline-recommended care.  Registry data collected and reported within 
a comparative effectiveness (CER) framework has the potential to provide clear 
measures of quality of care using evidence-based clinical process indicators. Adherence 
with quality processes of care and patient reported outcomes are clear measures of 
performance in the management of ACS for clinicians, hospital administrators and 
health departments.  It is the closing of this iterative loop that defines the premise of 
reporting on quality of 21st century health care in Australia and this is the primary 
purpose of this thesis.  
 
1.1 Stimulus for this research 
Overall national healthcare expenditure had an average annual growth of 5% over a 
decade from 2002 to 2013 which equated to an increase from approximately $95 billion  
                                                 
 
1 Australian Institute of Health and Welfare. Deaths from cardiovascular disease. Canberra: AIHW; 2017. Available 
from: http://www.aihw.gov.au/cardiovascular-disease/deaths 
2 Australian Institute of Health and Welfare. Cardiovascular disease, diabetes and chronic kidney disease – Australian facts: 
morbidity – hospital care. Canberra: AIHW; 2014. 
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to an estimated $155 billion in 2013–14. Of this, $59 billion was spent on admitted 
patient care for both public and private hospitals. In 2012–13 almost $5 billion was 
spent on hospital care (13%) for cardiovascular disease (CVD), making this the most 
expensive in-patient condition to treat. The growing prevalence of this disease in 
Australia gave rise to over 474,200 hospitalisations in 20143. Within the CVD clinical 
group, ACS accounts for more than 120,000 hospitalisations and costs the healthcare 
system more than $1.8 billion annually4, so the imperative to understand variation in 
care using clinical data for benchmarking and practice improvement is timely. 
National entities such as the Heart Foundation have provided an evidence-based ACS 
capability framework5 and the Australian Commission on Safety and Quality in 
Healthcare (ACSQHC) has delivered the Acute Coronary Syndrome Clinical Care 
Standard6. Yet, there are few mechanisms for data capture on evidence-based measures 
across disparate hospital clinical systems, and the process for evaluating and 
communicating success is less well understood. There is also growing awareness that 
performance metrics collated and reported within a quality reporting framework in 
collaboration with key stakeholders of the healthcare system (inclusive of clinicians, 
hospital administrators and policy advocates), may be a more effective engagement 
strategy for performance improvement than reporting on in-hospital mortality alone 
(Krumholz, H. M. 2008b).  
In the current era, quality measures of effective health service provision are restricted to 
broad measures of effectiveness such as surgical wait-times, time to treatment in the 
emergency department, infection rates and rates of all-cause mortality, and there is 
growing appreciation that hospital performance is largely influenced by factors affecting 
adherence to evidenced-based care – that is, clinical processes that influence patient 
                                                 
 
3 Australian Institute of Health and Welfare. Cardiovascular disease, diabetes and chronic kidney disease – Australian facts: 
morbidity – hospital care. Canberra: AIHW; 2014. 
4 Australian Institute of Health and Welfare. Deaths from cardiovascular disease. Canberra: AIHW; 2017. Available 
from: http://www.aihw.gov.au/cardiovascular-disease/deaths 
5 Heart Foundation of Australia. Australian Acute Coronary Syndromes Capability Framework. 2015. 
https://www.heartfoundation.org.au/images/uploads/publications/ACS_framework.pdf 
6 Australian Commission for Safety and Quality in Health care. Acute coronary syndromes clinical care standard. 2014 
https://www.safetyandquality.gov.au/our-work/clinical-care-standards/acute-coronary-syndromes-clinical-care-standard/ 
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outcomes, hospitalisation time and cost for health service provision (Krumholz, H. 
2013).  
In this thesis two ACS clinical registries are used to explore and explain how these 
reported data provide insights into temporal trends on adherence to evidence-based care 
and the association between adherence and patient outcomes. The Global Registry of 
Acute Coronary Events (GRACE) provided valuable insights into the in-hospital 
management of ACS and patient outcomes between 1999 and 2007. When the GRACE 
registry closed there was no Australian outcomes-research initiative reporting 
contemporary practice patterns in the management of ACS. Although Australia had a 
small footprint in this international endeavour, the contribution of data on more than 
5000 patients was the largest ACS dataset reporting local practice patterns at that time. 
In this thesis, the first analysis of these data in the Australian and New Zealand cohort 
of the GRACE registry ACS between 2000 and 2007 is reported.  
In the absence of any other quality Australian ACS clinical registry, the Cooperative 
National Registry of Acute Coronary Care Guideline Adherence and Clinical Events 
(CONCORDANCE) was then developed within a comparative effectiveness research 
(CER) framework. The design of the CONCORDANCE registry is described in this 
thesis and the constructs of the registry underpin the development of the composite 
measure of hospital performance using multiple clinical process indicators. The method 
for calculating the composite score is then presented in plain language for ease of 
stakeholder interpretation and to facilitate a future opportunity for health service 
providers, in partnership with clinicians and policy stakeholders, to review quality 
indicators for benchmarking within a quality-reporting framework. Further, a strategy is 
proposed for routine data capture using innovative information technology (IT) 
methodologies to develop dynamic reporting capability with incentivised participation 
through health department funding and a requirement for quality reporting that is 
aligned with hospital accreditation. This proposed strategy is provided as the conduit for 
data and reporting on current-practice patterns and patient-reported outcomes for 
practice improvement, reduced rates of hospital readmission and costs for health service 
provision.  
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1.2 Problem statement 
Can data reported within a comparative effectiveness research framework be used to 
understand hospital performance in the management of acute coronary syndromes? 
1.3 Research objectives 
The aim of this thesis is to explore and explain how data analysed within a CER 
framework can be used to report hospital performance in the management of acute 
coronary syndromes (ACS). The following objectives were developed to address this 
aim as a single case study with three sub-units of analysis: 
1. To aggregate population-level data from two aligned ACS clinical registries 
(GRACE and CONCORDANCE) and describe (i) longitudinal change in the 
management of ACS and associations with in-hospital clinical events and mortality, 
and hospital readmission and mortality at six months and (ii) longitudinal change in 
the management of the most acute cohort within the ACS population (ST-elevation 
acute myocardial infarction) and associations with in-hospital clinical events and 
mortality, and hospital readmission and mortality at six months. 
2. To develop a composite measure of hospital performance in the management of 
ACS. 
3. To test the relationship between adherence to the composite measure of performance 
and clinical outcomes. 
4. To develop a stakeholder report to be used as a means of communicating local 
hospital performance with state and national benchmarks.  
1.4 Thesis framework 
This thesis is based on an established theoretical framework that outlines the 
relationships between the parent principle, the research problem area and those parts of 
the research problem that have previously been studied. The ‘structured approach for 
presenting theses’ as described by Perry (1998) can be used as a map to navigate this 
thesis (Figure 1.1). The parent principle is embedded in the translational research 
Chapter 1: Introduction 
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pathway to explore and explain the contribution of comparative effectiveness research 
(CER) to reporting quality of care in the management of ACS. The research problem 
area explores the use of clinical process indicators to report quality of care and hospital 
performance. The borderline research problem area defines the ‘case’ (CER reporting in 
ACS) and the ‘context’ of the case study, (two ACS clinical registries GRACE and 
CONCORDANCE). To examine the ‘case’ in this ‘context’, the objectives are to: 
demonstrate the utility of clinical registries to report temporal trends in the management 
of ACS and ST-elevation acute myocardial infarction (STEMI) and secondly, to validate 
clinical process indicators (CPIs) as quality measures of hospital performance. The 
research objectives were explored in three separate units of analysis within the case 
study, and the results (clinical outcomes) are translated into a targeted strategy and key 
stakeholder report to provide direct comparisons of local hospital performance with 
state and national bench marks.  
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Figure 1.1  Thesis framework 
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1.5 Thesis outline  
This thesis is presented as eight chapters. A brief outline is provided below.  
Chapter 2 presents a narrative review of the literature which positions this research 
within the philosophical framework of epistemology and the translational research 
pathway. The utility of comparative effectiveness research to bridge the quality-
reporting gap in the second phase of the translational research pathway is then presented 
subsequent to an overview of the design features of clinical registries as the data 
warehouse through which comparative effectiveness data on hospital-based care may be 
collated and analysed. An overview of current approaches to measuring and reporting 
hospital performance in the management of ACS then follows with a summary 
discussion of current methods of communicating hospital performance.  
Chapter 3 provides the thesis methodology and the case-study constructs. This includes 
the rationale for the case-study design, the conceptual model, the theoretical statements 
and the analytical approach to testing the research propositions. The case-study 
constructs include the CONCORDANCE registry design within a quality comparative 
effectiveness research framework; the registry operational structure and governance 
framework; the method for hospital recruitment; patient case-selection and enrolment; 
processes for ensuring data quality and data completeness; data analysis and data 
sharing within a research collaborative.  
Chapter 4 provides the insights gained from the first analysis of the Australia and New 
Zealand cohort of the GRACE registry. This analysis provides insights into adherence to 
evidenced-based care longitudinally and provided the platform for establishing an 
ongoing Australian ACS registry (CONCORDANCE) within a CER quality reporting 
framework. 
Aliprandi-Costa B, Ranasinghe I, Chow V, Kapila S, Juergens C, Devlin G, Elliott J, 
Lefkowitz J and Brieger D.B. ‘Management and outcomes of patients with acute 
coronary syndromes in Australia and New Zealand, 2000–2007’.  
The Medical Journal of Australia 2011, 195(3):116–21.  
© Copyright 2011. The Medical Journal of Australia. Reproduced with permission.  
Chapter 1: Introduction 
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Chapter 5 presents the rationale for the design of the CONCORDANCE registry within 
a comparative effectiveness research framework. This registry design is unique in its 
focus on reporting quality clinical process indicators to participating clinicians and 
progresses the outcomes-research registry model.  
Aliprandi-Costa B, Ranasinghe I, Turnbull F, Brown A, Kritharides L, Patel A, Chew D, 
Walters D, Rankin J, Ilton M, Meredith I , Cass A, and Brieger D. ‘The design and 
rationale of the Australian Cooperative National Registry of Acute Coronary Care, 
Guideline Adherence and Clinical Events (CONCORDANCE).’  
Heart, Lung and Circulation 2013, 22(7):533–541. 
Reproduced with permission.  
Chapter 6 reports temporal changes in the application of evidence-based care in the 
highest risk ACS cohort over a 17-year period using data aggregated across both the 
GRACE and CONCORDANCE ACS registry datasets, and demonstrates the utility of 
the two aggregated datasets to progress the insights gained from the observations 
published in Chapter 4. In this analysis of ST-elevation acute myocardial infarction, pre-
hospital and in-hospital management is reported together with observed and risk-
adjusted outcomes.  
Aliprandi-Costa. B, Morgan. L, Snell. L, D Souza. M, Kritharides. L, French. J, Brieger. 
D, and Ranasinghe. I. ‘ST-elevation acute myocardial infarction in Australia –Temporal 
trends in patient management and outcomes 1999–2016.’  
Submitted to Heart, Lung and Circulation.  
Reproduced with permission. 
Chapter 7 is an analysis of the CONCORDANCE registry data which provides unique 
insights into the variable uptake of quality measures with national benchmarks in real-
time to inform local quality improvement initiatives. This chapter presents the method 
for calculating the composite score, using multiple clinical processes, as a single 
measure of hospital performance, and describes the association between the greater 
adherence to the composite of clinical processes and improved observed and risk-
adjusted patient outcomes.  
Chapter 1: Introduction 
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Bernadette Aliprandi-Costa, James Sockler, Leonard Kritharides, Lucy Morgan, Lan-
Chi Snell, Janice Gullick, David Brieger, Isuru Ranasinghe. ‘A composite score of 
clinical process indicators can measure the quality of hospital performance in the 
management of acute coronary syndromes.’  
European Heart Journal – Quality of Care and Clinical Outcomes 2016, 3(1):37–46  
Reproduced with permission.  
Chapter 8 presents the discussion of the case-study findings and the thesis conclusions. 
The prototype of the key stakeholder report is provided as an appendix to this chapter 
(Appendix 1) and a strategy for ongoing data capture within a quality framework is 
proposed. This strategy applies the principles and attributes of a CER clinical registry to 
a model for data-driven reporting on quality of care and health-service provision for 
ACS using new agile technologies and data-reporting solutions.  
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2 Literature review 
A narrative review of the literature has been undertaken to provide an overview of the 
historical context and the stimulus for this research as illustrated in the literature review 
schema (Figure 2.1). The exploratory domain is epistemology which is the 
philosophical underpinning of the translational research pathway and evidence-based 
practice. The body of literature that describes the contribution of clinical registries to 
outcomes research, and the theory of comparative effectiveness research as a quality 
reporting framework, is presented followed by an overview of current methods for 
reporting hospital performance as a precursor to describing what is currently understood 
about measuring and communicating hospital performance in the management of ACS.  
Figure 2.1  Literature review schema 
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2.1 Epistemology and the translation of evidence into practice 
The term ‘translational research’ is a relatively new term that describes the pathway ‘to 
connect scientific knowledge and the application of that knowledge’, yet the process 
required to measure how knowledge is applied is less clearly defined in the literature 
(Dougherty 2009). Translational research is most frequently linked to the generation of 
knowledge led by the basic sciences, but when viewed holistically describes the 
relationship between theory, evidence and knowledge – the scientific underpinning of 
which is understood to be the epistemological system. This system is the platform from 
which the translational research pathway emanates, describing the discovery of new 
treatments and interventions in early phase scientific research, the generation of 
evidence through clinical trials, and the translation of evidence into clinical care 
informing evidence-based practice (Djulbegovic, Guyatt, and Ashcroft 2009).  
The epistemological perspective of this research, as it relates to the translational 
research pathway, is research that is undertaken to generate and communicate 
meaningful outcomes determined by a logical method of deductive analysis. This is the 
logical positivist perspective (Achinstein 2005; Ivanova 2010). The development of 
theory in this research is grounded in the attribute of ‘good sense’ which is developed 
from epistemic enquiry known as ‘process reliablism’ (Roderick 1981). This attribute 
resides in the assumption that significant observations based on statistical probability 
are sufficient to prove or refute propositions and direct ongoing research (Djulbegovic, 
Guyatt, and Ashcroft 2009; Quine 1952; Achinstein 2004). 
More recently, the translational research pathway has been described as a process for 
conducting research across the continuum, applying the principles of ‘bench to bedside 
and bedside to bench’ in the design and conduct of clinical research and the 
communication of research findings. The National Institute of Health (NIH) has defined 
the translational research pathway as including:  
…two areas of research: one is the process of applying discoveries generated 
during research in the laboratory, and in preclinical studies, to the 
development of trials and studies in humans. The second area of translation 
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concerns research aimed at enhancing the adoption of best practice in the 
community.  
(Fontanarosa and DeAngelis 2002) 
This thesis is concerned with the second area of translation – that is, the translation of 
evidence into clinical practice distinguished as ‘bedside to bench’ research (Wang 
2012). In 2003 Sung and colleagues (Sung et al. 2003) began to describe significant 
blocks in the translational research pathway. Blocks in the latter stage of the 
translational pathway were impacted by limited avenues through which to translate 
knowledge generated in clinical practice into improved health decision-making and 
health service delivery (Perel et al. 2007). Moreover, bridging this gap was thought to 
be limited by funding opportunities, data sources by which to support health decision-
making, limited infrastructure to support data collection and variable access to, and 
sharing of, health information by health administrators and policy advocates (Figure 
2.2).  
Figure 2.2  Barriers in the translation of evidence into health outcomes reporting and improved 
clinical practice. Adapted from Sung and colleagues (Sung et al. 2003)  
 
 
In Australia the concept of translational research established a presence with the 
evolution of translational research centres over the last decade principally focussed on 
driving medical advances into new treatments and cures. However, there has been 
relatively little investment in research that bridges the divide between scientific 
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laboratory research and clinician-led research on the effective delivery of currently 
available treatments and interventions. This includes patient-orientated research which 
is the level of enquiry that links the generation of evidence on the use of therapeutic 
interventions in clinical practice and the benefits for patients. This aspect of translation 
is more closely related to problem-solving and decision-making in effectiveness 
research or clinical epidemiology using observational research methods (Tonelli 1998; 
Tonelli 2006). 
2.2 Effectiveness research 
Internationally, efforts to bridge the translational research gap have been informed by 
evidence-based patient-centred research models which aim to assess the effectiveness of 
new interventions or clinical services and broaden the level of data capture to address 
practice variation. Several research models have been promulgated as comprehensive 
frameworks through which to undertake this research, such as the Reach, Effectiveness, 
Adoption, Implementation and Maintenance (RE-AIM) Model. This patient-centred 
approach is attractive to clinicians but is limited in its capacity to describe the multiple 
individual and system-wide barriers to the implementation of evidence-based practice  
(Glasgow, Vogt and Boles 1999).   
The Promoting Action on Research Implementation in Health Services (PARIHS) 
framework obliges the researcher to describe the professional expertise required to 
implement the evidence, the context (including the physical, social, professional and 
cultural environment), and the management and administrative attributes that assist the 
implementation of an evidence-based intervention (Kitson, Harvey, and McCormack 
1998; Rycroft-Malone et al. 2002; Rycroft-Malone, Harvey et al. 2004; Rycroft-Malone, 
Seers et al. 2004; Kitson et al. 2008). The investigators for the Good Research for 
Comparative Effectiveness initiative and the Agency for Health Care Research and 
Quality (AHRQ) (Dreyer and Garner 2009; Dreyer et al. 2010; Gliklich and Campion 
2010) suggest clinical registries and the electronic medical records will provide 
evidence of effectiveness. However, while there have been technology advances with 
implementation of the electronic medical record, disparate clinical systems and 
governance structures limiting the computation of local hospital data have limited the 
expected gains of this applied framework, and processes for communicating outcomes 
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have not been delivered7. In aggregate, each of these models has similarities that can be 
collectively operationalised within a comparative effectiveness research (CER) 
framework to report on the application of treatments for ACS at the individual patient 
and population level, together with patient-reported outcomes (Hlatky et al. 2012). 
2.3 Comparative effectiveness research (CER)  
There are few comprehensive comparative effectiveness quality-reporting frameworks 
described in the literature. As strategies to improve public health and contain healthcare 
expenditure became part of the national and international discourse of policy makers, 
the focus of CER endeavours has largely been on cost containment (Steinbrook 2009). 
Throughout the last decade, CER initiatives conducted in patient-centred research 
models were mainly associated with policy and economic considerations rather than 
quality of care or adherence to evidence-based care (Sung et al. 2003). This is reflected 
in an earlier definition of CER that was ‘to assess the benefits of a particular treatment 
strategy in the context of everyday practice’ (Rothwell 2005a; Fontanarosa and 
DeAngelis 2002; Duyk 2003). In the most definitive sense CER was viewed as ‘an 
analytic activity drawing on clinical information regarding the relative merits of one 
intervention over another “clinical effectiveness” and the costs of the medical services, 
procedures and therapies to treat the same condition’ (Chalkidou et al. 2009). 
In 2002, Califf and colleagues expanded this view to describe CER as research 
comparing ‘clinical outcomes, effectiveness, and appropriateness of items, services and 
procedures that are used to prevent, diagnose or treat diseases, disorders and other 
health conditions’ and encouraged ‘the development and use of clinical registries, 
clinical data networks and other forms of electronic health data that can be used to 
generate or obtain outcomes data’ (Califf et al. 2002; Sox and Greenfield 2009). 
This view expressed a shift away from targeting research only at expenditure reduction 
towards a strategy that incorporated quality measures of healthcare delivery for 
improved patient outcomes as illustrated in Figure 2.1. This concept was reiterated by 
Tunis, Stryer and Clancy (2003) then Shah and colleagues in 2010 (Shah, Drozda, and 
                                                 
 
7 The Grattan Report. https://grattan.edu.au/report/strengthening-safety-statistics 
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Peterson 2010) who posited observational clinical registries, practical clinical trials and 
administrative datasets as potential avenues for evidence generation and the 
dissemination of findings through ‘real-time’ surveillance and feedback to inform 
clinical decision-making and further development of quality metrics (Tunis, Stryer, and 
Clancy 2003; Handley, Hammer, and Schillinger 2006; Rothwell 2005b). 
 
 
 
2.4 Comparative effectiveness research in Australia  
Models of CER contributing to policy development in Australia have largely focussed 
on cost-effectiveness research. This has been a demand-driven activity that governments 
and health policy makers employed to control healthcare expenditure (Chalkidou et al. 
2009). The Pharmaceutical Benefits Scheme (PBS) in Australia is a cost-effectiveness 
CER strategy. The pharmaceutical benefits advisory committee (PBAC) conducts 
rigorous assessment of systematic reviews and efficacy data to determine which 
therapies they will provide based on primary marketing data submitted by industry 
(Lopert 2009; Fox 2009). 
Figure 2.3  Health outcomes reporting within a comparative effectiveness research reporting 
framework. Adapted from the integration of quality into the therapeutic development cycle 
(developed by Califf et al. 2002; adapted by Shah, Drozda, and Peterson 2010) 
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The key agenda for the Australian healthcare system in the early 2000s was to avoid 
wasteful use of resources (therapies and interventions), improve the quality of medical 
care and reduce the frequency of adverse events and the associated costs of managing 
these events in the healthcare system (Southby 2008). Policy changes brought about by 
the National Health and Hospitals Reform Commission (Bennett 2008) led to a 
commitment to report measures of performance from administrative datasets. Costing 
data for a particular diagnostic group or procedure enabled resource utilisation to be 
quantified for predefined conditions – that is, costs associated with certain procedures 
that are allocated to individual patients, for example drug therapy, nursing costs, 
administrative costs, technician costs, laboratory investigations, radiology and imaging, 
specialist consultations and theatre costs (Department of Health and Ageing 2007 
Clinical profiles for private hospitals; Department of Health and Ageing 2009 National 
Hospital Cost Data Collection). Even so, while administrative data sets have the 
advantage of being large and capturing almost every interaction with the healthcare 
system, they lack detailed information on comorbid conditions and complications of 
care that are captured and reported in observational datasets (Cameron et al 2005). 
In the Australian context, literature recognising the scope of a more comprehensive 
CER framework, beyond cost containment began to emerge in 2009 (McNeil et al. 
2010). These authors recognised the value of reviewing data from observational 
datasets, clinical guidelines, evidence reviews and decision models in the context of 
trying to determine whether appropriate patient populations and settings are included in 
these cohorts and whether these data, when properly analysed, informed health service 
provision decision-making (Evans et al. 2011).  
2.5 Clinical registries  
Outcomes research in cardiovascular disease has had a growing presence over the last 
decade in Australia8, and elsewhere (Myers et al. 1999) and is now at the forefront of 
effectiveness research, enabling researchers to define contemporary practice patterns 
together with short and medium to long-term patient outcomes (Krumholz 2008a). The 
attributes of well-designed clinical registries are comprehensively defined in the 
                                                 
 
8 ACOR http://acor.net.au/registries/ 
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literature (Investigators 2001; Ispe 2008; Lyratzopoulos, Patrick, and Campbell 2008; 
Dreyer and Garner 2009), and the Australian Commission on Safety and Quality in 
Healthcare (ACSQHC) has provided technical standards for the design of clinical 
registries in Australia.9 These standards are largely concerned with maintaining external 
validity and endorse the following design characteristics: a clearly defined study 
population and participant inclusion and exclusion criteria; a ‘time zero’ for determining 
a patient's eligibility for enrolment; the capacity to adjust for differences in baseline 
characteristics; accounting for prognostic factors and limit bias – that is, defining 
standardised data definitions and data collection methods to minimise patient selection 
and detection bias, and processes to ensure complete data capture of late outcomes 
either through direct patient-reported outcomes or data linkage to limit attrition bias.  
The Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse 
Outcomes with early implementation (CRUSADE) (Blomkalns et al. 2007) reported 
variation in practice patterns in the application of relatively new therapies on the 
background of clinically important antiplatelet (Mitka 2001) and anticoagulant trials 
(Ferguson et al. 2004). The CRUSADE initiative uniquely reported on guideline 
adherence and patient outcomes, subsequent guideline implementation 
recommendations and provided feedback to healthcare providers. As a direct response 
the American College of Cardiology Foundation established The National 
Cardiovascular Data Registry (NCDR) ACTION-GWTG (Messenger et al. 2012) with 
initiatives which combined CRUSADE with other acute myocardial infarction quality 
improvement initiatives. The NCDR now reports hospital outcomes using quality 
measures of adherence with evidence-based care. More recently the ACSQHC has 
published a framework for clinical registries10 however the concept of CER as a quality 
framework to monitor and report healthcare performance, and track clinical outcomes 
via observational registries, has not been evaluated in the Australian context. 
Initiatives such as the Global Registry of Acute Coronary Events (GRACE) 
(Investigators 2001) were emerging with other local registry initiatives (Graves et al. 
                                                 
 
9 Australian Commission on Safety and Quality in Healthcare: Infrastructure & Technical Standards Australian Clinical Quality 
Registries May 2012 
10 Australian Commission on Safety and Quality in Healthcare: Framework for Australian clinical quality registries 2014 
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2004; Cameron et al. 2005; Schwamm, Reeves, and Frankel 2006). The design of 
GRACE was consistent with the design and technical requirements for clinical registries 
(Anderson et al. 2013) to monitor quality of care, in-hospital management and the 
effectiveness of treatments in routine clinical settings. The GRACE registry was 
established essentially to report on the use of new therapies such as low molecular 
weight heparin, platelet inhibitors and thrombolytic agents to treat ST-segment-
elevation myocardial infarction (STEMI) following clinical trials demonstrating the 
effectiveness of these treatments (GRACE Investigators 2001). GRACE was an 
international endeavour to document and analyse how these therapies were used on an 
international scale. The GRACE registry documented the in-hospital management and 
outcomes of over 100,000 patients from 89 hospitals in 17 clusters across 14 countries 
between 1999 and 2007.  
Important landmark publications were generated through this initiative internationally 
(Fox et al. 2007; Eagle et al. 2004; Fox et al. 2006) and important local manuscripts 
(Chow et al. 2009; French et al. 2009; Naoum et al. 2009; Ranasinghe, Chow et al. 
2009; Ranasinghe, Naoum et al. 2012) described regional similarities and differences in 
ACS patient management and outcomes compared with the international cohort. The 
single most important limitation of the GRACE registry was the funding model. The 
GRACE registry was funded by a single pharmaceutical company through a series of 
unrestricted educational grants which were administered by local affiliates of the 
company internationally. Once the therapies of interest (such as low molecular weight 
heparin) were off-patent the drive for the pharmaceutical company to continue to invest 
in the registry diminished. When GRACE ceased recruiting in 2007 there was no 
avenue to report on unwarranted variation in ACS-care delivery locally in Australia.  
Although observational registries vary in size, longevity and the volume of data 
collected, the value of clinical registries is recognised by The Australian Commission 
for Safety and Quality in Healthcare. The Commission published a report in 201611 on 
the economic value of leading clinical Australian registries. This report was a 
                                                 
 
11 Australian Commission on Safety and Quality in Healthcare. Economic evaluation of investigator-initiated clinical trials 
conducted by networks. 31 July 2017 
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descriptive economic analysis of the Victorian Prostate Cancer Registry (Victorian 
PCR); Victorian State Trauma Registry (VSTR); Australia and New Zealand Intensive 
Care Adult Patient Database (ANZICS APD); Australia and New Zealand Dialysis and 
Transplantation (ANZDATA) Registry and the Australian Orthopaedic Association 
National Joint Replacement Registry (AOANJRR). Each registry reported annual 
running costs of approximately $1 million for a return on investment of 23 to 52 per 
cent. Other benefits were also identified such as indicator feedback to participating 
hospitals.  
2.6 Current methods for measuring and reporting hospital 
performance  
Having described the theoretical underpinning of evidence translation and quality 
reporting frameworks, an overview of current methods for reporting and communicating 
hospital performance is provided. A report released by the World Health Organization 
(WHO) Regional Office for Europe Health Evidence Network (HEN) report12 identified 
the ‘principal methods of measuring hospital performance as regulatory inspection, 
public satisfaction surveys, third-party assessment, and statistical indicators’. In this 
report, the adoption of clinical process measures to measure hospital performance 
presented the opportunity to quantify and identify practices that led to higher quality of 
care and patient outcomes, and to learn how high-quality care was delivered.  
In Australia over two-thirds of funding for healthcare is provided by the 
Commonwealth, state and local governments and one-third is funded by health funds 
and individuals. Funding for healthcare represents 10 per cent of the gross domestic 
product (GDP) and the rising costs of healthcare currently exceed the annual growth of 
the Australian economy.13 Despite this, there is no unified framework or strategic plan at 
the national or NSW state level for performance monitoring, reporting and 
benchmarking. Government agencies engage organisations such as the Independent 
Pricing and Regulatory Tribunal (IPART) to undertake reviews of potential avenues for 
                                                 
 
12 http://www.euro.who.int/document/e82975.pdf 
13 Australian Government http://www.australia.gov.au/information-and-services/health 
Chapter 2: Literature review 
20 
 
reporting health outcomes and performance monitoring across a range of diverse 
healthcare settings and clinical conditions 14.  
From 2013 until June 2016, the National Health Performance Authority (NHPA), as an 
independent agency developed through the Council of Australian Governments (COAG) 
(N.H.P.A. 2011), provided broad measures of healthcare performance in Australia. This 
agency was supported by the Council of Australian Governments National Health 
Reform Performance and Accountability Framework (PAF) to review and identify 
performance indicators used nationally and internationally, and to report publicly on 
healthcare organisations’ pricing, quality and performance. This agency closed in June 
2016 and its functions were distributed across other federal and state agencies. In NSW, 
the Bureau of Health Information (BHI) serves the function of reporting on broad 
measures of equity, efficiency and effective healthcare delivery15 such as access to 
health services, overall hospital readmission rates and costs of acute and chronic disease 
states. However clinical process indicators in high-cost disease states such as ACS are 
not included in these reports. 
Other agencies such as the Australia Council on Health Care Standards (ACHCS), 
which is a voluntary collaboration of 36 medical specialists and medical associations, 
have developed 22 sets of clinical indicators and over 338 individual indicators largely 
to involve healthcare providers in performance review within their healthcare 
organisations, and to engage them in performance review and resource utilisation and 
resource planning. However, the voluntary nature of the program means 
underperforming organisations may disengage from performance improvement 
initiatives.16  
2.7 Measures of performance  
Outcome measures such as hospital admission rates, infection rates, mortality rates and 
surgical wait-times are routinely used to report hospital performance in Australia as 
these measures are readily available from administrative data sets. Administrative data 
                                                 
 
14 IPART Framework for performance in health. https://www.ipart.nsw.gov.au/Home/Industries/Special-
Reviews/Reviews/Health/Framework-for-performance-improvement-in-Health 
15 Bureau of Health Information http://www.bhi.nsw.gov.au/BHI_reports 
16 Australia Council on Health Care Standards (ACHCS) https://www.achs.org.au/programs-services/clinical-indicator-program/ 
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are collected for the purpose of costing healthcare, hospital and health service-provider 
reimbursement and for streamlining resource allocation (Krumholz et al. 2006). 
Measures of clinical effectiveness are generally reported using mortality rates which are 
possible to aggregate as a surrogate measure of all aspects of care delivery. The 
limitation of using mortality alone is that it is impossible to be sure that the cause of 
death is attributable to any specific aspect of care. Mortality alone does not reflect 
whether the right patient received the right treatment and how timely the treatment was 
delivered (Krumholz 2008a). It is also difficult to adjudicate the role of adherence to 
evidence-based care with the cause of death, as only age, gender, race, admission status 
and socioeconomic status are captured in these datasets. Additionally, hospitals may 
have small numbers of patients with a specific condition which would preclude them 
from measures of hospital performance unless complex statistical modelling is 
undertaken (Gardner et al. 2010).  
Clinical process measures provide much more detailed information and, when collected 
systematically, are both sensitive and specific measures of quality of care. Clinical 
process measures are a more preferred method of assessing health service delivery 
because they are easily understood and actionable by both administrators and clinicians. 
For example, antiplatelet use is a direct measure of adherence with guideline- 
recommended care and can be used as a direct measure of quality of care because the 
link between process (prescription of antiplatelet agents) and outcome (mortality) has 
been demonstrated in clinical trials (Mitka 2001).  
Aggregating process measures to demonstrate hospital performance in a specific disease 
state (such as ACS) can be undertaken either as a single measure (such as door-to-
balloon time for primary percutaneous coronary PPCI intervention), or multiple 
measures (referral to secondary prevention services and risk assessment on admission to 
hospital) or as a composite measure that uses multiple clinical processes, health-service 
access measures and outcome measures (Gardner et al. 2010). In comparative 
effectiveness research the purpose is not to identify failures of individuals, and for that 
reason reporting within this framework does not rely on a single measure (Masoudi et 
al. 2008). A single process measure describes the cohort of patients eligible for a 
specific treatment and many patients are excluded on the basis of therapeutic 
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contraindications. Moreover, a single measure is only a snapshot, and may be of lesser 
value if performance in a particular measure is always high or ‘topped out’ (Masoudi et 
al. 2008). There are now guidelines and pre-emptive studies providing methods for 
evaluating multiple measures as a ‘set’ of measures (two or more measures) which are 
calculated separately and presented as a set. However, aggregating a number of process 
measures as a single composite score better characterises those hospitals with greater 
adherence to a range of clinical processes.  
2.8 Methods for calculating the composite measure of performance  
Several methods for calculating a composite score have been described and are outlined 
below (Nolan and Berwick 2006; Peterson et al. 2010; Simms, Batin et al. 2013; 
Simms, Baxter et al. 2013; Bebb et al. 2017).  
The any or none approach combines outcomes rather than care processes and is most 
commonly used in clinical trials analysis of endpoints. This method counts the number 
of times an end point is reached, such as hospital readmission, and does not distinguish 
between the treatments or interventions received (Ferreira-Gonzalez et al. 2007). There 
are also more complex methods to report performance such as random effects or 
hierarchical model, which ranks performance based on a single outcome such as 
mortality. The incommensurable approach applies a different scale to the calculation of 
each component of the composite measure, so that each measure must be transformed 
into a common scale before the composite score is calculated. Linear combinations are 
a weighted sum of each measure which are then added together to derive the mean 
score. The opportunity based score (OBS) has been applied previously to calculate a 
composite measure of hospital performance in the Myocardial Ischaemia National Audit 
Project (MINAP) (Simms et al. 2013) by counting the number of times a predetermined 
process was performed (numerator) against the total number of instances the process 
was required (denominator). All these approaches have limitations. All are statistically 
valid methods for calculating a composite score but none are practical to apply, 
calculate or interpret by the wider stakeholder group (Nolan and Berwick 2006; 
Peterson et al. 2010; Simms, Batin et al. 2013; Simms, Baxter et al. 2013; Bebb et al. 
2017). 
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The approach used to calculate the quality composite score in this research is the all or 
none approach, as it accounts for the number of times patients received all required care 
processes (numerator) against the total number of patients eligible for each care process. 
This approach considers those patients who may have a contraindication to a therapy or 
intervention and is concerned with the sequence of care delivery in addition to the 
individual components of the care received (Simms, Baxter et al. 2013; Bebb et al. 
2017). 
2.9 Chapter summary  
In this chapter the narrative review of the literature has provided the philosophical 
underpinning of CER as a quality-reporting research framework. An overview of the 
epistemological view of health-science research and quality reporting through 
observational registries has been presented as the method for purposively and rigorously 
reporting healthcare delivery and patient outcomes to report hospital performance 
(Djulbegovic and Djulbegovic 2011). The translational research pathway was presented 
in the light of barriers to rapid evidence translation into improved health decision-
making and the benefits of increasing the usefulness of policy-relevant clinical research. 
Measures of hospital performance and the method for calculating a composite measure 
of quality clinical indicators to measure hospital performance were then presented (Sox 
and Greenfield 2009; Sung et al. 2003; Woolf 2008).  
It is the purpose of this research to demonstrate the added value of prospectively 
collected data that measures the application of evidence-based care and patient 
outcomes to reporting hospital performance (Craft et al. 2000). This additional focus on 
patient-level data within a registry complements the current reporting strategy of the 
Bureau of Health Information in NSW and could be used to evaluate quality initiatives 
implemented locally within hospitals and across NSW. A case study of CER as a 
framework for reporting and communicating quality of care has not been undertaken in 
Australia. This single case study with embedded units of analysis facilitates the 
discussion of CER as a framework for reporting on quality of care using clinical 
processes as measures of hospital performance, and to inform the development of a 
report prototype through which to communicate hospital performance to a wider 
stakeholder group (Brown and Sorrell 2009).  
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3  Methodology 
The preceding chapter provided the narrative review of the literature and an overview of 
suitable research frameworks designed to monitor and report on quality of care within 
the health system. The purpose of Chapter 3 is to present the research methodology 
including the rationale for the case-study design, the conceptual model and the analytic 
approach to testing the research propositions. The constructs of the case-study and the 
objectives and methods of prospective data collection within the CONCORDANCE 
registry will also be detailed in this chapter.  
3.1 Rationale for single case-study design  
The quality of case studies as described by Yin (1999) and applied by Kim and 
colleagues (Kim, Price, and Lau 2014) are determined by the following attributes: the 
alignment of the research purpose and study objectives within the conceptual 
framework; the development of theories and propositions to be tested; the philosophical 
approach to data collection, data management and data analysis; and the chronology of 
findings which facilitate an in-depth discussion of the research outcomes.  
Case-research enables an in-depth examination of a phenomena or paradigm in its real-
world context (Yin 2014). In selecting the research methodology for this thesis, both 
multiple-case versus single-case, and holistic versus embedded designs were reviewed. 
It is possible to design a case study in which each case study consists of multiple 
holistic cases or of multiple embedded cases (Yin 2009) – which allows the pooling of 
data across a number of cases (multiple holistic cases), rather than reporting the data 
individually for each case. Multiple case-study design is frequently preferred to single 
case-study design since results arising from two cases may increase the possibility of 
direct replication, whereas a single case-study design could limit the value of the work 
that would be reinforced by two comparative or contrasting cases (Yin 2014). 
Nevertheless, multiple case studies for comparison requires a-priori data and, while 
there may be some differences in the design of clinical registries in ACS, there are no a-
priori data evaluating CER in this context so a replication multiple case-study design 
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does not meet the objective of this research. Yin states that single case-study design is 
best suited to the examination of situations which are ‘critical, unusual, common 
revelatory, or longitudinal’ (Yin 2014). The rationale for using a single case-study 
design in this thesis is based on the understanding that this research is testing a 
longitudinal ‘case’ (CER) that is critical to the proposition: ‘clinical process measures 
captured within a quality (comparative effectiveness) reporting framework enhance 
hospital performance reporting on the management of ACS’.  
Additionally, single-case research facilitates the examination of the ‘case’ in its 
everyday context (Yin 2009; Yin 2014). That is, this method takes into account both the 
‘case’ (CER) and/or the ‘context’ (clinical registries) may vary throughout the research 
period. For example, participating hospitals contribute data to clinical registries and, 
over time, participating hospital services may change, the evidence for treatments and 
interventions may change, which may in turn lead to the need to modify the clinical 
processes to be measured and/or the nature of the analyses to be performed (Figure 3.1). 
This case study is conducted from a positivist perspective (Achinstein 2005; Ivanova 
2010) which is aligned with case-study research in health science and health informatics 
research (Yin 1999). The positivist perspective is a structured approach of deductive 
investigation which considers the ‘case’ from the point of view of the research ‘design’ 
rather than the type of data to be collected. That is, data may be either quantitative 
and/or qualitative. The design of this case study is both exploratory and explanatory 
which enables the development of a conceptual framework within the parent principle 
or research framework (epistemology) so that theories and propositions may be 
developed and tested deductively. This satisfies the requirements for robust positivist 
case-research which, in this thesis, is the use of observational data captured via clinical 
registries (GRACE and CONCORDANCE) to report comparisons of data in order to 
make the findings of the research understandable to a broad stakeholder group (Yin 
2014; Ragin 1999). 
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Figure 3.1 Case, context and units of analysis 
 
3.2 Conceptual framework   
The conceptual framework is informed by the epistemic system that underpins CER and 
clinical effectiveness reporting within the translational research paradigm – that is, 
research beyond the laboratory and early and late-phase clinical trials to research driven 
by clinical evidence gaps, using clinical process indicators to report hospital 
performance with peer comparisons (Tunis, Stryer, and Clancy 2003). Other quality 
research frameworks were reviewed in Chapter 2.  
A single case study with three embedded units of analysis has been undertaken to 
explore the ‘context’ (ACS clinical registries) of this ‘case’ (CER) as an exemplar of a 
research model within a quality-reporting framework to capture and describe the 
potential translation of evidence into improved health-service provision reporting. The 
deductive design of this case study underpins the organisation and analysis of data using 
descriptive statistics and risk-adjusted regression analysis to determine the level of 
effect on health outcomes. Case-study research conducted through this lens facilitates 
the testing of propositions to determine, with certainty (p<0.05), the research findings 
(Roderick 1981; Carrier 2014).  
The research problem area is the phenomenon of generating evidence on effective 
healthcare delivery using observational datasets on evidence-based practice in acute 
coronary syndromes (ACS). Data have been aggregated for this predefined clinical 
group from two ACS clinical registries: the Australian cohort of the Global Registry of 
Acute Coronary Events (GRACE) (Investigators 2001) and the Cooperative National 
Registry of Acute Coronary Care Guideline Adherence and Clinical Events 
(CONCORDANCE) (Aliprandi-Costa et al. 2013). To facilitate reporting on trends in 
patient management over time the rationale and design of the CONCORDANCE 
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registry progressed the design of the GRACE registry from a population-based 
observational registry to an operational quality-reporting resource. These two clinical 
registries form the ‘context’ of the case study, and it is within this context that the study 
explains how these data can be analysed and presented to report temporal trends in 
patient management and patient outcomes, and then, using the composite of evidence-
based clinical processes, to report hospital performance using clinical process measures.  
In summary, this case study examines the ‘case’ (CER) in the real-world context of data 
capture through observational registries that are case sensitive (ACS). The context 
contains a number of variables including; hospital characteristics, clinical information 
including patient demographics, specialised medical therapies and interventions, process 
measures and patient-reported outcomes. For explanatory purposes the type of data 
included in the embedded units of analysis are presented in Figure 3.2. 
Figure 3.2  Data elements within the single case-study design 
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3.3 Conceptual model 
The conceptual model provides the framework for the development of the case-study 
theories and propositions which will be tested through the study design and the analytic 
strategies. The theoretical statements and the propositions to be tested have been 
developed from the literature and are outlined below. The conceptual model illustrates 
the components of CER as a paradigm of interrelated parts within which the case study 
is conducted comprising three (embedded) units of analysis. Figure 3.3 illustrates: the 
association between the research framework and the propositions to be tested, the 
method of data collection via the clinical registries, the analyses to be performed, and 
the development of a stakeholder report.  
This case study adopts a structured approach to explain how the ‘case’ (CER in acute 
coronary syndromes) can be used to bridge the quality reporting gap. The ‘context’ is 
the aggregation of patient-level registry data from two aligned ACS clinical registries 
with the following objectives:  
1. To aggregate population-level data from two aligned ACS clinical registries 
(GRACE and CONCORDANCE) and describe (i) longitudinal change in the 
management of ACS and associations with in-hospital clinical events and mortality, 
and hospital readmission and mortality at six months and (ii) longitudinal change in 
the management of ST-elevation acute myocardial infarction and associations with 
in-hospital clinical events and mortality, and hospital readmission and mortality at 
six months. 
2. To develop a composite measure of hospital performance in the management of 
ACS. 
3. To validate the relationship between adherence to the composite measure of 
performance and clinical outcomes. 
4. To develop a stakeholder report to be used as a means of communicating local 
hospital performance with state and national benchmarks. 
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3.4 Theoretical statements  
1. This case study will demonstrate that clinical process measures captured within a 
quality (comparative effectiveness) reporting framework enhance hospital 
performance reporting on the management of ACS.  
2. This case study will also demonstrate the limited value of reporting mortality alone 
as a measure of quality of care. 
3.5 Propositions  
 
P1 Measuring temporal changes in the delivery of guideline-recommended care 
longitudinally provides valuable insights into the management of ACS overtime.  
P2 Evidence-based clinical process indicators can be used to construct a quality 
composite score and hierarchy of hospital performance.  
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Figure 3.3  Conceptual model – Single case study with embedded units of analysis 
 
   
3.6 Case-study constructs 
The constructs of the case study presented in this chapter were based on the concept of 
observational data contributing to health-outcomes reporting when the design of the 
registry is consistent with the key attributes of clinical quality registries (Shah, Drozda, 
and Peterson 2010)17 – that is, the registry governance structure; the methods applied to 
hospital selection; the registry inclusion criteria; patient case-selection; data collection; 
processes for ensuring data quality and data analysis were consistent across both 
registries. As a global initiative, more than 5000 patients were recruited into the 
GRACE registry between 1999 and 2007. Data were contributed from nine Australian 
                                                 
 
17 Australian Commission on Safety and Quality in Healthcare: Infrastructure & Technical Standards Australian Clinical Quality 
Registries. May 2012 
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hospitals and two New Zealand hospitals. This was the only ACS clinical registry 
measuring and reporting on variation on care locally during this period. The design of 
the GRACE registry is not the subject of this thesis but is presented here as the 
precursor to the development of the CONCORDANCE registry. To aggregate data from 
both registries it was important to align variable definitions and the processes for patient 
recruitment, data collection and data quality.  
Following the closure of GRACE, the overarching purpose for developing the 
CONCORDANCE registry was to ‘provide data to healthcare providers and hospitals to 
characterise existing and evolving practice patterns, delivery of care and resource 
utilisation in management of ACS across Australia’18. The registry was established as a 
vanguard approach to quality reporting and, by design, intended that the captured data 
were representative of the Australian ACS population. Achievable objectives and a 
written protocol were developed stating the aims, the clinical data required and how 
data would be used, protected and disseminated in a manner that was compliant with 
standards for reporting performance including (Krumholz et al. 2006) compliance with 
the International Council for Harmonisation of Technical Requirements and Guidelines 
for Good Clinical Practice for research (ICH-GCP)19 and research ethical and 
governance requirements.  
Key attributes of clinical registries capable of generating data suitable for measuring 
and reporting hospital performance have been described in Chapter 1. The operational 
design of the CONCORDANCE registry included processes for the organisation of data 
and quality assurance measures to safeguard the quality of the evidence generated and 
facilitate the translation of these findings into quality hospital performance reporting 
(Krumholz et al. 2006; Krumholz 2008b).  
Following the definition of patient case-selection and the evidence-based clinical 
indicators to be measured, a dataset with clearly defined data fields, and a process for 
                                                 
 
18 Cooperative National Registry of Acute Coronary care, Guideline Adherence And Clinical Events. Protocol Version 3.0 dated  
20 November 2009  
19 International Council for Harmonisation of Technical Requirements and Guidelines for Good Clinical Practice for research (ICH-
GCP) http://www.ich.org/home.htmlhttp://www.ich.org/home.html 
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ensuring data quality at the system level to minimise missing data, incorrectly coded 
data and incomplete data was implemented (Shah, Drozda, and Peterson 2010; 
Krumholz et al. 2006). Controlled database logic checks, frequent monitoring of data 
reliability and clear lines of communication between the data management, the registry-
coordination centre and participating clinicians ensured mandatory data items were 
complete so that the clinical process indicators could be calculated and reported.  
Ultimately the quality of the data captured relied on the accuracy of the data entered by 
individuals. Data quality at the point of data extraction from the medical record for both 
the GRACE and CONCORDANCE registries, and data entry into the electronic clinical 
record form (eCRF) were monitored by the clinical trials research unit in the 
Department of Cardiology at Concord Hospital. The group was responsible for staff 
training at each site, implementing data quality processes and monitoring data quality. 
Site visits for quality data audit purposes were performed at each site following 
initiation, and at yearly intervals or as required so that a minimum of 10 per cent of all 
data captured at each participating hospital was audited for consistency with the 
protocol and for confirmation of the recruited patient’s authenticity. Site training 
included full coverage of the following topics: selection of patient eligibility; 
determination of eligibility for inclusion; methods for abstracting detailed information 
from the patient’s medical record; the method for eCRF completion; the definition of 
variables; critical variables; responding to data queries; audit procedures and lines of 
support and communication. The recommended record-keeping procedures were 
consistent with the national guidelines and were reviewed during site audits.20   
                                                 
 
20 http://www.tga.gov.au/ct/cthandbook.pdf 
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3.7 CONCORDANCE registry objectives  
The objectives of the CONCORDANCE registry as outlined in the protocol21 were:  
‘To document the association between systems of delivery of care as 
determined at government, area and individual hospital levels and 
implementation of evidence-based guidelines. 
  To document and inform the appropriate use of medications in the Australian 
ACS population, including higher risk subsets not well represented in 
clinical trials. 
  Identify mechanisms whereby data collection within a hospital can be 
incorporated into a sustainable component of clinical practice to allow 
internal and external standards and benchmarking of treatment patterns and 
patient outcomes.’ 
The purpose of designing a registry within a CER framework was to report 
comprehensively on the ACS population in Australia and provide data to participating 
clinicians in real-time as a web-based resource: 
‘The utility of provisioning these data was to enable clinicians and hospitals to 
measure their performance using a set of key performance indicators (KPIs) 
benchmarked against national aggregate data. The ultimate aim being, to use 
these KPIs to identify areas in which practice is not in line with best 
evidence and to formulate strategies to address these gaps.’  
Examples of the calculated KPIs in the original protocol are listed below.  
‘– Door to balloon time for patients with ST-elevation MI receiving PCI 
  – Door to needle time for patients with STEMI receiving fibrinolysis 
  – Proportion of high risk non-ST-elevation ACS patients receiving in-
hospital angiography 
  – Proportion of STEMI and high risk non-ST-elevation ACS patients 
receiving in hospital 
  – Clopidogrel 
                                                 
 
21 Cooperative National Registry of Acute Coronary care, Guideline Adherence And Clinical Events. 
Protocol Version 3.0 dated 20 November 2009 
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  – Proportion of high risk non-ST-elevation ACS receiving glycoprotein 
GPIIb/IIIa antagonist 
  – Therapy 
  – Proportion of ACS patients discharged on beta-blocker 
  – Proportion ACS patients discharged on ACE-inhibitor or     
Angiotensin Receptor Blocker 
  – Proportion ACS patients discharged on aspirin.’  
 
Building on this program of work, the registry provided the platform for endeavours 
including the Aboriginal and Torres Strait Islander Initiative, the Qualitative Initiative 
the Biobank Initiative, and a mechanism providing effectiveness data to registry 
sponsors that met their reporting needs. For example, aggregated data (de-identified by 
hospital and clinician) were provided quarterly to sponsors for marketing purposes 
and/or to support applications to national regulatory authorities on the effective use of 
drugs and devices.   
3.8 Registry funding 
As the cluster coordinating site for the GRACE registry across Australia and New 
Zealand, the coordinating centre had received substantial recognition for the 
completeness and accuracy of the data contributed to that initiative and had the 
proficiency required to initiate and lead the CONCORDANCE registry. A single 
financial sponsor for the initiative was an identified risk in the design of the GRACE 
registry so it was anticipated that multiple sponsors would contribute to funding 
CONCORDANCE.  
The initial seed-funding strategy leveraged on the expertise gained from the 
coordination of GRACE Australia and New Zealand (ANZ) and existing relationships 
with the local Sanofi Affiliate and the Heart Foundation of Australia to establish ten 
registry sites nationally with sufficient funds to reimburse sites for data capture over a 
three-year period. As the registry gained momentum and recognition, sponsorship was 
expanded to include a range of pharmaceutical and non-pharmaceutical sponsors with 
interests across a range of therapeutic treatments and interventions. As a result the 
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number of participating hospitals also expanded, so that 41 hospitals nationally were 
participating in the registry by 2016. 
From the outset, the CONCORDANCE registry funding was assured prospectively in 
three yearly increments, so that obligations as set out in the funding schedules with 
participating hospitals and the registry sponsor agreements could be met. A registry 
website was established with links to publications and resources, and a sponsor 
expression-of-interest form. Without rigorous oversight of this financial edifice and a 
compliant governance structure, funding levels were expected to diminish expeditiously.  
Funding supported data management, registry-coordination activities, patient screening 
and recruitment, data extraction from the medical record, and completion of the web-
based clinical record form. Patient screening and recruitment is labour intensive and 
requires a stable workforce with clinical expertise. This was arguably the most 
expensive activity of the registry to support. To retain a fully trained workforce with 
knowledge of the registry protocol, hospital re-imbursement was calculated based on the 
number of hours per month required for all registry-related activity and aligned with the 
pattern of recruitment, and paid the hourly rate of a registered nurse for a minimum of 
16 hours per week. Reimbursing hospital staff appropriately achieved significant gains 
for the registry and relationships with hospital staff and staff at the coordinating centre.  
3.9 Governance structure  
The governance structure of the CONCORDANCE registry is described in Chapter 4 
(Aliprandi-Costa et al. 2013). As a legal requirement of a funded research collaborative, 
the chairperson is obliged to be an employee of a legal entity. The legal entity in this 
collaborative was Sydney Local Health District (SLHD) which acted as the overarching 
governing body. The chief executive of SLHD and the chairperson were therefore the 
custodians of the database, and ultimately responsible for compliance with ethical and 
regulatory requirements. The George Institute was contracted to undertake the database 
build and data-management activities initially, and later the database was rebuilt and 
managed by the Centre for Outcomes Research (COR) at the University of 
Massachusetts Medical School. The custodians, together with members of the scientific 
committee, registry-coordination and data-management teams, were experienced 
managing a clinical registry and had the infrastructure and expertise in handling large 
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clinical datasets, and ensured high levels of data security and compliance with the data 
protection of Health Records and Information Privacy Act 2002 (NSW) and Privacy Act 
1988 (Cwlth) and Information Privacy Principles.  
This structure ensured the integrity of procedures for data collection, data quality 
auditing and the security of identifying information. As outlined in the protocol:  
‘Identifiers such as the patient initials, date of birth and postcode were 
encrypted at the time of registration. Electronically stored data were 
identified only by a unique identifier. The master list linking the patient ID 
to the patient’s identifying information were maintained in a separate server 
accessible only for data linkage purposes. The collection, storage and 
transmission of clinical registry data met all standards relating to the use of 
paperless records under the Good Clinical Practice regulations. The systems 
and procedures complied with the Electronic Records; Electronic Signatures; 
Final Rule: Electronic Submissions; Establishment of Public Docket; Notice 
of CRF 21 Part 11 of these regulations.  
  The system also complied with the National E-Health Transition Authority 
(NEHTA) standard of reporting and storing data. Checks were used to 
determine the validity of the source of data input or operation instruction; 
and written policies were established and adhered to holding individuals 
accountable and responsible for actions initiated under their electronic 
signatures, so as to deter record and signature falsification.’ 22 
Site (hospital) agreements with the governing body (SLHD) were put in place outlining 
the responsibilities, intellectual property and financial aspects of the registry. The 
publication guidelines were consistent with clauses in Medicines Australia CTA for a 
Collaborative Research Group (CRG)23 and, importantly, access to data contributed by 
investigators was provisioned on request for local analysis.  
As guidelines and operational frameworks for clinical registries emerged, the scientific 
committee ensured compliance with these standards. The Operating Principles and 
Technical Standards for Australian Clinical Quality Registries (ACSQHC)24 and the 
                                                 
 
22 Cooperative National Registry of Acute Coronary care, Guideline Adherence And Clinical Events.  
Protocol Version 3.0 dated 20 November 2009 
23 Clause 11 Medicines Clinical Trial Agreement Collaborative or Cooperative Research Group (CRG) dated March 2010) 
24 www.registries.org.au/reports_publications/guidelines_registries.pdf 
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NHMRC Centre of Research Excellence in Patient Safety25 were published during this 
period and these standards are now the blueprint for the design and sustainability of 
clinical registries. 
3.10 Hospital recruitment  
A unique feature of the GRACE registry was the selection of hospitals to reflect a 
population-based sample of people with an ACS (Table 3.1) – that is, a cluster of 
between four to six hospitals were selected within each participating region to capture 
data on the population being treated in that region. The CONCORDANCE registry 
undertook a purposive sampling strategy. The first ten hospitals invited to participate in 
CONCORDANCE were invited based on: geographic location (both regional and 
metropolitan hospitals); those hospitals with percutaneous interventional (PCI) 
capabilities and non-PCI capabilities; and an experienced research department or a track 
record for contributing timely and accurate data to clinical registries and/or clinical 
trials. Several of these had participated in GRACE as indicated below in Table 3.2. 
Subsequent hospitals were recruited via a snowball approach and were predominantly 
principal referral hospitals, as specified by the Australian Bureau of Statistics – that is, 
‘hospitals located in major cities with more than 20,000, and regional hospitals with 
more than 16,000 acute (case mix-adjusted) separations per year and considered to be 
moderately accessible, accessible or highly accessible by the Accessibility and 
Remoteness Index of Australia (ARIA)’26. Each hospital had an experienced research 
department and/or a track record for contributing timely and accurate data to clinical 
registries and completed the Hospital Services Form each year, so that the availability of 
clinical services at each hospital could be taken into account when analyses were being 
undertaken.  
  
                                                 
 
25 http://www.registries.org.au/ 
26 Remoteness Index of Australia (ARIA) Information and Research Branch, Department of Health and Aged Care Australia (2001). 
‘Measuring Remoteness: Accessibility/Remoteness Index of Australia (ARIA).’ Occasional Paper New Series: Number 14. 
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Table 3.1  GRACE registry hospitals in Australia and New Zealand 
Concord Hospital (NSW) Dandenong Hospital (Vic) 
Canterbury Hospital (NSW) Liverpool Hospital (NSW) 
Royal Prince Alfred Hospital (NSW) Bankstown Hospital (NSW) 
Bathurst Hospital (NSW) Christchurch Hospital (NZ) 
Coffs Harbour Hospital (NSW) Waikato Hospital (NZ) 
Royal Melbourne (Vic)  
 
 
Table 3.2  CONCORDANCE registry hospitals in Australia 
Alfred Health (Vic) Concord Hospital* Maitland Hospital  Royal Darwin Hospital 
Alice Springs Hospital Dubbo Hospital Monash Heart Royal Hobart Hospital 
Austin Hospital Flinders Medical Centre Nambour General Hospital Royal Perth Hospital 
Bairnsdale Regional Geelong Hospital Nepean Hospital Royal Prince Alfred* 
Bankstown Hospital* Gold Coast Hospital Northern Hospital Sir Charles Gairdner Hospital  
Bathurst Hospital* John Hunter Hospital Nowra Base Hospital St Vincent's Hospital (Victoria) 
Box Hill Hospital Launceston General Orange Base Hospital The Queen Elizabeth Hospital 
Campbelltown Hospital Lismore Base Hospital Port Macquarie Hospital Toowoomba Hospital 
Canberra Hospital Liverpool Hospital* Prince Charles Hospital Townsville Hospital 
Coffs Harbour Hospital* Lyell McEwin Hospital Royal Brisbane Hospital Westmead Hospital  
   Wollongong Hospital 
*Hospitals that had also participated in the GRACE registry 
3.11 Participant recruitment 
As in GRACE, the patient inclusion and exclusion criteria were clearly defined in the 
registry protocol27. Both registries adopted a restricted cohort design so that there was a 
‘time zero’ for the recruitment of patients and details were collected on the patient’s 
clinical history and comorbid conditions. Having identified the data items to be captured 
on patient clinical presentation, past medical history, hospital admission details, in-
hospital investigations and interventions in the GRACE registry and, consistent with the 
requisite for applying standard definitions according to the Australian Institute of Health 
and Welfare (AIHW) Metadata Online Registry (METeOR)28 for data capture, it was a 
priority to align the patient eligibility criteria and data definitions in the analytic strategy 
                                                 
 
27 Cooperative National Registry of Acute Coronary care, Guideline Adherence And Clinical Events. 
Protocol Version 3.0 dated 20 November 2009 
28 http://meteor.aihw.gov.au/content/index.phtml/itemId/356777/meteorItemView/long 
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for longitudinal data aggregation. The method of patient recruitment and the process for 
data collection were consistent across both GRACE and CONCORDANCE. Patients 
were recruited sequentially, that is, admission lists were reviewed and the first ten 
patients admitted to hospital with a suspected ACS at the beginning of each month, and 
meeting the inclusion criteria, were approached to participate in the registry.  
3.12 Participant inclusion and exclusion criteria  
As outlined in the registry protocol29:  
 
‘To be enrolled in both registries, patients must have presented to hospital 
with a suspected acute coronary syndrome including acute myocardial 
infarction; Non-ST ACS, unstable angina or high-risk ACS^ as defined 
below: 
− Must be ≥ 18yrs old; 
− Must be alive at the time of hospital presentation; 
− The qualifying acute coronary syndrome must not be precipitated by 
or accompanied by a co-morbidity such as trauma, gastrointestinal 
bleeding, operation or motor vehicle accident. Patients already 
hospitalised for any reason when the ASC develops are not eligible 
for enrolment. 
− Patients transferred into or out of a registry hospital can be enrolled 
regardless of the time spent at the transferring institution, provided 
the inclusion criteria are met. 
− For patients transferred out of the registry hospital data collection for 
the initial CRF ends with transfer and the indication for of the 
purpose of the transfer. 
− Patients previously enrolled cannot be re-enrolled with two years of 
the index admission.  
  Patients hospitalised for <1 day are not eligible for enrolment. There is one 
exception: patients hospitalised for < 1 day who die and do not meet the 
                                                 
 
29 Cooperative National Registry of Acute Coronary care, Guideline Adherence And Clinical Events. 
Protocol Version 3.0 dated 20 November 2009 
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criteria maybe enrolled provided the cause of death is confirmed to be due to 
ACS.  
  Patients are eligible if they present to hospital with symptoms felt to be 
consistent with acute cardiac ischaemia for >10mins within 24 hours of 
presentation to hospital plus one of the following: ECG changes; elevated 
enzymes; documentation of CAD or documentation of 2 or more high risk 
features for CAD.^ 
ECG changes:  
− transient ST-segment elevation of 0.5mm in two or more contiguous 
leads^; 
− ST-segment depression of 0.5mm in two or more contiguous leads^ 
− new T wave inversion of 1 mm in two or more contiguous leads 
− new Q waves (1/3 height of R wave or >0.04 seconds) 
− new R wave > S wave in lead V1 (posterior MI) 
− new left bundle branch block 
Increase in cardiac enzymes:  
− increase in troponin T above the upper limit of normal; 
− increase in troponin I above the upper limit of normal; 
− CK-MB 2x upper limit of the hospitals normal range or if there is no 
CK-MB available, then total CK greater than the upper limit of 
normal.  
Documentation of coronary artery disease:  
− history of MI, angina, congestive cardiac failure due to ischaemia or 
resuscitated sudden cardiac death; 
− history of, or new positive stress test with or without imaging; 
− prior or new, cardiac catheterisation documenting coronary artery 
disease; 
− prior, or new percutaneous coronary artery intervention or coronary 
artery bypass graft surgery.  
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At least 2 of the following High Risk features^: 
− haemodynamic compromise (BP<90 and HR >100) 
− left ventricular systolic dysfunction (LVEF<0.40); 
− presence of known diabetes 
− documentation of chronic kidney disease.’ 
^ECG criteria in GRACE was 1 mm of ST-elevation or depression; high risk features of ACS were unique to the CONCORDANCE 
registry.  
 
An overview of the process undertaken for CONCORDANCE patient case-selection 
process and patient recruitment is provided in Figure 3.4, and an overview of processes 
undertaken to ensure data quality is provided in Figure 3.5. Patients were enrolled via 
individual patient consent (GRACE) or an ‘opt-out’ consent (CONCORDANCE). By 
2009 there was a growing appreciation of the importance of an opt-out consent process 
for the recruitment of patients to a clinical registry to avoid ‘cherry picking’ and to 
ensure registries could report on the receipt of all treatments and interventions and 
outcomes, and have the capacity to undertake statistical risk adjustment, and account for 
other confounding factors.  
The Human Research Ethics Committees (HREC) approved our application to move to 
an opt-out consent process for the recruitment of patients to the CONCORDANCE 
registry in order ensure there was systematic approach to the screening and recruitment 
of patients and avoid biased sampling. A waiver of consent was also approved for the 
collection of information on patients who had died as a result of an ACS during the 
screening period. The approach of consecutive patient screening and enrolment was to 
ensure the sickest, and those patients who died early during their admission, were 
included in the registry. In-hospital investigations, treatment and adverse clinical events 
were extracted from the medical record (paper and electronic medical records) and 
clinical events and hospital readmission rates at six months (and then 24 months) 
follow-up were captured via a review of the hospital admission lists and direct patient 
contact. 
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Figure 3.4  Process for CONCORDANCE patient case-selection process  
and patient recruitment  
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Figure 3.5  Process for ensuring data quality 
 
3.13 Data analysis  
Descriptive analysis in this thesis were undertaken to: 
1. Describe the in-hospital management of ACS patients enrolled in the Australian and 
New Zealand cohort of the GRACE registry 2000–2007 and observed rates of in-
hospital adverse events including death, and death and hospital readmission at six 
months.  
2. Describe the pre-hospital and in-hospital management of ST-elevation acute 
myocardial infarction (STEMI) and rates of observed, and risk-adjusted in-hospital 
adverse events, and adverse events at six months.  
3. Develop a hospital quality composite measure of performance in the management of 
ACS in Australian hospitals participating in the CONCORDANCE registry and 
confirm the association between adherence with the composite measure of 
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performance and in-hospital adverse clinical events, and death and hospital 
readmission at six months.  
Statistical methods for data analysis are described in each unit of analysis as published 
or submitted manuscripts.  
3.14 Chapter summary  
In summary, this chapter presented the conceptual framework for the thesis and case-
study constructs including the registry governance structure, hospital recruitment, 
patient case-selection, the process for ensuring data quality and the approach to data 
analysis. Both the GRACE and CONCORDANCE registries applied standard data 
definitions and data collection methods and ensured detailed information was captured 
about each patient and each participating hospital. Clinical outcomes were collected 
both during the index admission and after the index admission at six months by direct 
patient contact and by review of local hospital admission lists. In this way both 
registries were concerned with controlling for unmeasured patient selection which may 
have impacted our ability to describe the effects of multiple treatments and interventions 
on in-hospital adverse clinical events, and adverse events and hospital readmission rates 
over the medium term (six months).  
The following chapter (Chapter 4) presents the first longitudinal publication on the 
management and outcomes of patients admitted to hospital with an ACS in Australia 
and New Zealand which strengthened the case to develop an Australian ACS clinical 
registry (CONCORDANCE), and Chapter 5 presents the rationale and design of the 
CONCORDANCE registry.  
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Research
n 2009, acute coronary syndromes
(ACS) accounted for about 80 000 hos-
pital admissions and 10 000 deaths in
Australia.1 Rising levels of obesity and dia-
betes in an ageing population suggest the
number of events is likely to double by the
year 2030.2 Randomised clinical trials have
demonstrated the mortality benefit of phar-
macological and procedural interventions
for this condition, and cross-sectional stud-
ies have shown th t better adherence to
these therapies is effective in reducing mor-
tality and morbidity.3,4 However, the appli-
cation of therapeutic strategies across
different regions varies.5
In Australia and New Zealand, gaps exist
between guideline-recommended care and
the inhospital application of recommended
therapy.6,7 This information has been
derived from registry studies of disparate
populations of patients with ACS that used
different recruitment strategies from differ-
ent hospitals over varying periods of time
and are not directly comparable.
The Global Registry of Acute Coronary
Events (GRACE) recorded comprehensive
information on ACS patients from a consist-
ent cohort of Australian and New Zealand
hospitals over an 8-year period (January
2000 to December 2007). A recent analysis
of the global GRACE cohort, capturing data
to 2005, reported a direct association
between improvements in the management
of patients with ACS and significant
improvements in inhospital outcomes and
outcomes at 6 months.8 We aimed to deter-
mine whether outcomes demonstrated for
the global cohort as a whole are true for the
patient cohort recruited from Australia and
New Zealand and whether the trends
towards improvement continued through
the latter years of the registry.
METHODS
Details of the GRACE methodology have
been described previously.9
Participating Australian and New Zealand
institutions were selected to encompass a
range of facilities and geographical loca-
tions. Of the 11 centres contributing data,
six were metropolitan centres, five had pro-
vision for 24-hour percutaneous coronary
intervention (PCI) and four had onsite car-
diac surgery. By the end of the recruitment
phase in 2007, one regional centre had
acquired a cardiac catheter laboratory with
daytime PCI capabilities. One metropolitan
centre had evolved from providing only
diagnostic angiography to a 24-hour, 7-day-
per-week interventional service. Six of the
11 institutions provided data to the registry
throughout the entire enrolment period.
Patients enrolled during 2000–2007 who
had a discharge diagnosis of either ST-seg-
ment-elevation myocardial infarction
(STEMI), including new left-bundle branch
block, or non-ST-segment-elevation ACS
(NSTEACS), including non-STEMI and
unstable angina, were included in this anal-
ysis. Outcomes reported include inhospital
death, recurrent myocardial infarction,
stroke, heart failure, cardiogenic shock and
fatal or life-threatening bleeding events. Sur-
viving patients were contacted 6 months
after discharge to establish the incidence of
death, stroke, myocardial infarction and
readmission for ischaemic heart disease.
In Australia and New Zealand, partici-
pants’ informed consent was required before
the extraction of their medical information
and to facilitate follow-up. In January 2002,
the ethics committees of participating insti-
tutions agreed to waive consent in one
circumstance — so that eligible patients
who died before they could be approached
for participation in the registry could be
enrolled.
Statistical analysis
Categorical data are presented as frequencies
and percentages, and means and SDs are
provided for continuous variables. The double-
sided Cochran-Armitage test was used to
evaluate time trends at a significance level of
α= 0.05. Analyses were carried out using
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Gerard Devlin, John Elliott, Jeff Lefkowitz and David B Brieger
ABSTRACT
Objectives:  To describe temporal trends in the use of evidence-based medical 
therapies and management of patients with acute coronary syndromes (ACS) in Australia 
and New Zealand.
Design, setting and participants:  Our analysis of the Australian and New Zealand 
cohort of the Global Registry of Acute Coronary Events (GRACE) included patients with 
ST-segment-elevation myocardial infarction (STEMI) and non-ST-segment-elevation ACS 
(NSTEACS) enrolled continuously between January 2000 and December 2007 from 11 
metropolitan and rural centres in Australia and New Zealand.
Results:  5615 patients were included in this analysis (1723 with STEMI; 3892 with 
NSTEACS). During 2000–2007 there was an increase in the use of statin therapy, 
angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and 
thienopyridines (P < 0.0001 for each). Among patients with STEMI, there was an increase 
in emergency revascularisation with PCI (from 11% to 27% [P < 0.0001]), and inhospital 
coronary angiography (from 61% to 76% [P < 0.0001]). Among patients with NSTEACS, 
there was an increase in revascularisation with PCI (from 20% to 25% [P = 0.004]). Heart 
failure rates declined substantially among STEMI and NSTEACS patients (from 21% to 
12% [P = 0.0002], and from 13% to 4% [P < 0.0001], respectively) as did rates of hospital 
readmission for ischaemic heart disease at 6 months (from 23% to 9% [P = 0.0001], and 
from 24% to 15% [P = 0.0001], respectively).
Conclusions:  From 2000 to 2007 in Australia and New Zealand, there was a fall in 
inhospital events and 6-month readmissions among patients admitted with ACS. This 
showed an association with improved uptake of guideline-recommended medical and 
interventional therapies. These data suggest an overall improvement in the quality of 
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care offered to contemporary ACS patients in Australia and New Zealand.
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SAS (SAS Institute Inc, Cary, NC, USA), and
SPSS software, version 16.0 (SPSS Inc, Chi-
cago, Ill, USA). GRACE risk scores were
calculated as previously reported.10
Data were greater than 97% complete for
all variables, with the exception of Killip
Class, which was complete for 93.7% of
patients. Six-month follow-up data and out-
comes are reported for all patients, includ-
ing those who were enrolled before the
consent waiver was applied in 2002.
RESULTS
From 2002 to 2007, a total of 5615 patients
with a diagnosis of STEMI (1723) or
NSTEACS (3892) were recruited from nine
Australian centres and two New Zealand
centres. The age and sex distribution of the
patients did not change over time (Box 1).
Although there were some variations in
baseline characteristics, the GRACE risk
score predicting in-hospital mortality did
not change in either cohort over time.
Management practices for STEMI
Medical management
From 2000–2007 among patients with
STEMI, our data showed a 15.6% decline in
the use of unfractionated heparin
(P < 0.0001) and a non-significant 5.3%
increase in the use of low-molecular-weight
heparin (Box 2). Use of glycoprotein (GP)
IIb/IIIa receptor antagonists increased by
6.3% during 2000–2005, after which the
rate of use declined by the end of 2007,
returning to a similar rate of use as in 2000
(Box 2). Treatment with aspirin remained
high throughout 2000–2007. Prescription
of a thienopyridine derivative (clopidogrel
or ticlopidine) increased significantly from
27.6% in 2000 to 80.4% in 2007
(P < 0.0001). This rise was influenced by an
increase in the use of thienopyridines for
medically managed patients (P < 0.0001).
Prescription of statin therapy increased by
24.0% overall (P < 0.0001), and prescription
of angiotensin-converting enzyme (ACE)
inhibitors or angiotensin receptor blockers
(ARBs) increased by 13.3% (P < 0.0001).
There was no significant change in the
prescription of β-blockers during this period
(Box 2).
Revascularisation
Reperfusion with primary PCI increased by
15% (P < 0.0001), accompanied by an over-
all decrease in fibrinolytic therapy of 26%
(Box 3). The rates of rescue PCI (for failed
thrombolysis) remained constant (Box 3).
1 Characteristics for patients treated for STEMI and NSTEACS between 2000 
and 2007, at baseline and at the end of the study period
STEMI* NSTEACS*
2000–2001 
(n = 533)
2006–2007 
(n = 306) P†
2000–2001 
(n = 1069)
2006–2007 
(n = 800) P†
Demographics
Men 375 (70.4%) 233 (76.1%) 0.07 718 (67.2%) 534 (66.7%) 0.78
Age, mean 64.1 63.2 0.30 64.1 63.2 0.33
Medical history
Prior MI 93 (17.5%) 59 (19.3%) 0.51 449 (42.0%) 318 (39.8%) 0.37
Prior CHF 34 (6.4%) 20 (6.5%) 0.93 143 (13.4%) 101 (12.6%) 0.61
Angina 208 (39.0%) 64 (20.9%) < 0.0001 746 (70.0%) 419 (52.4%) < 0.0001
Prior CABG surgery 25 (4.7%) 19 (6.2%) 0.33 233 (21.8%) 144 (18.0%) 0.04
Prior PCI 37 (7%) 21 (6.9%) 0.96 186 (17.4%) 175 (22.0%) 0.01
Hypertension 246 (46.2%) 156 (50.9%) 0.17 616 (57.6%) 509 (63.6%) 0.005
Diabetes (type 1 or 2) 107 (20.1%) 68 (22.2%) 0.47 280 (26.2%) 235 (29.4%) 0.12
Hyperlipidaemia 219 (41.1%) 140 (46.0%) 0.16 627 (58.7%) 519 (65.0%) 0.006
Renal impairment 18 (3.4%) 13 (4.2%) 0.51 77 (7.2%) 64 (8.0%) 0.50
Smoker (current) 169 (31.7%) 97 (31.7%) 0.64 211 (19.7%) 153 (19.1%) 0.01
Smoker (ex) 345 (64.7%) 188 (61.4%) 0.28 664 (62.2%) 488 (61.0%) 0.45
Prior TIA/stroke 51 (9.6%) 19 (6.2%) 0.08 127 (12.0%) 106 (13.3%) 0.39
PVD 40 (7.5%) 16 (5.2%) 0.19 118 (11%) 51 (6.4%) 0.0005
Index ECG result
ST elevation 462 (86.7%) 249 (81.4%) 0.03 54 (5.1%) 32 (4.0%) 0.28
LBBB 31 (5.8%) 30 (9.8%) 0.03 86 (8.0%) 43 (5.4%) 0.02
Abnormal for 
ischaemia 
511 (95.9%) 293 (95.8%) 0.93 696 (65.1%) 439 (54.9%) < 0.0001
ST deviation (non-
specific)
478 (89.7%) 265 (86.6%) 0.17 291 (27.2%) 204 (25.5%) 0.40
ST depression 265 (49.7%) 125 (41.0%) 0.01 245 (22.9%) 181 (22.6%) 0.88
T wave inversion 158 (29.6%) 51 (16.7%) < 0.0001 338 (31.6%) 202 (25.3%) 0.002
Physical characteristic
Systolic BP, mean (SD) 139.5 (28.6) 140.5 (30.8) 0.64 139 (28.6) 140 (30.8) 0.64
Diastolic BP, mean (SD) 81.4 (18.1) 81.9 (19.1) 0.73 81.4 (18.1) 81.9 (19.0) 0.70
Heart rate, mean (SD) 78.5 (21.0) 79.9 (30.8) 0.38 78.5 (21.0) 79.9 (23.3) 0.38
Killip Class I 409 (77.8%) 224 (81.8%) 0.13 823 (77.6%) 611 (83.7%) 0.0014
Killip Class II–IV 117 (22.2%) 50 (18.2%) 0.18 238 (22.4%) 119 (16.3%) 0.0014
Cardiac arrest 22 (4.2%) 12 (4.0%) 0.88 7 (0.7%) 13 (1.6%) 0.04
Laboratory test
Positive initial cardiac 
enzymes
251 (47.1%) 199 (65.9%) < 0.0001 319 (30.0%) 361 (45.4%) < 0.0001
Serum creatinine 
(μmol/L ), mean (SD)
81 (53.0) 97 (44.0) < 0.0001 81 (53.0) 103 (44.0) < 0.0001
Serum cholesterol 
(mmol/L), mean (SD)
5.3 (1.2) 4.9 (1.2) 0.0002 5.3 (1.2) 4.9 (1.2) < 0.0001
GRACE risk score‡ (SD) 139.6 (35.7) 139.1 (36.9) 0.18 121.7 (35.6) 122 (35.7) 0.15
Data in italics were calculated using a different denominator owing to missing data. BP = blood pressure. 
CABG = coronary artery bypass graft. CHF = congestive heart failure. ECG = electrocardiogram. GRACE =Global 
Registry of Acute Coronary Events. LBBB =left-bundle branch block. MI =myocardial infarction. 
NSTEACS = non-ST-segment-elevation myocardial infarction. PCI =percutaneous coronary intervention. 
PVD =peripheral vascular disease. STEMI = ST-segment-elevation myocardial infarction. TIA = transient 
ischaemic attack. * Figures are no. (%) unless otherwise stated. † P<0.05 significant. ‡ For inhospital morbidity. ◆
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Overall coronary angiography rates during
admission increased by 15.0% (P < 0.0001)
and overall PCI rates increased by 17.0%
(P < 0.0001) while coronary artery bypass
graft (CABG) surgery rates remained
unchanged (Box 2).
Outcomes among patients with STEMI
Overall, data from 2000–2007 that did not
include patients who died soon after admis-
sion during the early years of the registry
showed no change in inhospital mortality
(Box 4). After the introduction of the con-
sent waiver in 2002, collection of more
complete mortality data was possible.
Between 2002 and 2007, there was a 3.9%
reduction in in-hospital deaths (P = 0.04),
and a significant decline in stroke (P =
0.004), although the numbers reported for
stroke were small (Box 4). There was an
8.2% reduction in congestive heart failure
events in hospital (P = 0.003), and there was
no change in fatal or life-threatening bleed-
ing event rates or episodes of acute renal
failure (Box 4). Among the cohort of
patients surviving to hospital discharge, the
incidences of death and stroke at 6-month
follow-up did not change between 2000 and
2007; there was, however, a 4.2% reduction
in rates of reported MI (P = 0.01) and a
13.1% reduction in hospital readmissions
for ischaemic heart disease (P < 0.0001).
Management practices for NSTEACS
Medical management
From 2000 to 2007 among people with
NSTEACS, the inhospital use of unfrac-
tionated heparin declined by 20.2%
(P < 0.0001) but use of low-molecular-
weight heparin did not change (P = 0.33)
(Box 2). Use of GP IIb/IIIa receptor antag-
onists fluctuated between 2000 and 2007,
with a peak use in 10.1% of participants
during 2004–2005, and then a fall to 7.0%
during 2006–2007. The overall trend was
significant (P = 0.01) (Box 2). Thienopyrid-
ine use increased by 43.6% (P < 0.0001)
overall, and by 37.4% in patients who did
not undergo PCI (P < 0.0001). Prescription
of aspirin remained consistently high, β-
blocker therapy increased by about 10%
(P = 0.01) and the prescription of both statin
and ACE inhibitors or ARBs increased by
about 20% (P < 0.0001 for both) (Box 2).
Revascularisation
Between 2000 and 2007 there was a 3.9%
increase in coronary angiographic pro-
cedures (P = 0.03) and a 5.5% increase in
revascularisation with PCI (P = 0.004).
Revascularisation with CABG surgery
remained unchanged.
Outcomes among patients with 
NSTEACS
Throughout 2000–2007, inhospital mor-
tality rates for patients with NSTEACS
were low (Box 4). When the analysis was
limited to patients who were recruited
after the consent waiver in 2002, there was
a 1.8% reduction in inhospital mortality
(P = 0.04). There was also a significant
reduction in episodes of heart failure for
this period (P = 0.0001). Inhospital stroke
and MI rates remained unchanged. Out-
comes at 6 months following hospital dis-
charge revealed an overall fall in the rates
of death (P = 0.02), stroke (P = 0.001) and
an 8.7% reduction in hospital readmission
rates  for  i schaemic hear t  d isease
(P < 0.0001) (Box 4).
DISCUSSION
Our analysis of data from this large cohort of
patients provides evidence of substantial
2 Changes in medical therapy for patients treated for STEMI and NSTEACS, 
2000–2007
Total no. of patients (%)
2000–2001 2002–2003 2004–2005 2006–2007 P for trend*
STEMI n = 533 n = 369 n = 354 n = 306
Aspirin (excl CI) 501 (94.0%) 333 (90.2%) 337 (96.3%) 291 (95.0%) 0.43
β-blocker (excl CI) 415 (78.0%) 290 (78.5%) 259 (73.0%) 259 (85.0%) 0.60
Statin 344 (64.5%) 295 (80%) 314 (89.0%) 269 (88.5%) < 0.0001
ACE inhibitor/ARB 355 (67.0%) 275 (74.5%) 274 (77.8%) 237 (80.3%) < 0.0001
Total LMWH 241 (45.5%) 193 (52.3%) 180 (51.5%) 155 (50.8%) 0.13
UFH 377 (71.5%) 235 (63.7%) 213 (60.3%) 170 (55.9%) < 0.0001
Thienopyridine (total) 146 (27.6%) 207 (56.1%) 248 (70.3%) 246 (80.4%) < 0.0001
Thienopyridine (without PCI) 14 (2.6%) 65 (17.6%) 86 (24.3%) 106 (34.6%) < 0.0001
GP IIb/IIIa receptor 
antagonists
111 (20.8%) 97 (26.3%) 96 (27.1%) 68 (22.0%) 0.06
Calcium channel blockers 59 (11.1%) 32 (8.7%) 20 (5.6%) 32 (10.5%) 0.10
Coronary angiography 324 (60.8%) 255 (69.1%) 288 (81.4%) 232 (75.8%) < 0.0001
PCI (all) 192 (36.0%) 169 (45.8%) 204 (57.6%) 162 (53.0%) < 0.0001
CABG surgery 48 (9.0%) 46 (12.5%) 28 (7.9%) 19 (6.2%) 0.09
NSTEACS n = 1069 n = 849 n = 811 n = 800
Aspirin (excl CI) 954 (89.2%) 712 (83.8%) 731 (90.1%) 732 (91.5%) 0.11
β-blocker (excl CI) 772 (72.2%) 652 (76.8%) 653 (80.6%) 654 (81.8%) 0.01
Statin 699 (65.4%) 684 (80.6%) 690 (85.1%) 683 (84.4%) < 0.0001
ACE/ARB antagonist 557 (52.1%) 512 (60.3%) 523 (64.5%) 574 (71.8%) < 0.0001
Total LMWH 768 (71.8%) 635 (74.8%) 581 (71.6%) 595 (74.4%) 0.33
UFH 449 (42.0%) 309 (36.4%) 239 (29.5%) 174 (21.8%) < 0.0001
Thienopyridine (total) 209 (19.5%) 378 (44.5%) 432 (53.3%) 505 (63.1%) < 0.0001
Thienopyridine (without PCI) 72 (6.7%) 225 (26.5%) 258 (31.8%) 353 (44.1%) < 0.0001
GP IIb/IIIa receptor 
antagonists
69 (6.5%) 69 (8.1%) 82 (10.1%) 56 (7.0%) 0.01
Calcium channel blockers 318 (29.8%) 185 (21.8%) 203 (25.0%) 209 (26.1%) 0.01
Coronary angiography 574 (53.7%) 500 (58.9%) 491 (60.5%) 461 (57.6%) 0.03
PCI 212 (19.8%) 234 (27.6%) 222 (27.4%) 202 (25.3%) 0.004
CABG surgery 120 (11.2%) 114 (13.4%) 101 (12.5%) 79 (9.9%) 0.39
Total revascularisation 337 (31.5%) 345 (40.6%) 321 (39.6%) 287 (35.9%) 0.04
Data in italics were calculated using a different denominator owing to missing data. ACE = angiotensin-
converting enzyme. ARB = angiotensin-II receptor blocker. CABG = coronary artery bypass graft. Excl CI =
excluding contraindications. GP = glycoprotein. LMWH = low-molecular-weight heparin. PCI = percutaneous 
coronary intervention. NSTEACS = non-ST-segment-elevation acute coronary syndrome. STEMI =
ST-segment-elevation myocardial infarction. UFH = unfractionated heparin. * P < 0.05 significant. ◆
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improvement in outcomes in Australian and
New Zealand patients with ACS over an 8-
year period from 2000 to 2007. This was
accompanied by an increase in the uptake of
evidence-based medical therapies.
In Australia and New Zealand there has
been limited opportunity to describe and
follow management and outcomes in well
defined ACS populations. This reflects a
lack of organised state and national regis-
tries coupled with limited funding for clini-
cal data collection at an institutional level.
Our analysis represents the first opportunity
to evaluate changes in practice patterns and
outcomes in a well defined population of
ACS patients in Australia and New Zealand
over time, and is the largest cohort to date.
The local cohort was limited to 11 parti-
cipating institutions, restricting the extra-
polation of results across either country as a
whole. However, our data are very similar to
those from other national ACS registries that
recruited patients during this period. Addi-
tionally, it is likely that unmeasured pre- and
posthospital factors, such as improved pri-
mary and secondary risk-factor management
in the Australian and New Zealand popula-
tions as a whole, contributed to improve-
ment in outcomes, and this information was
not collected in the hospital-based GRACE
registry.
During the 8 years of data collection for
this study there were significant changes in
patient management, particularly in the
uptake of specific evidence-based medical
therapies. The use of thienopyridines
increased incrementally over time, predom-
inantly in medically managed patients. Our
data showed a significant increase in the use
of statin therapy among patients with
STEMI and patients with NSTEACS follow-
ing outcomes of secondary prevention trials
coupled with more recent studies advocat-
ing the benefits of commencing lipid-lower-
ing therapy early during hospitalisation for
an ACS.11-14
The implementation of all evidence-based
guideline-recommended therapies among
patients in our study was non-uniform, in
particular, the use of intravenous heparin
and GP IIb/IIIa receptor-antagonist therapy,
which fell among patients with NSTEACS
after 2005. The low use of GP IIb/IIIa
therapy has been a consistent feature of
Australian and New Zealand practice,
despite local guidelines supporting its
use.7,15,16 The lack of enthusiasm for GP IIb/
IIIa therapy may be driven by cost con-
straints, together with concerns that the
reduction in cardiovascular events is offset
4 Changes in clinical outcomes for patients with STEMI and NSTEACS, 2000–2007
Total no. of patients (%)
2000–2001 2002–2003 2004–2005 2006–2007 P for trend*
STEMI n = 529 n = 369 n = 354 n = 306
Inhospital death 20 (3.8%) 33 (8.9%) 26 (7.4%) 15 (5.0%) 0.32
Stroke 4 (0.8%) 9 (2.4%) 4 (1.1%) 0 0.32
Cardiogenic shock 18 (3.4%) 25 (7.0%) 25 (7.1%) 12 (4.0%) 0.36
MI > 24hrs after presentation 0 14 (3.8%) 8 (2.3%) 13 (4.2%) 0.20
CHF/pulmonary oedema 111 (21.0%) 76 (20.6%) 47 (13.3%) 38 (12.4%) 0.0002
Renal failure 23 (4.3%) 21 (5.7%) 19 (5.4%) 16 (5.2%) 0.52
Major bleeding event† 7 (1.3%) 8 (2.2%) 7 (2.0%) 3 (1.0%) 0.88
Outcomes from discharge to 6 months
Death 23 (4.3%) 12 (3.3%) 5 (1.4%) 9 (2.9%) 0.13
Stroke 11 (2.1%) 4 (1.1%) 1 (0.3%) 3 (1.1%) 0.08
MI 22 (5.2%) 10 (3.3%) 7 (2.3%) 5 (1.0%) 0.01
Readmission for IHD 119 (22.5%) 73 (19.8%) 48 (13.5%) 29 (9.4%) < 0.0001
NSTEACS n = 1045 n = 849 n = 811 n = 800
Inhospital death 12 (1.1%) 35 (4.1%) 34 (4.2%) 18 (2.3%) 0.06
Stroke 5 (0.5%) 1 (0.1%) 5 (0.6%) 1 (0.1%) 0.52
Cardiogenic shock 5 (0.5%) 11 (1.3%) 22 (2.7%) 10 (1.3%) 0.01
MI > 24 hrs after presentation 0 6 (0.7%) 7 (0.9%) 9 (1.1%) 0.92
CHF/pulmonary oedema 138 (13.2%) 78 (9.2%) 62 (7.6%) 33 (4.1%) 0.0001
Renal failure 20 (1.9%) 30 (3.5%) 31 (3.8%) 20 (2.5%) 0.25
Major bleeding event 13 (1.2%) 6 (0.7%) 9 (1.1%) 7 (0.9%) 0.62
Outcomes from discharge to 6 months
Death 57 (5.5%) 30 (3.5%) 18 (2.2%) 22 (2.8%) 0.02
Stroke 21 (2.0%) 9 (1.1%) 6 (0.7%) 3 (0.4%) 0.001
MI 37 (3.5%) 33 (3.9%) 24 (3.0%) 30 (3.8%) 0.83
Readmission for IHD 249 (23.8%) 163 (19.2%) 132 (16.3%) 121 (15.1%) < 0.0001
Data in italics were calculated using a different denominator owing to missing data. CHF = congestive heart 
failure. CV = cardiovascular. IHD = ischaemic heart disease. MI = myocardial infarction. NSTEACS =
non-ST-segment-elevation acute coronary syndrome. STEMI = ST-segment-elevation myocardial infarction. 
* P < 0.05 significant. † Fatal or life-threatening. ◆
3 Temporal trends in reperfusion therapy for patients with ST-segment-elevation 
myocardial infarction from Jan 2000 to Dec 2007
PCI = percutaneous coronary intervention. ◆
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by an increased bleeding risk in the presence
of combination oral antiplatelet therapy.7,16
This observation serves to highlight the
reality of physicians applying the guidelines
selectively as they use their clinical judge-
ment when choosing appropriate therapies
for their patients.17,18 The factors that influ-
ence this decision-making process warrant
further study.
One of the main practice changes in the
management of STEMI in urban centres has
been the evolution from fibrinolysis as the
predominant treatment to primary PCI.19,20
Among the Australian and New Zealand
cohort we found a 26% reduction in fibri-
nolysis, accompanied by only a 15%
increase in primary PCI. This apparent fall
in total reperfusion may in fact be artefac-
tual. A significant proportion of STEMI
patients (10%–25%), who according to
earlier accepted practice would have
received fibrinolysis, undergo angiography
and turn out to have minor coronary dis-
ease or disease that is not amenable to
percutaneous revascularisation, and there-
fore do not receive PCI.21,22 As recruitment
ended in 2007, there may have been insuf-
ficient time to determine the impact of
additional access to PCI on the absolute
increase in PCI rates and the corresponding
decrease in fibrinolysis.
A second notable observation from our
analysis was the modest increment in coro-
nary angiography and PCI offered to
patients with NSTEACS, with no increase in
CABG surgery during the study period. This
failure to offer coronary angiography and
subsequent revascularisation may be due in
part to clinicians’ uncertainty of the risk
versus the benefit of undergoing an inter-
ventional procedure, particularly for higher-
risk patients who are not well represented in
the randomised trials.18 It would seem that
this concern is unfounded, as multiple lines
of evidence suggest the higher the stratified
risk for an ACS, the greater the benefit from
an invasive strategy.23,24
Despite limited application of evidence-
guided therapies during the 8 years of data
collection for this study, we observed signi-
ficantly reduced inhospital heart failure epi-
sodes among patients with STEMI and
patients with NSTEACS. These data are not
implausible and reflect findings in the over-
all GRACE cohort.8 A recent Australian
Institute of Health and Welfare (AIHW)
analysis reported a 20% decline in hospital
admission among patients with heart failure
between the financial years 1996–07 and
2003–04, thought to be due, among other
things, to improvements in heart failure
treatment.25 It is plausible that improve-
ments in revascularisation, together with
increased use of ACE inhibitors, are contrib-
uting to reduce acute heart failure among
patients with ACS.
Additionally, with the collection of more
complete mortality data from 2002 onward,
a fall in hospital mortality was evident in
both groups of patients. These mortality
data are consistent with a recent Access
Economics report derived from AIHW data
suggesting a fall in 28-day mortality for ACS
patients in Australia of about 0.5% per year
from 2004 to 2009.1 Among patients with
STEMI or NSTEACS who survived to hospi-
tal discharge and were contacted after 6
months, there was a reduction in hospital
readmissions for ischaemic heart disease,
and a fall in stroke among those with
NSTEACS. These data point to an overall
salutary effect associated with the improve-
ment in the quality of care offered to con-
temporary ACS patients in Australia and
New Zealand.
Further study is required to evaluate
whether the improvements in therapies are
appropriately directed towards the highest-
risk patients. Important practice gaps
remain, particularly in the provision of
emergency reperfusion for STEMI and revas-
cularisation for NSTEACS. Future efforts
should be directed toward identification of
the patient-, clinician- and system-related
factors that impede practice improvement in
these areas.
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Background: Cardiovascular observational registries characterise patients and describe the manner and use of therapeu-
tic  strategies. They facilitate analyses on the quality of care among participating institutions and document variations in
clinical  practice which can be benchmarked against best practice recommendations. The Cooperative National Registry
of  Acute Coronary care, Guideline Adherence and Clinical Events (CONCORDANCE) is  an Australian observational
registry that describes management and outcomes in patients with acute coronary syndromes (ACS) and feeds back both
performance  and outcome measures to participating hospitals.
Methods:  The CONCORDANCE registry has been designed within a comparative effectiveness research (CER) frame-
work  to  collect and report data from hospitals located in geographically diverse regions of Australia. Information
including  patient demographics, presenting characteristics, past medical history, in-hospital management and outcomes
at  six months and two years are entered into a web-based database using an electronic clinical record form (eCRF).
Individual  hospital information is returned to the sites in a real time conﬁdential report detailing information on key
performance  Indicator (KPI) process measures and outcomes benchmarked against the aggregated study cohort. Gov-
ernance  rules ensure data security and protect patient and clinician conﬁdentiality. Consistent with a CER framework,
additional characteristics of the registry include: (a) the capacity to evaluate associations between the inter and intra
hospital  systems and the provision of evidence based care and outcomes, (b) ongoing data collection from representative
hospitals which allow spatial and temporal analysis of change in practice and the application of treatment modalities in
the  real world setting and (c) the provision of a data spine for  quality improvement strategies and practical clinical trials.
Conclusion:  The CONCORDANCE registry is a clinician-driven initiative describing clinical care for ACS patients
admitted to Australian hospitals. The registry generates high quality data which is fed back to clinicians, and key
stakeholders  in ACS care. Using a CER approach, the registry describes the translation of randomised trial evidence into
practice,  and provides insights into strategies that could improve care and ultimately patient outcomes.
(Heart,  Lung and Circulation 2013;xxx:1–9)
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Introduction
In  Australia,  acute  myocardial  infarction  (AMI)accounted  for  more  than  56,000  hospitalisations
between  2007  and  2008  with  an  additional  39,000  hospi-
talisations  for  unstable  angina  (UA)  [1].  It  is  estimated
that  19%  of  the  Australian  population  have  a  long-term
cardiovascular  condition  and  approximately  1.4  mil-
lion  Australians  have  a  disability  associated  with  the
Crown  Copyright  ©  2013  Published  by  Elsevier  Inc  on  behalf  of  Aus-
tralian  and  New  Zealand  Society  of  Cardiac  and  Thoracic  Surgeons
(ANZSCTS)  and  the  Cardiac  Society  of  Australia  and  New  Zealand
(CSANZ).  All  rights  reserved.
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disease  [2,3]. Although  mortality  rates  from  cardiovascu-
lar  disease  are  falling,  an  ageing  population  and  the  rising
prevalence  of  risk  factors  such  as  obesity  and  diabetes
means  that  the  future  burden  of  CVD  is  likely  to  remain
substantial,  reﬂected  by  increasing  hospital  separations
for  ACS  and  spiralling  health  care  expenditure  for
cardiovascular  conditions  [2].
Available  Australian  data  suggest  many  who  experience
an  ACS  event  do  not  receive  optimal  care.  For  example,
30%  of  patients  with  ST  elevation  myocardial  infarction
(STEMI)  fail  to  receive  reperfusion  therapy  [4,5]  and  the
discordance  between  assessed  risk  level  and  the  intensity
of  treatment  received  by  non  ST  elevation  acute  coronary
syndrome  (NSTEACS)  patients  suggests  risk  stratiﬁcation
is  often  poorly  performed  [6,7].  Less  than  60%  of  ACS
patients  are  referred  to  cardiac  rehabilitation  [8]  despite
the  proven  reduction  in  rates  of  readmission,  repeat  revas-
cularisation  and  mortality  associated  with  the  use  of  these
programmes  [9].  Our  unique  geographic,  demographic
and  complex  state/federal  systems  provide  obstacles  to
uniform  health  care  delivery.  Systematic  and  systemic
improvement  in  health  care  for  all  Australians  is  not  pos-
sible  without  robust  methods  to  measure  and  report  on
the  quality  of  care.
In  Australia,  nationally  reported  measures  on  hospital-
based  care  of  ACS  are  currently  derived  from  hospital
administrative  datasets.  These  data  are  retrospective  and
reported  with  lengthy  delays,  use  complex  coding  meth-
ods  of  varying  accuracy  and  often  have  limited  relevance  to
clinical  practice  [10].  For  instance,  one  key  quality  measure
derived  from  these  datasets  has  been  the  standardised
mortality  rate  [11].  This  is  a  relatively  blunt  tool  as  con-
temporary  in-hospital  mortality  from  ACS  occurs  in  fewer
than  3%  of  the  admitted  population  [4],  and  the  provi-
sion  of  poor  quality  care  rarely  results  in  in-hospital  death,
but  is  more  likely  to  impact  on  morbidity  or  longer  term
mortality  [10].  Prognosis/risk  not  measured  in  case-mix
reports  inﬂuences  the  quality  processes  being  measured
across  hospitals  just  as  the  differences  in  process  measure
deﬁnitions  and  the  manner  in  which  they  are  applied  as
hospital  performance  measures  contribute  to  the  variation
in  case-mix  adjustment.  Moreover,  some  hospitals  should
be  excluded  from  risk-standardised  comparisons  as  they
have  insufﬁcient  patients  with  the  disease  to  ensure  a  dif-
ference  in  outcomes  is  measureable  with  any  precision
[12].  The  absence  of  comprehensive  Australian  national
standards  for  the  evaluation  of  quality  of  care  in  ACS  mean
associations  between  hospital  performance,  quality  of  care
and  patient  outcomes  cannot  be  inferred  [13].
There  are  well  described  process  measures  for  evalu-
ating  performance  of  the  individual  steps  along  the  ACS
care  pathway  with  demonstrated  high  validity  and  reliabil-
ity  [14].  These  measures  are  relevant  to  all  ACS  patients,
are  well  proven  surrogates  for  both  short  and  long  term
outcomes  [15]  and,  provide  a  readily  identiﬁable  target  for
quality  improvement  initiatives.
Information  on  these  process  measures  is  best  acquired
through  interrogation  of  the  clinical  record  of  individ-
ual  patients,  which  may  then  be  aggregated  in  a  clinical
registry.  Indeed,  our  understanding  of  the  beneﬁts  of
adherence  to  evidence-based  therapies  and  best  practice
recommendations  has  been  informed  by  observational
registries  in  the  past  [4,5,16–20].  In  Australia,  the  Acute
Coronary  Syndrome  prospective  Audit  (ACACIA)  and
Heart  Protection  Partnership  (HPP)  provided  time-point
insights  into  clinical  practice  patterns  in  a  dynamic  land-
scape.  The  Global  Registry  of  Acute  Coronary  Events
(GRACE)  recently  reported  temporal  changes  in  practice
patterns  and  patient  outcomes  for  ACS  patients  from
Australia  and  New  Zealand  between  1999  and  2007  [4].
These  vehicles  for  observational  data  collection  have  now
concluded,  leaving  a  void  in  our  ability  to  document  con-
temporary  ACS  care.
The  CONCORDANCE  Registry
The  CONCORDANCE  Registry  is  an  ongoing  (prospec-
tive)  clinical  initiative  that  provides  continuous  real-time
reporting  on  the  clinical  characteristics,  management  and
outcomes  of  hospitalised  ACS  patients  to  clinicians,  hospi-
tal  administrators,  sponsors/interested  stakeholders  and,
upon  request,  to  government.  The  speciﬁc  objectives  of
the  registry  are:  to  provide  data  to  health  care  providers
describing  change  in  practice  patterns  overtime;  to  docu-
ment  and  inform  the  appropriate  use  of  medications  in  the
Australian  ACS  population,  including  higher  risk  subsets
not  well  represented  in  clinical  trials;  to  inform  improve-
ments  in  the  effectiveness  of  care  by  understanding  the
association  between  systems  of  care  delivery  and  health
outcomes,  and  to  provide  a  platform  for  research  initia-
tives  including  develop  an  ACS  patient  bio-bank  (Table  1).
Registry  Design  (Fig.  1)
Participating  Centres
Ongoing  data  collection  from  representative  hospitals
facilitates  spatial  and  temporal  analysis  of  change  in
practice  and  the  application  of  treatment  modalities  in
the  real  world  setting.  The  cohort  of  participating  centres
currently  includes  20  hospitals  representative  of  regional
and  metropolitan  acute  care  facilities  with  a  range  of
clinical  and  treatment  characteristics,  procedural  services
and  hospital  systems  (Table  2).  To  meet  our  strategic
objectives,  a  purposive  sampling  strategy  was  adopted
to  include  hospitals  serving  Indigenous  patients,  hos-
pitals  in  metropolitan,  rural  and  remote  locations,  and
those  with  and  without  cardiac  catheterisation  labs  and
percutaneous  interventional  (PCI)  capabilities.  We  also
sought  to  recruit  hospitals  that  had  demonstrated  a  sen-
tinel  capacity  for  the  implementation  of  quality  initiatives
[21,22].
Patient  Identiﬁcation
In  order  to  reﬂect  a  true  ACS  population  with  objective
evidence  of  coronary  disease,  clearly  deﬁned  inclusion
criteria  [23]  have  been  adopted  and  sites  recruit  the
ﬁrst  10  consecutive  patients  admitted  with  a  diagnosis
of  ACS  from  the  beginning  of  each  month.  This  prag-
matic  approach  [17]  is  coupled  with  safeguards  to  ensure
unbiased  patient  recruitment.  These  measures  include  an
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Table  1.  CONCORDANCE  Registry  Objectives.
CONCORDANCE Registry Objective Corresponding CONCORDANCE Registry Initiative
Registry Objective 1: To provide data to health care
providers and hospitals to characterise existing and
evolving practice patterns, delivery of care, and resource
utilisation in the management of ACS across Australia
• Site reports are provided to participating centres as on line real-time
KPI, patient demographic, pre-hospital treatment, in-hospital treatment
and in-hospital event reports. Evidence based benchmarks are used to
calculate these KPI’s (see supplement). These reports document site
adherence to guideline recommended treatment and may be used by the
site as a quality improvement tool
• The Qualitative Evaluation of ACS processes of care sub-study
reports on resource utilisation in the management of ACS Nationally
Registry Objective 2: To document the
association between systems of delivery of
care as determined at government, area and
individual hospital levels and implementation
of evidence based guidelines
•  The Qualitative Evaluation of ACS processes of care sub-study
includes detailed interviews with clinicians and hospital administrators
regarding the enablers and barriers to performance at the hospital level
Registry Objective 3: To document and inform the
appropriate use of medications in the Australian ACS
population, including higher risk subsets not well
represented in clinical trials
•  The registry collects detailed information on the prescription of
evidenced based therapies both in-hospital and at hospital discharge.
Patient compliance with medical therapy is collected at 6 month and 2
year follow-up
• Limited information on medication compliance maybe acquired via
data linkage with existing datasets. More comprehensive data
acquisition is the subject of an application to the AIHW
Registry Objective 4: Identify mechanisms whereby data
collection within a hospital can be incorporated into a
sustainable component of clinical practice to allow
internal and external standards and benchmarking of
treatment patterns and patient outcomes;
•  The possibility of integrating the registry data base with hospital
databases to collect non-clinical data elements is being investigated
• A trial of providing the dataset at no cost to hospitals with a quality
improvement focus is underway
Registry Objective 5: To provide a platform for the
conduction of practical clinical trials
•  Impact of risk stratiﬁcation on the management and outcome of
patients with acute coronary syndromes. This is a quality intervention
sub-study applying a risk stratiﬁcation decision tool at the point of
admission to determine its’ impact on the choice of treatment and
intervention prescribed by clinicians on clinical outcomes over the long
term
• Randomised control trial of text messaging to improve adherence to
medical therapy following hospital discharge (TEXTMED) funding:
NHMRC Project Grant
opt-out  consent  process  and  a  consent  waiver  for  patients
who  die  or  are  too  ill  to  provide  consent  (see  Ethics  and
Privacy  section).  Additionally,  a  broad  screening  approach
from  hospital  admission  lists  has  been  implemented.  Dis-
charge  lists  are  screened  for  records  of  patients  admitted
to  hospital  with  a  suspected  ACS  to  determine  those  who
have  died  as  a  result  of  an  ACS  event.  Detailed  screening
and  enrolment  logs  are  maintained  and  these  are  reviewed
for  consistency  at  regular  intervals  by  the  Study  Coordinat-
ing  Centre.  Each  year,  a  sample  of  de-identiﬁed  screening
logs  is  audited  by  the  Study  Coordinating  Centre  during
the  site  visits.
Patient  Inclusion  Criteria
The  CONCORDANCE  patient  enrolment  criteria  are
evidence-based  [23]  and  consistent  with  other  national
and  international  ACS  registries  [24].  Patients  older  than  18
years  of  age  admitted  to  hospital  with  an  ACS  including  ST
elevation  Myocardial  Infarction  (STEMI),  Non  ST  eleva-
tion  ACS  (NSTEACS)  are  eligible.  Enrolled  patients  must
have  at  least  one  of  the  subsequent  criteria:  electrocar-
diographic  (ECG)  changes,  elevated  cardiac  biomarkers,
a  previous  history  of  coronary  heart  disease  (CAD),
new  documentation  of  CAD  or  two  high  risk  features
predictive  of  recurrent  in-hospital  events  (Table  3).
Patients  with  an  ACS  event  precipitated  by  non-
cardiovascular  co-morbidity  such  as  anaemia  or  trauma
are  excluded.  Patients  transferred  into,  or  out  of,  a  registry
hospital  can  be  enrolled  regardless  of  the  time  spent  at
the  transferring  institution.
Data  Elements,  Collection  and  Quality
Standard  deﬁnitions  for  data  elements  as  deﬁned  in  the
National  Health  Data  Dictionary  (NHDD)  have  been
applied  [25].  The  information  is  entered  into  a  web-based
electronic  case  report  form  (eCRF)  and  details  pre-hospital
assessment  and  management,  patient  demographics,
admission  diagnosis,  medical  history,  in-hospital  inves-
tigations  and  management  and  in  hospital  morbidity
and  mortality.  Additionally,  six-month  and  two-year
follow-up  is  performed  with  collection  of  data  regarding
vital  status,  medication  compliance,  participation  in
cardiac  rehabilitation,  CVD  risk  reduction  interventions
and  quality  of  life  as  measured  by  the  EQ-5D  [26].
A  number  of  strategies  ensure  the  validity  (accuracy)
of  the  data.  These  include  initial  and  ongoing  training  for
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Figure 1. CONCORDANCE Registry Design.
Table  2.  Participating  Centres.
State Hospital Name Peer Group Remoteness
Area
Number of
Available
Beds
Cardiac
Cath Lab
PCI
Capable
CABG
NSW Concord Principal referral Major cities 435 1 1 0
NSW Campbelltown Principal referral Major cities 311 0 0 0
NSW Bankstown/Lidcombe Principal referral Major cities 386 0 0 0
NSW Coffs Harbour Principal referral Inner regional 222 1 1 0
NSW Dubbo Principal referral Inner regional 160 0 0 0
NSW Liverpool Principal referral Major cities 683 1 1 1
NSW Orange Principal referral Inner regional 204 1 1 0
NSW Port Macquarie Principal referral Inner regional 170 0 0 0
NSW Royal Prince Alfred Principal referral Major cities 711 1 1 1
NSW Wollongong Principal referral Major cities 428 1 1 0
NSW Westmead Principal referral Major cities 801 1 1 1
NT Alice Springs Hospital Principal referral Remote 171 0 0 0
QLD Nambour hospital Principal referral Inner regional 361 0 0 0
QLD The Prince Charles Hospital Principal referral Major cities 604 1 1 1
QLD Gold coast hospital Principal referral Major cities 855 1 1 0
SA Flinders Medical Centre Principal referral Major cities 556 1 1 1
VIC Monash Medical Centre [Clayton] Principal referral Major cities 581 1 1 1
WA Royal Perth Hospital Wellington
Street Campus
Principal referral Major cities 648 1 1 1
WA Sir Charles Gairdner Hospital Principal referral Major cities 587 1 1 1
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Table  3.  Inclusion  Criteria.
All patients must have symptoms of an ACS plus one of the following: ECG changes, elevated enzymes, previous history of CAD,
new documentation of CAD or two features of high risk ACS
Patients are eligible if they present to hospital with symptoms felt to be consistent with acute cardiac ischaemia for >10 min within
24 h of presentation to hospital plus one of the following: ECG changes; elevated enzymes; documentation of CAD or
documentation of 2 or more high risk features for CAD
ECG changes
- transient ST segment elevation of 0.5 mm in two or more contiguous leads
- ST segment depression of 0.5 mm in two or more contiguous leads
- new T wave inversion of 1 mm in two or more contiguous leads
- new Q waves (1/3 height of R wave or >0.04 s)
- new R wave > S wave in lead V1 (posterior MI)
- new left bundle branch block
Increase in cardiac enzymes
-  increase in troponin T above the upper limit of normal
- increase in troponin I above the upper limit of normal
- CK-MB 2× upper limit of the hospitals normal range or if there is no CK-MB available, then total CK
greater than the upper limit of normal
Documentation of coronary artery disease
- history of MI,  angina, congestive cardiac failure due to ischaemia or resuscitated sudden cardiac death
- history of, or new positive stress test with or without imaging
- prior or new, cardiac catheterisation documenting coronary artery disease
- prior, or new percutaneous coronary artery intervention or coronary artery bypass graft surgery
At least 2 of the following high risk features
- haemodynamic compromise (BP < 90 and HR > 100)
- left ventricular systolic dysfunction (LVEF < 0.40)
- presence of known diabetes
- documentation of chronic kidney disease (estimated GFR < 60 mls/min
Note:  The qualifying acute coronary syndrome must not be precipitated or accompanied by a co-morbidity such as trauma or major bleeding and patients
already hospitalised for any reason when the ACS develops are not eligible for enrolment in CONCORDANCE.
all  staff  involved  in  data  collection;  automated  database
functions  including  mandatory  ﬁelds,  range  checks,  and
the  generation  of  data  queries  to  enable  data  collectors  to
rapidly  retrieve  outstanding  data  items.  In  addition,  there
are  regular  meetings  between  study  management  and
data  management  staff  and  ﬁeld  audits  and  re-abstraction
of  data  from  a  random  sample  of  submitted  case  report
forms.
Reporting
Descriptive  analyses  are  available  for  review  by  partic-
ipating  institutions  in  a  real-time  electronic  site  report.
The  report  includes  more  than  35  measures  including  a
key  performance  indicator  report  (KPI).  The  pre-speciﬁed
KPIs  have  been  selected  on  the  basis  of  providing  robust
measures  of  the  effectiveness  of  systems  of  care  (for
example  time  to  access  to  coronary  angiography)  or
having  proven  associations  with  improved  clinical  out-
comes  (for  example  reperfusion  times  for  ST  elevation
myocardial  infarction)  (supplement). Using  these  reports,
individual  hospitals  are  benchmarked  against  aggregate
measures,  but  not  against  other  individual  hospitals.
Data  are  fed  back  to  senior  hospital  staff  who  have  the
opportunity  to  address  identiﬁed  evidence  treatment
gaps.  Government  (Australian  Commission  for  Quality
and  Safety  in  Healthcare,  AIHW)  and  non-government
organisations  (National  Heart  Foundation)  have  also  been
provided  with  de-identiﬁed  aggregate  information.  All
requests  for  data  are  approved  by  an  executive  of  the  Steer-
ing  Committee  (see  below)  [8].
Operational  Framework
Data  Management  and  Security
Data  are  managed  by  The  George  Institute  for  Global
Health.  The  Institute  meets  standards  relating  to  the  use  of
paperless  records  under  the  Good  Clinical  Practice  regula-
tions  and  complies  with  the  National  E-Health  Transition
Authority  (NEHTA)  standard  of  reporting  and  storing
data.  The  systems  and  processes  with  respect  to  privacy
and  data  protection  comply  with  Health  Records  and
Information  Privacy  Act  (NSW)  2002  and  Privacy  Act  (1988)
and  Information  Privacy  Principles.  Measures  to  ensure
the  integrity  of  the  stored  information  are  applied  rigor-
ously.
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Ethics  and  Privacy
Each  centre  receives  written  Human  Research  Ethics
Committee  (HREC)  approval  prior  to  participation.
When  the  registry  commenced,  local  Ethics  Committees
required  written  informed  patient  consent.  Patients  were
approached  while  hospitalised  to  consent  to  the  collection
of  their  medical  and  post  discharge  information.  A  relative
was  permitted  to  consent  to  the  collection  of  an  individ-
ual’s  medical  information  was  permitted  if  the  patient  had
limited  command  of  English.  A  waiver  of  consent  was
also  approved,  allowing  the  collection  of  information  on
patients  without  available  next  of  kin  who  were  too  ill  to
read  a  consent  form  or  died  as  a  consequence  of  an  ACS
during  their  hospital  admission.
Since  early  in  2010  (six  months  after  commencing  data
collection)  CONCORDANCE  investigators  were  permit-
ted  to  follow  an  opt-out  consent  process  which  includes  the
consent  for  follow-up  at  six  months  and  at  two  years.  This
enables  automatic  inclusion  of  patients  into  the  registry
unless  the  patient  notiﬁes  the  registry  they  do  not  wish
their  details  to  be  included.  Patients  receive  an  information
sheet  in  lay  language  detailing  the  purpose  and  methodol-
ogy  of  the  ACS  registry.  Opt-out  consent  may  be  provided
by  a  relative  if  the  patient  has  limited  command  of  English
and  a  waiver  of  consent  still  applies  for  the  collection  of
information  on  patients  who  die  as  a  consequence  of  an
ACS  during  their  hospital  admission.
The  identity  of  the  patient  remains  the  conﬁdential
information  of  the  participating  hospital,  as  follow-up
is  completed  locally  and  no  patient  identifying  data  are
held  by  the  Coordination  or  the  data  management  cen-
tres.  Patients  are  identiﬁed  by  a  unique  identiﬁer  which  is
generated  automatically  as  the  patient  is  entered  into  the
registry.
Funding
Securing  adequate  funding  and  developing  a  business
model  is  a  singularly  inﬂuential  factor  in  initiating
and  sustaining  a  clinical  registry  [27]. Funding  for  the
CONCORDANCE  Registry  has  been  provided  by  pharma-
ceutical  and  non-government  agencies  [28].  These  funds
have  been  distributed  between  project  coordination  and
database  management  and  provision  to  the  sites  with  per
patient  payments.  Pharmaceutical  sponsors  receive  peri-
odic  reports  on  the  use  of  therapies  from  aggregate  data
de-identiﬁed  to  hospital,  physician  and  patient.
Registry  Governance
The  registry  is  directed  by  a  nationally  representative
Steering  Committee  comprising  representatives  from  the
participating  centres  and  additional  members  with  exper-
tise  in  clinical  registries,  bench  research  and  public  health.
This  Committee  provides  advice  on  scientiﬁc  issues  (e.g.
relevance  of  selected  KPIs,  hypotheses  to  be  tested  and
potential  quality  improvement  initiatives  arising  from
analysis  results).  A  number  of  subcommittees  devolve
from  the  Steering  Committee  including  an  Executive
Committee;  Management  Committee;  Publications  Com-
mittee  and  Biomarker  data  bank  Committee.
CER  Related  Outcomes
In  systematically  collecting  clinically  relevant  and  stan-
dardised  information  from  a  well  deﬁned  unbiased  cohort
of  ACS  patients,  CONCORDANCE  provides  an  oppor-
tunity  to  explore  the  application  of  randomised  trial
evidence  in  clinical  practice  and  thus  forms  a  platform  for
clinical  effectiveness  research.  Speciﬁc  research  initiatives
that  have  been  embedded  into  the  registry  are  described
below.1
Qualitative  Evaluation  of  ACS  Processes  of  Care
The  qualitative  initiative  has  been  designed  to  docu-
ment  the  association  between  systems  of  care  delivery
as  implemented  at  the  individual  hospital  level  and  the
implementation  of  evidence-based  guidelines.  The  aim  is
to  describe  the  drivers  of  variations  in  practice  between
centres  and  understand  the  factors  impacting  inconsisten-
cies  in  service  delivery  across  the  country.  These  insights
are  provided  through  the  collection  of  detailed  informa-
tion  on  individual  hospital  stafﬁng  and  resource  levels  (e.g.
access  to  echocardiography,  exercise  stress  testing,  coro-
nary  angiography  and  cardiac  rehabilitation)  and  peer  to
peer  interviews  with  administrative,  medical  and  nursing
staff  at  selected  hospitals.  The  insights  gained  are  analysed
against  the  patient  level  process  measures  and  outcomes
using  mixed  qualitative  and  quantitative  methodology.
The  Aboriginal  and  Torres  Strait  Islander  Initiative
The  Aboriginal  and  Torres  Strait  Islander  initiative  is
a  sub-study  conducted  in  collaboration  with  the  Baker
IDI  in  Alice  Springs  across  hospitals  serving  large
Indigenous  populations  purposively  enrolled  in  the  CON-
CORDANCE  Registry.  Details  regarding  reported  Abo-
riginality  are  collected  permitting  comparisons  between
process  measures  and  clinical  outcomes  between  Indige-
nous  and  non-Indigenous  patients.  Because  the  registry
includes  urban,  rural  and  remote  hospitals  particular
insights  speciﬁc  to  these  Aboriginal  and  Torres  Strait
Islander  communities  in  these  locations  can  be  explored
[29].
Biomarker  Data  Bank
Although  our  prognostic  stratiﬁcation  of  patients  with
acute  coronary  syndromes  has  improved,  current  clinical
models  have  modest  discriminatory  power  in  predicting
further  acute  events  [30].  The  premise  for  the  biomarker
data  bank  is  to  determine  the  role  of  biomarkers  in
risk  stratiﬁcation  for  prediction  of  re-occurrence  of  car-
diac  events.  For  example,  further  investigation  of  urinary
11-dehydro  thromboxane  B2  is  determinant  of  stroke,
1 Centres participating in these initiatives obtain informed con-
sent from the participant. The opt-out applies only to the patient
level data obtained via the registry.
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myocardial  infarction,  or  cardiovascular  death  in  patients
at  risk  for  atherothrombotic  events  are  being  under-
taken  [31]. The  bio-bank  facilitates  further  investigation  of
plasma  oxidised  proteins  to  predict  prognosis  in  patients
with  cardiovascular  disease  [32]  and  there  is  the  oppor-
tunity  to  investigate  the  relatively  unexplored  and  a
potentially  important,  novel  marker  of  renal  dysfunction
and  oxidative  injury-Urinary  N-gal  [33].
Genetic  analyses  are  conﬁned  to  the  pre-speciﬁed
genetic  polymorphisms  such  as  allelic  variants  of
clopidogrel  absorption  and  metabolic  activation  [34],  poly-
morphism  of  the  epidermal  growth  factor  receptor  gene
(EGFR)  [35]  and  the  A1075G  polymorphism  of  the  ACE2
receptor  [36].  In  the  event  that  other  speciﬁc  mutations
are  to  be  investigated,  formal  approval  from  the  Ethics
Committee  will  be  sought.
Discussion
Effective  clinical  registries  describe  clinical  characteris-
tics,  management  practices  and  outcomes  from  a  broad
range  of  patients  and  provide  the  opportunity  to  docu-
ment,  understand,  and  potentially  improve  processes  of
care.  Informed  by  previous  local  registry  initiatives  includ-
ing  GRACE,  ACACIA,  and  HPP,  the  CONCORDANCE
registry  meets  the  strategic  and  operating  principles
of  Clinical  Quality  Registries  described  by  the  Aus-
tralian  Commission  on  Safety  and  Quality  in  Healthcare
(ACSQH)  and  includes  a  standardised  methodological
approach  to  data  collection,  quality,  security,  governance
and  output  [37–39].
In  recent  years  the  importance  and  scientiﬁc  validity  of
initiatives  of  this  type  have  become  increasingly  recog-
nised.  Driven  by  imperatives  to  improve  cost  effective
delivery  of  care,  in  2009  the  US  congress  committed  $1.1
billion  to  support  Comparative  Effectiveness  Research,  the
key  elements  of  which  include  the  application  of  a  variety
of  research  methodologies  to  evaluate  medical  interven-
tions  shown  to  be  effective  in  randomised  clinical  trials
in  more  diverse  populations  and  diverse  clinical  contexts.
The  purpose  of  CER  is  to  ‘assist  consumers,  clinicians,
and  policy  makers  to  make  informed  decisions  that  will
improve  health  care  at  both  the  individual  and  population
levels”  [40].  Clinical  registries  have  become  an  important
avenue  for  CER  and  CONCORDANCE  has  evolved  to
embody  many  of  the  characteristics  that  underpin  CER.
This  includes  the  real  time  return  of  robust  information
on  care  processes  and  outcomes  to  practicing  clinicians.
Feedback  of  this  nature  has  been  shown  to  be  important
in  practice  improvement  and  indeed  may  have  been  one
of  the  contributing  factors  to  the  improvement  in  care
and  outcomes  that  was  documented  over  the  nine  years
in  hospitals  participating  in  the  GRACE  registry.
One  unresolved  feature  of  CONCORDANCE  is  the
devolution  of  responsibility  for  hospitals  that  appear  to
perform  less  effectively  than  their  peers.  Currently,  this
information  is  fed  back  to  the  clinicians  practicing  at
the  hospital  and  they  have  the  opportunity  to  imple-
ment  practice  changes.  Ongoing  data  collection  and  real
time  feedback  permits  quasi-experimental  quantiﬁcation
of  the  impact  of  these  changes  on  process  measures.
The  ACSQH  recommends  that  Clinical  registries  work
closely  with  expert  national  clinical  groups  to  develop
governance  principles  to  manage  outlier  performance  of
this  type.  The  CSANZ  is  in  the  process  of  establishing  a
company  with  responsibility  for  oversight  of  National  Reg-
istries.  One  possibility  is  that  future  expanded  National
ACS  registries  will  be  established  under  the  auspices  of
this  company  with  responsibility  for  management  of  out-
lier  performance  including  facilitating  implementation  of
quality  improvement  measures.
A  major  challenge  facing  clinical  registries  is  the  iden-
tiﬁcation  of  a  guaranteed  funding  stream  to  ensure
sustainability  over  the  long  term.  Currently  CON-
CORDANCE  is  funded  primarily  by  of  pharmaceutical
companies  and  in  each  case  duration  of  funding  is
determined  by  the  commercial  interest  of  these  spon-
sors.  During  the  life  of  the  registry,  two  companies
have  completed  cycles  of  funding  and  been  replaced
by  two  different  ones  with  emerging  therapies  in  the
market.  Ongoing  ﬁnancial  support  requires  the  engage-
ment  of  a  broader  range  of  interested  stakeholders.  These
may  include  consumer  groups,  professional  bodies,  non-
government  organisations,  device  companies,  medical
and  allied  health  care  bodies  and  academic  institutions.
Engaging  interested  stakeholders  also  potentially  enriches
the  academic  process,  for  example  in  identifying  priority
areas  of  research  and  contributing  to  research  methodol-
ogy.
A  ﬁnal  important  characteristic  for  the  sustainability
of  clinical  registries  is  ﬂexibility  of  design.  The  electronic
medical  record  (eMR)  has  promised  to  revolutionise  clin-
ical  data  collection.  While  there  is  no  doubt  that  wider
application  of  the  eMR  will  boost  the  availability  of  infor-
mation  to  hospital  administrations  in  its  current  iteration,
there  is  not  the  capacity  for  the  granular  level  of  data
acquisition  required  for  detailed  patient  characterisation
and  reliable  determination  of  the  range  of  process  meas-
ures  that  are  currently  captured  by  CONCORDANCE.
The  eMR  does  provide  opportunities  for  improving  and
economising  clinical  quality  registries.  Speciﬁcally,  ongo-
ing  and  future  registries  should  include  the  capacity  for
selected  ﬁelds  to  be  populated  by  the  eMR  minimising
the  burden  of  data  entry  on  hospital  staff.  In  addition,
there  is  now  capacity  for  low  cost  data  linkage  in  most
states  of  Australia  and  nationally  with  Admitted  Hospital
Datasets  and  the  National  Death  Index.  This  can  provide
an  effective  method  of  gathering  clinically  relevant  patient
outcomes  without  the  cost,  inconvenience  and  potential
stress  of  direct  patient  contact.
Conclusion
The  CONCORDANCE  registry  currently  provides  a
robust,  high  quality  tool  to  measure  quality  of  care  for
ACS  patients  admitted  to  Australian  hospitals.  Using
a  CER  framework,  the  registry  provides  empirical  data
on  clinical  effectiveness  with  the  potential  to  inform
improvement  in  processes  of  care  and  consequently
ACS  outcomes  nationally.  Practical  lessons  from  this
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clinician-driven  initiative  will  aid  in  future  broader-based
approaches  to  a  national  ACS  registry.
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management and outcomes of the STEMI population in Australia.  
Methods: Temporal trends with multiple regression analysis on the management and 
outcomes of STEMI patients enrolled across 46 Australian hospitals in the Australian 
cohort of the Global Registry of Acute Coronary Events (GRACE) and the Cooperative 
National Registry of Acute Coronary Care Guideline Adherence and Clinical Events 
(CONCORDANCE) between February 1999 and August 2016.  
Results: 4110 patients were treated for STEMI, mean age 62.5±13.7 years (SD). The 
median door-to-balloon time of primary percutaneous coronary intervention (PPCI) 
decreased by 11 minutes (p<0.01) although there was no increase in rates of PPCI 
(p=0.35). Access to non-primary PCI increased by 39% (p<0.01), provisioning of 
fibrinolysis decreased by 13% (p<0.01) and the median door-to-needle time of 35 
minutes remained unchanged (p=0.09). Prescription of medical therapies in-hospital 
remained high, and at discharge there was an increase in prescription of statins 
(p<0.01); antiplatelets (p<0.01), beta-blockers (p=0.023) and angiotensin converting 
enzyme inhibitors (ACE) and angiotensin-receptor blockers (ARB) (p=0.02). The 
occurrence of any in-hospital adverse clinical events declined by 78% (p<0.01) albeit, 
there was no reduction in mortality in-hospital (p=0.84) or within six months (p=0.81).  
Conclusion: Over time there has been increased access to non-primary PCI; shorter 
door-to-balloon times for PPCI; less adverse events in-hospital and fewer readmissions 
for unplanned revascularisation without the realisation of reduced mortality in-hospital 
or at six months.   
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Introduction 
In 2009 we published the first bi-national report on temporal trends in the management 
of patients admitted to hospital with an acute coronary syndrome (ACS) across 11 
Australian and New Zealand Hospitals (Aliprandi-Costa et al. 2011) and provided 
evidence of adherence with evidence-based care and improved in-hospital survival and 
survival at six months. Decreasing mortality rates from acute myocardial infarction (MI) 
have been attributed to earlier acute treatment and improved medical management 
locally and internationally (Smolina et al. 2012; Krumholz et al. 2008; Herrett et al. 
2010) and the benefits of both early reperfusion for ST-elevation myocardial infarction 
(STEMI) through pre-hospital triage (Hutchison et al. 2009) and the benefits of 
revascularisation for non ST-elevation acute coronary syndrome (NSTEACS) have also 
been realised (Van de Werf, et al. 2008). There is also an appreciation that both patient 
risk (Simms et al. 2013) and access to clinical services such as a percutaneous coronary 
intervention (PCI) capable hospitals impacts long-term survival (Gale et al. 2014; 
Aliprandi-Costa et al. 2016; Chew et al. 2008; Chew et al. 2013). 
The Australian cohort of the Global Registry of Acute Coronary Events (GRACE) and 
subsequently the Cooperative National Registry of Acute Coronary Care Guideline 
Adherence and Clinical Events (CONCORDANCE) are observational registries (Ray 
2003; Myers et al. 1999) developed within a clinical quality framework. Collectively, 
the GRACE and CONCORDANCE registries present the most extensive data on 
outcome measures of patients admitted to hospital with STEMI in Australia. These data 
include process and outcomes measures that are reproducible and build on current 
knowledge on the management and outcomes of patients admitted to hospital with an 
ACS. The Australian arm of the GRACE registry reported outcome data on more than 
5600 patients recruited from nine Australian hospitals between 1999 and 2007. The 
CONCORDANCE registry was launched in 2009 in 10 hospitals and expanded over 
Chapter 6:  ST-elevation acute myocardial infarction in Australia ‒ Temporal 
trends in patient management and outcomes 1999‒2016 
65 
 
time so that by 2016, the management and outcomes of more than 9500 patients have 
been reported across 41 Australian hospitals.  
In this merging of the GRACE and CONCORDANCE registry cohorts we provide a 
maturity exemplar of the STEMI population for the purpose of informing health policy 
and health service provision for this population in Australia. The aim of this analysis is 
to describe temporal trends on the characteristics of the STEMI population, their pre-
hospital and in-hospital management, clinical events and mortality in-hospital and at six 
months following the index event.  
Methods  
Study design 
The design of the GRACE and CONCORDANCE (Aliprandi-Costa et al. 2013) registries 
have been reported previously. Both GRACE and CONCORDANCE are prospective, 
observational registries reporting on the medical management, clinical events and six 
months outcomes of the first 10 consecutively admitted ACS patients per month. 
CONCORDANCE was designed within a comparative effectiveness research (CER) 
framework to facilitate web-based real-time reporting of clinical process indicators 
(CPIs) to participating clinicians for quality review and process improvement. In order 
to ensure data were similar across the two datasets, standardised data definitions and 
data collection methods were applied. Trained hospital staff abstracted data, and the data 
captured were audited to ensure accuracy and consistency with the registry protocols. 
All participating hospitals received human research ethics approval to participate in 
both registries.  
Inclusion and exclusion criteria 
Patients were enrolled into both registries based on symptoms of an ACS and one or 
more of either ST-segment electrocardiographic (ECG) changes of >0.5mm, and/or 
elevation of cardiac biomarkers, new or previous documentation of heart disease. 
Additionally, patients were enrolled into CONCORDANCE based on symptoms of ACS 
and/or two high risk features of ACS including: haemodynamic compromise 
(BP<90mmHg and HR>100 bpm), left ventricular systolic dysfunction (LVEF<40%), 
presence of known diabetes and/or documentation of chronic kidney disease (estimated 
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GFR<60mls/min). Patients admitted to hospital with a co-existent condition such as 
trauma or bleeding or those patients hospitalised for less than 24 hours were excluded 
from both registries with the exception of those patients who died within 24 hours of 
admission and death was attributed to an ACS. Patients with a non-ACS diagnosis and 
hospitals with fewer than 10 patients’ data were excluded from the analysis. 9, 15  
(Aliprandi-Costa et al. 2016; Aliprandi-Costa et al. 2013).  
Patient consent was required for participation in the GRACE registry with a waiver of 
consent applied to patients who had died in-hospital as a result of an ACS. To ensure 
consecutive participant recruitment, an opt-out consent process was approved for 
participation in the CONCORDANCE registry.  
Analysis 
This analysis was limited to patients with a discharge diagnosis of STEMI.  Patient 
demographic and clinical characteristics and in-hospital management, including time 
from symptom onset to presentation, were stratified by year of enrolment and the 
merged registry datasets were divided into six time periods. Categorical data are 
presented using frequency and percentage. The Cochrane Armitage test was performed 
to assess trend across time and Rao-Scott Chi-square test was used to account for 
clustering within hospitals. Numeric data are presented using summary statistics. 
Differences in means were tested using a general linear mixed modelling that accounted 
for clustering within hospitals and differences in medians were tested using the non-
parametric Kruskal-Wallis test. Multiple logistic regression analyses determined the 
association between admission time period and outcomes, including in-hospital 
mortality, (re)MI, heart failure, and mortality to six months, and unscheduled 
readmission within six months – after adjustment for admission characteristics 
including age, previous history of exertional angina, coronary intervention, coronary 
artery bypass grafts (CABG), stroke, peripheral arterial disease (PAD) and smoking. All 
statistical analyses were conducted using SAS version 9.4 SAS Institute Inc. 
Results 
This analysis includes 4110 STEMI patients enrolled into either the GRACE (n=1279) 
or CONCORDANCE (n=2832) registries between February 1999 and August 2016 
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across 46 Australian hospitals. Data are complete for 96% of data items in both datasets 
relating to pre-hospital and in-hospital and outcomes. 
Characteristics of the study population 
Patient characteristics by year group are presented in Table 6.1. Throughout this period 
3062 males and 1048 females were treated for STEMI (p<0.01). There was an overall 
decrease of two years in the mean age of the STEMI cohort from 64.5 years in 1999–
2002 to 62.5 years in 2015 (p<0.01). On admission to hospital these patients reported 
less history of heart failure (p<0.01), exertional angina (p<0.01), peripheral arterial 
disease (p<0.01) and stroke and/or episodes of transient ischaemia (p<0.01). There was 
no change in the rates of smoking (p=0.12) and these patients were more likely to have 
undergone prior revascularisation with percutaneous coronary intervention (PCI) 
(p<0.01) or coronary artery bypass graft surgery (p<0.01). Temporal changes in 
presenting clinical characteristics included reduced systolic blood pressure on 
presentation (p<0.01), a lower GRACE Risk Score (p<0.01), lower serum creatinine 
concentration (p=0.03) and a lower mean total cholesterol (p<0.01). There were also 
decreasing rates of heart failure at presentation (p<0.01). 
Pre-hospital treatment 
Pre-hospital strategies inclusive of timing of first medical contact, pre-hospital ECG and 
the receipt of pre-hospital fibrinolysis were captured from 2009 in the 
CONCORDANCE registry only. From 2009 to 2016 there was no significant change 
observed in time from symptom onset to first medical contact either by ambulance or 
patient arrival to hospital from a median time of 1.48 to 1.21 hours (p=0.09). There was 
no change in the proportion of patients presenting by ambulance (1619/4111; 61%; 
p=0.97) or performance of pre-hospital ECG (875/1619; 57%; p=0.41), and there was 
no change in the provision of pre-hospital fibrinolysis overtime (p=0.26) (Table 6.2). 
In-hospital management 
Medical management  
The use of aspirin or aspirin/clopidogrel remained static over the study period so that 
96% of STEMI patients received either of these therapies in-hospital (p=0.98) (Figure 
6.1). Rates of prescription of antiplatelets with either clopidogrel, prasugrel or ticagrelor 
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varied over time. Overall, 88% of STEMI patients were prescribed statins reflecting a 
19% increase over time from 69% in 1999–02 to 93% in 2016 (p<0.01). Throughout 
this period rates of prescription of beta-blockers remained unchanged. Overall 85% of 
patients received a beta-blocker in-hospital (p=0.03) and over time 78% of patients 
received other ACE or ARB (p=0.27). At hospital discharge aspirin was frequently 
prescribed so that overall, 95% of STEMI patients were prescribed aspirin or 
aspirin/clopidogrel with no change over time. Of STEMI patients, 83% were prescribed 
a second antiplatelet (either clopidogrel, prasugrel or ticagrelor) at discharge, and 
although the rates of prescription fluctuated initially there was an increase for trend 
overtime (p<0.01). There was a 10% increase for trend in the prescription ACE or ARB 
(p=0.02) at hospital discharge; a 19% increase in the prescription of statin therapy 
(p<0.01) and a 12% increase in the prescription of beta-blockers (p=0.03) (Figure 6.2) 
Reperfusion  
From 1999 no significant change was observed in the provision of PPCI, so that 65% of 
STEMI patients (n=1663) underwent PPCI throughout the study period (Figure 6.3). 
Overall, the median time from door-to-primary PCI fell from 95 to 84 minutes 
(n=1428/4110; p<0.01). The median time from door-to-rescue PCI was 7.3 hours with 
little change over time (p=0.06). Coronary angiography rates for the STEMI population 
increased from 49% to 95%, (p <0.01), and PCI at any time in hospital increased from 
23% to 78% (p<0.01). For STEMI patients not receiving emergent revascularisation 
with primary PCI the median door-to-non-primary PCI was 27 hours with no 
improvement over time (p=0.09). The use of fibrinolysis decreased from 51% (1999–
02) to 38% (2015–16) (p<0.01), with the median door-to needle time remaining 
constant at 35mins (p=0.09). Rates of failure to deliver reperfusion approximated 8% 
and did not change throughout the period and CABG was performed in less than 5% of 
STEMI patients (p=0.10).  
In-hospital outcomes  
Rates of in-hospital congestive heart failure declined by 16% (p<0.01) and there were 
fewer episodes of recurrent ischaemia (p<0.01). Following adjustment for age, previous 
history of exertional angina, coronary intervention, coronary artery bypass grafts 
(CABG), stroke, peripheral arterial disease (PAD) and smoking, the reduction in in-
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hospital events persisted so that patients admitted early in the study period were 3.66 
fold more likely to experience heart failure and more than 10 times more likely to 
experience recurrent ischaemia than those admitted during the latter years of the study. 
Death in-hospital was 6% overall, with no difference observed over time either before 
(p=0.84) or after (p=0.55) adjustment (Table 6.3; Appendix 1). 
Outcomes at six months  
Consistent with the unadjusted results, mortality at six months did not change over time 
after adjusting for covariates inclusive of age, previous history of exertional angina, 
coronary intervention, coronary artery bypass grafts (CABG), stroke, peripheral arterial 
disease (PAD) and a past history of smoking. Follow-up data are complete for 93% of 
patient-reported outcomes in the GRACE registry and 65% of the cohort in the 
CONCORDANCE registry. Of these, 97% were alive following treatment for the index 
event (p=0.81). There was no pattern in the manner of missing data at follow-up in the 
CONCORDANCE registry. There was no change in mortality during the time period 
either before (p=0.81) or after (p=0.74) adjustment. However, readmission for 
unplanned revascularisation fell significantly during the study period (p<0.01), a 
difference that persisted following adjustment for differences in baseline characteristics 
(Table 6.3; Appendix 1). 
Discussion  
In this analysis of patients presenting with STEMI across 46 Australian hospitals over a 
17-year period, we found some gains in pre-hospital care and an overall increase in 
access to PCI although PPCI rates were not significantly different despite achieving 
shorter door-to-balloon times. Over time there was a reduction in the occurrence of in-
hospital clinical events, and readmission for urgent revascularisation without the 
realisation of a reduction in in-hospital or six month mortality.  
There was no statistically significant trend observed in the time taken for this population 
to make initial contact with medical care following symptom onset, which may have 
contributed to the falling incidence of congestive cardiac failure on presentation, and 
possibly the lower incidence of in-hospital adverse clinical events. Overall rates of 
access to PPCI did not change, although an 11-minute improvement in door-to-balloon 
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time was achieved for those who underwent emergent revascularisation with PPCI. 
There was a fall in the provision of fibrinolysis, and no change in the timely delivery of 
this therapy during the 17-year period of this study.  
Over time, STEMI patients were more likely to be younger males with fewer comorbid 
medical conditions and were increasingly more likely to have undergone a previous 
PCI. The patient demographics reported here are consistent with previous studies 
reporting STEMI patients are younger with a current history of smoking (Jernberg et al. 
2011; Schiele et al. 2010). These studies suggest improved survival may be in line with 
improved pre-hospital primary prevention strategies including better management of 
hypercholesterolemia, hypertension and diabetes (Schiele et al. 2010). In this analysis 
the prescription of medical therapies with antiplatelets and statins increased 
significantly and there were more modest increases in the prescription of aspirin, 
ACE/ARB and beta-blockers.  
Other cohort studies suggest the ability to demonstrate the association between risk-
adjusted short-term survival benefit in patients receiving PPCI has become increasingly 
difficult to achieve at a population level (Menees et al. 2013). However, when these data 
are calculated at the patient level improved time to reperfusion therapy resulted in a 
reduction in in-hospital mortality (Nallamothu et al. 2015) and an overall survival 
benefit. The authors attributed this finding to reduced ischaemia time quantified by 
shorter door-to-balloon times (Dasari et al. 2016).  
The observation of no temporal change in mortality in this analysis may be influenced 
by the fact that approximately 35% of patients exceeded the 90-minute threshold for 
realisation of a mortality benefit with primary PCI. Thus, despite expanded access to 
non-primary PCI and improved use of medical therapy, a large proportion of STEMI 
patients did not undergo PPCI fast enough to benefit from the mortality gain associated 
with this procedure. Bearing in mind the nature of Australia’s geography where 
approximately 30% of ACS patients live in rural locations, there are limitations in 
improvements that can be made in the timely provision of primary PCI. So, the 
imperative becomes one of improving access to reperfusion (either primary PCI or 
fibrinolysis with timely transfer to a catheterisation-laboratory-capable hospital) earlier 
if we are to realise the benefits of these strategies. 
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An additional explanation for our lack of mortality benefit may be explained by a 
survivor cohort effect that has been described as a consequence of improving systems of 
care being offered to our STEMI population (Terkelsen et al. 2010) – that is, we are 
now treating patients such as late presenters who in the earlier years may have died 
outside of hospital and therefore were not included in the registry. These patients still 
have an increased mortality relative to the overall cohort and thus may mask the benefits 
of shorter door-to-balloon times.   
Encouragingly, diminishing rates of congestive heart failure on admission are likely to 
be the result of increased awareness by patients to access acute care. While the catalyst 
for patients seeking timely medical care is unclear, as local public health campaigns 
such as the National Heart Foundation ‘Warning Signs’ campaign occurred relatively 
late in 2012, it is possible that increased medical awareness more generally may be 
related to accessibility of the internet and social media. Additionally, following local 
evidence on the direct benefits of improved systems of care such as ECG-capable 
ambulances and processes for direct transport of STEMI patients to PCI-capable 
hospitals, these services and processes of care have been in place in some jurisdictions 
since 2011 (Hutchison et al. 2013).  
Finally, these data augment our understanding on the management and outcomes of 
people admitted to hospital with STEMI. Assigning the likely contribution of 
differences in patient characteristics and substantial changes in treatment over time 
highlights the benefit of CER initiatives such as clinical quality registries to provide a 
continuous data source on adherence with evidence-based processes of care and 
measure clinical effectiveness. The data reported here were collected and reported 
systematically to facilitate comparisons for benchmarking clinical practice thereby 
enabling clinicians and health administrators to monitor and report on practice patterns 
and patients outcomes. Clinical registries in the Australian healthcare system should be 
engineered to realise their potential to contribute to health-service-delivery evaluation 
and inform health-policy development.  
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Limitations 
This analysis reports observed and risk-adjusted outcomes from two prospective 
observational registries and, although data capture for in-hospital management are 
complete, follow-up data were complete for only 65% of patients enrolled in the 
CONCORDANCE registry. The diminished follow-up rates in the CONCORDANCE 
registry could represent a potential bias, and other potential factors such as changing 
temporal prevalence of unmeasured confounders may have influenced our findings.  
Additionally, although there was the application of the consent waiver in the GRACE 
registry and the early adoption of the opt-out consent in the CONCORDANCE registry, 
it is not inconceivable that selection bias may have impacted our ability to demonstrate 
a difference in mortality in-hospital and during the follow-up period because of failure 
to include the sickest of the cohort.  
Conclusion  
Describing the management and outcomes of STEMI patients in Australia over a 
17-year period has not been undertaken previously. International studies have 
demonstrated the benefits of improved access to early reperfusion on reduced mortality 
for STEMI, and in this analysis of the combined Australian GRACE and 
CONCORDANCE registries we found an encouraging although non-significant 
reduction in the time taken to access medical care from the time of symptom onset; 
increased access non-primary PCI, and reduced door-to-balloon times for primary PCI. 
We found improved adherence to the prescription of evidence-based medical therapies 
in-hospital and at hospital discharge and an overall decrease in in-hospital clinical 
events, and reduced readmission for urgent revascularisation. Yet, despite these gains, 
we found no increase in access to reperfusion with PPCI or thrombolysis and no 
reduction in in-hospital mortality or mortality at six months. Ongoing data capture and 
reporting would facilitate continuous monitoring of systems of care to inform future 
health policy development in this high-risk population.  
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Table 6.1  Patient characteristics 
 
1999-2002 
n (%) 
2003-2005 
n (%) 
2006-2008 
n (%) 
2009-2011 
n (%) 
2012-2014 
n (%) 
2015-2016 
n (%) 
Overall 
n (%) P value 
Female 186 (31) 106 (25) 58 (23) 159 (24) 407 (25) 132 (25) 1048 (25) 0.0611 
Male 415 (69) 323 (75) 191 (77) 506 (76) 1231 (75) 396 (75) 3062 (75) . 
Age (years) Mean (SD) 64.5(13.3) 63.7(13.5) 62.5 (13.3) 61.2 (13.6) 62.4 (13.4) 62.5 (15.4) 62.6 (13.7) 0.0013 
Past medical history        0.2558 
Previous MI 100 (17) 71 (17) 43 (17) 104 (16) 241 (15) 66 (13) 625 (15) 0.2558 
Heart Failure 40 (7) 26 (6) 17 (7) 30 (5) 47 (3) 7 (1) 167 (4) <.0001 
Exertional Angina 208 (35) 76 (18) 49 (20) 63 (9) 158 (10) 32 (6) 586 (14) <.0001 
Positive Stress Test 22 (4) 9 (2) 6 (2) 13 (2) 26 (2) 8 (2) 84 (2) 0.0207 
Coronary Intervention 30 (5) 31 (7) 16 (6) 59 (9) 175 (11) 59 (11) 370 (9) 0.0006 
Coronary Arterial Bypass Graft (CABG) 30 (5) 15 (4) 17 (7) 24 (4) 47 (3) 12 (2) 145 (4) 0.0064 
Hypertension 311 (52) 199 (47) 131 (53) 321 (49) 842 (51) 257 (49) 2061 (50) 0.6225 
Dyslipidaemia 266 (44) 174 (41) 118 (47) 299 (46) 692 (42) 223 (42) 1772 (43) 0.6408 
Diabetes 138 (23) 95 (22) 54 (22) 141 (21) 329 (20) 110 (21) 867 (21) 0.7791 
Chronic Renal Failure 26 (4) 28 (7) 11 (4) 27 (4) 82 (5) 15 (3) 189 (5) 0.2869 
Stroke or TIA 54 (9) 30 (7) 13 (5) 27 (4) 90 (5) 17 (3) 231 (6) 0.0017 
Peripheral Arterial Disease (PAD) 41 (7) 24 (6) 15 (6) 19 (3) 76 (5) 11 (2) 186 (5) 0.0077 
Current smoker 198 (34) 147 (35) 84 (34) 285 (44) 627 (38) 203 (39) 1544 (38) 0.1276 
Clinical characteristics at hospital admission        
Heart rate Mean (SD) 80.6 (22.9) 79.9 (22.3) 80.3 (23.3) 80.8 (21.2) 78.4 (20.2) 77.0 (18.4) 79.2 (21) 0.0104 
Systolic blood pressure (mmHg) Mean (SD) 140.1(28.2) 139.4 (29.2) 142.5 (30.2) 136.9(29.1) 136.0 (28.1) 137.7 (27.7) 137.7 (28.5) 0.0041 
Diastolic blood pressure (mmHg)Mean 
(SD) 
81.7(17.8) 80.6(18.5) 82.8(19.1) 83.3(18.4) 81.1(18) 81.8(17.2) 81.7 (18.1) 0.2396 
Killip Class I 451 (76) 346 (84) 201 (82) 577 (87) 1470 (90) 495 (94) 3540 (87) <.0001 
Creatinine Mean (SD) 99.8 (37.5) 97.3 (44.2) 100.9 (37.9) 94.6 (54.9) 94.8 (53.6) 90.8 (45.2) 95.6 (49) 0.0307 
GRACE Risk Score (Mean) 112.6 (33.7) 110.4 (32.3) 108.3(32.8) 113.4(32.6) 115.5 (31.8) 115.6 (26.2) 113.6 (32.3) 0.0091 
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Table 6.2  Pre-hospital investigations and treatment 
 2009-2011 2012-2014 2015-2016 Overall P value 
Symptom onset to first medical contact* (hours) 1.48 1.28 1.21 1.33 0.0949 
      
 2009-2011 
n (%) 
2012-2014 
n (%) 
2015-2016 
n (%) 
Overall 
n (%) p Value 
STEMI patients presenting by ambulance 384 (62) 939 (61) 296 (61) 1619 (61) 0.9685 
STEMI presenting by ambulance who have a pre-hospital ECG 235 (64) 481 (54) 159 (56) 875 (57) 0.4068 
STEMI patients who present by ambulance who have pre-hospital fibrinolysis 89 (23) 250 (27) 98 (33) 437 (27) 0.2615 
*Ambulance arrival or hospital arrival 
 
 
 
Table 6.3  In-hospital outcomes and outcomes at six months 
 
1999-02 
n (%) 
2003-05 
n (%) 
2006-08 
n (%) 
2009-11 
n (%) 
2012-14 
n (%) 
2015-16 
n (%) 
Overall 
n (%) P value 
Congestive  cardiac failure 133 (22) 76 (18) 34 (14) 101 (15) 148 (9) 33 (6) 525 (13) <.0001 
Recurrent ischaemia 267 (45) 185 (44) 98 (40) 68 (10) 109 (7) 22 (4) 749 (18) <.0001 
In-hospital adverse event* 359 (60) 238 (56) 125 (51) 228 (35) 443 (27) 108 (21) 1501 (39) <.0001 
In-hospital death 37 (6) 32 (7) 12 (5) 51 (8) 104 (6) 24 (5) 260 (6) 0.84 
Death at six months follow-up 65 (5) 20 (3) 16 (4) 50 (4) 133 (5) 20 (3) 304 (4) 0.87 
Readmission for unplanned CABG or PCI at 6 months 47 (9) 21 (6) 6 (4) 14 (3) 26 (2) 4 (2) 118 (4) <.0001 
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Figure 6.1  Medical therapies in-hospital 
 
 
 
Figure 6.2  Medical therapies at hospital discharge 
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Figure 6.3  Receipt of reperfusion in-hospital 
 
 
 
Figure 6.4  Median time to reperfusion 
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Appendix figures 
Figure A1: Adjusted incidence of in-hospital congestive cardiac failure 
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2003 to 2005 
2006 to 2008 
2009 to 2011 
2012 to 2014 
2015 to 2016 
Level 1 
3.66 (2.12, 6.30) 
3.07 (1.86, 5.07) 
2.41 (1.34, 4.33) 
2.45 (1.44, 4.17) 
1.46 (0.93, 2.29) 
Reference group 
Odds Ratio (95% CI) 
    1 .159 6.3 
Figure A1  Adjusted incidence of in-hospital congestive cardiac failure 
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Figure A2  Adjusted incidence of recurrent ischaemia in-hospital 
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Figure A3  Adjusted in-hospital mortality 
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Figure A4  Adjusted mortality at 6month follow-up 
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Figure A5  Adjusted readmission for unplanned CABG or PCI at 6month follow-up 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1999 to 2002 
2003 to 2005 
2006 to 2008 
2009 to 2011 
2012 to 2014 
2015 to 2016 
Level 1 
6.75 (3.08, 14.79) 
3.88 (1.87, 8.02) 
2.78 (1.00, 7.70) 
1.82 (1.01, 3.27) 
1.38 (0.59, 3.27) 
Reference group  
Odds Ratio (95% CI) 
 
    1 .0676 14.8 
84 
 
7 Published paper: ‘A composite 
score of clinical process indicators 
can measure the quality of hospital 
performance in the management of 
acute coronary syndromes’ 
This chapter presents the rationale for developing a composite of multiple clinical 
processes to provide a single measure of hospital performance in the management of 
ACS, and the method for calculating the composite score by which to benchmark 
individual hospitals. In this thesis performance is defined as adherence to evidence-
based clinical care. Despite having published evidence on adherence to evidence based 
care and improved patient outcomes in Chapter 4, early evaluation of the 
CONCORDANCE data suggested real-time reporting of CPIs to clinicians alone was 
insufficient to improve the quality of hospital base-care. While we observed significant 
improvement in adherence to evidence-based care30 we also observed that, despite 
feeding back comprehensive CPI reports to participating clinicians, there was no 
reduction in the performance gap between the best and poorest performing hospitals in 
the registry. This suggested that while tremendous resources were spent on measuring 
and reporting CPIs, the value of this reporting to clinicians alone was not leading to 
meaningful practice improvement. Additionally, when compared, hospitals that adhered 
to the system-level performance measure of providing access to reperfusion for ST-
elevation acute myocardial infarction (STEMI) were more likely to provide timely 
access to angiography for high-risk ACS. These hospitals also treated more high-risk 
patients, attended to more in-hospital cardiovascular events effectively, and had lower 
readmission rates for cardiovascular disease. Therefore, it was also likely that those 
                                                 
 
30 B. Aliprandi-Costa et al; Real-time reporting of clinical process measures reveals improved performance, yet differences persist 
between hospitals in the Australian Cooperative National Registry of Acute Coronary Care, Guideline Adherence and Clinical 
Events (CONCORDANCE). American College of Cardiology May 2014 
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patients attending hospitals with a system-level process for providing access to 
reperfusion derived a mortality benefit31.  
To define the clinical process indicators to be included in this analysis the level of 
evidence supporting the process of care and the relationship of adherence to the process 
measure with clinically meaningful outcomes was taken into account. In determining 
the weight of individual process markers on the determination of outcomes we 
considered the findings of Simms and Baxter et al, who found that modelling for 
coronary artery catheterisation did not alter the direction of the results and 
acknowledged that the all-or-nothing method was a more than acceptable aggregation 
method to measure hospital performance.   
Table 3 in the published manuscript (reproduced below) provides the processes of care 
included in this analysis. 
 
 
                                                 
 
31 B. Aliprandi-Costa et.al Hospital performance in the treatment of ST-elevation myocardial infarction correlates with overall 
adherence to evidenced-based care in the treatment of acute coronary syndromes in the Australian Cooperative National Registry of 
Acute Coronary Care, Guideline Adherence and Clinical Events (CONCORDANCE). American College of Cardiology May 2014 
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Non-adherence with the composite of clinical process indicators and the association 
with patient in-hospital clinical events, and outcomes at six months, was then tested. 
These results are presented as a published manuscript in this chapter. Further, the utility 
of using a quality composite score to measure and report hospital performance is 
presented as an appendix to Chapter 7 (Appendix 1) as a tool for government, hospital 
administrators and clinicians to communicate and compare performance between 
hospitals within a local health district (LHD) and other hospitals in NSW with a national 
benchmark.  
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Aims Acute coronary syndrome (ACS) is a costly condition for health service provision yet variation in the delivery of care
between hospitals persists. A composite measure of adherence with evidence-based clinical-process indicators (CPIs)
could better inform hospital performance reporting and clinical outcomes in the management of ACS.
Methods Data on 7444 ACS patients from 39 Australian hospitals were used to derive a hospital-specific composite quality score
by calculating mean adherence to 14 evidence-based CPIs. Using the generalized estimating equation to account for
clustering of patients within hospitals and the GRACE risk score to adjust for differences in presenting risk, we evaluated
associations between the hospital-specific composite quality score, in-hospital major adverse events, in-hospital mor-
tality and mortality and readmission for ACS at 6 months.
Results Hospitals had a mean adherence of 68.3% (SD 21.7) with the composite quality score. There was significant variation
between hospital adherence tertile 1 (79%) and tertile 3 (56%), P, 0.0001. With risk adjustment, there was an asso-
ciation between hospitals with a higher composite quality score and reduced in-hospital adverse events (OR: 0.85, CI:
0.71–0.99) and survival at hospital discharge (OR: 0.47; 95% CI: 0.28–0.77). There was trending improvement in
survival at 6 months (OR 0.48; CI: 0.20–1.16) and fewer readmissions to hospital for ACS at 6 months (OR 0.79;
CI 0.60–1.05).
Conclusion The association between the quality composite score and reduced in-hospital events and survival at hospital discharge
supports the utility of reporting CPIs in routine hospital performance reporting on the management of ACS.
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Introduction
Acute coronary syndrome (ACS) accounts for more than half of
healthcare expenditure for cardiovascular disease,1 yet despite
this, the quality of the care delivered within and between hospitals
varies widely.2 Moreover, the efficacy of standard clinical guidelines
on adherence is unknown due to the lack of reporting metrics.
Results from previous local and international studies demonstrate
a correlation between variable adherence with evidence-based
care and adverse clinical events.3,4 These studies also suggest that
variation in patient characteristics, hospital clinical services and sys-
tems of care may be contributing factors. In Australia, health depart-
ments and national bodies such as the National Health Performance
Authority (NHPA) and the Australian Commission on Safety and
Quality in Health Care (ACSQHC) have identified in-hospital man-
agement of ACS as a priority for health service provision evaluation.
However, while evidence-based minimum clinical standards have
been defined to guide medical care,5 there is limited capacity to
report on adherence with guideline recommended treatment as a
measure of hospital performance in the management of ACS.
In Australia, the traditional method of assessing quality of care for
ACS has been in-hospital mortality associated with acute myocardial
infarction (AMI), yet relatively few patients die in-hospital as a result
of an ACS.6 Measuring adherence to several evidence-based clinical
process measures with patient reported outcomes enables overall
appraisal of quality of care and is an alternative option to reporting
a single outcome measure such as mortality. Reporting multiple pa-
tient level process measures also takes into account the complexity
of the care provided and differentiates those care practices that lead
to the highest (and lowest) quality of care, to produce important in-
sights into how care is delivered.7 A composite measure of adher-
ence with multiple evidence-based clinical process indicators
(CPIs) together with patient-reported outcomes would support
hospital performance reporting and guide the direction of quality
improvement initiatives, to reduce variation in clinical care between
hospitals.1,8,9 Using CPIs in this way provides clinicians and health
administrators with measures that are easy to interpret and facilitate
comparisons between hospitals with defined evidence-based per-
formance targets, to support performance improvement.10,11
Despite evidence that composite scores discriminate perform-
ance more readily than a single performance measure,11,12 a com-
posite quality score in the management of ACS has yet to be
developed in the Australian context. The aim of this study is to dem-
onstrate the importance of adherence to evidence-based indicators
by quantifying relationships between a hospital level composite
quality adherence score and multiple patient level risk-adjusted out-
comes. The objective is to use the quality composite score to (i)
measure variation in adherence to evidence-based CPIs between
hospitals and (ii) determine if high levels of adherence (as measured
by the quality composite score) are associated with lower observed
and risk-adjusted in-hospital clinical events, in-hospital death and
readmission to hospital for ACS and death at 6 months.
Methods
Study population
We used patient and hospital level data from the Cooperative National
Registry of Acute Coronary Care Guideline Adherence and Clinical
Events (CONCORDANCE). CONCORDANCE is a prospective,
observational clinical quality registry designed within a comparative
effectiveness research (CER) framework that captures and describes
overall adherence with evidence-based care on the in-hospital manage-
ment of ACS.13 CONCORDANCE initially reported outcomes on the
management of ACS from 10 Australian hospitals in 2009. The number
of participating hospitals expanded to 19 in 2011, and additional hospitals
joined the registry over time so that in 2015, 41 hospitals are contributing
data. The first 10 consecutively admitted ACS patients per month are en-
rolled into the registry, and patient-reported outcomes are collected at 6
months, systematically using a standard data collection form by trained
research coordinators located at the site where the patient was enrolled.
The CONCORDANCE registry uses standardized definitions, and clinic-
al data are abstracted by trained hospital staff and audited to ensure ac-
curacy and consistency with the registry protocol.
Participating hospitals are predominantly principal referral hospitals,
that is, ‘located in major cities with more than 20 000, and regional hos-
pitals with more than 16 000 acute (case mix-adjusted) separations per
year’. There is a broad geographical distribution of hospitals in this
cohort, and the availability of hospitals are considered to be moderately
accessible, accessible or highly accessible by the Accessibility and
Remoteness Index of Australia (ARIA).14
Inclusion and exclusion criteria
The patient population included in this analysis are those patients eli-
gible for registry inclusion based on symptoms of an ACS and one or
more of either ST segment electrocardiographic (ECG) changes of
.0.5 mm, and/or elevation of cardiac biomarkers, new or previous
documentation of heart disease or symptoms of an ACS and/or two
high-risk features of ACS including haemodynamic compromise (BP,
90 and HR . 100), left ventricular systolic dysfunction (LVEF, 40%),
presence of known diabetes and/or documentation of chronic kidney
disease (estimated GFR , 60 mLs/min). Patients admitted to hospital
with a co-existent condition such as trauma or bleeding or those pa-
tients hospitalized for ,24 h are excluded, with the exception of those
patients who died within 24 h of admission and death was attributed to
an ACS. Additionally, patients with a non-ACS diagnosis and hospitals
with fewer than 10 patients’ data were excluded from these analyses.
Clinical process indicators measured
Using the collected data, CONCORDANCE reports on 14 CPIs that re-
flect adherence to Class I, Class Ia, Class II and Class IIa guideline recom-
mended care, with levels of evidence A, B, and C.1,2 CPIs included in this
analysis, and routinely reported by the registry provide robust measures
of systems of care and are associated with improved clinical outcomes.
Adherence with CPIs was determined using the All or None
Approach15–17 and aggregated to provide a composite measure of ad-
herence with evidence-based CPIs. The All or None Approach counts
the number of eligible patients receiving each required care process (nu-
merator) against the total number of patients eligible for this process
(denominator). For example, only ST elevation MI (STEMI) patients
were included in adherence measures for primary percutaneous inter-
vention (PPCI) and/or thrombolysis and only patients who survived be-
yond 12 h were included in the CPIs for acute treatment. Those patients
surviving to hospital discharge were included in measures for access to
discharge therapies and referral to secondary prevention.
Hospital composite adherence score
Patients were grouped by presenting hospital, and the proportion of pa-
tients receiving each care process at each site was determined. The next
stepwas to calculate themean of the proportion adherence values with-
in each hospital to determine the composite measure of hospital adher-
ence with all CPIs. The higher adherence value represented greater
B. Aliprandi-Costa et al.Page 2 of 10
 by guest on July 5, 2016
http://ehjqcco.oxfordjournals.org/
D
ow
nloaded from
 
compliance with clinical processes. The mean for each hospital was then
ordered from highest to lowest, and hospital adherence tertiles were
determined18 (Table 1).
Hospital clinical services
The characteristics of hospitals captured by the registry and reported
here to describe clinical services include the location of the hospital
and details of pre-hospital care. For example, the care provided in co-
ordination with the ambulance service and the hospital local area health
district for the direct transport of acute ACS patients to a PCI-capable
hospital and ambulance 12-lead ECG recording capability. In-hospital
clinical services included the presence of a cardiac catheter lab, a percu-
taneous coronary intervention (PCI) service, cardiac surgery and echo-
cardiography. In-hospital care processes were also captured, including
ACS risk stratification on admission to hospital, a clinical pathway for
the transfer of STEMI patients from the Emergency Department (ED)
to a PCI-capable hospital; single call activation of the cardiac catheter
lab for STEMI; a pathway to guide the prescription of evidence-based
medical therapy, the presence of in-hospital secondary prevention ser-
vices and processes for the referral of ACS patients to outpatient sec-
ondary prevention and heart failure services.
Outcome measures
The outcome measures of interest were aggregated in-hospital major
adverse events (defined as episodes of heart failure, cardiogenic shock,
recurrent ischaemia, in-hospital MI or re-MI, cardiac arrest, stroke and
acute renal failure), in-hospital mortality and mortality and readmission
for ACS at 6 months following hospital discharge.
Analysis
Statistical analyses were conducted using SAS version 9.4 SAS Institute
Inc. Categorical variables are presented as proportions, and continuous
variables are presented as means with standard deviation (SD).
Chi-squared analysis determined the probability for a difference (a ¼
0.05) between hospital adherence tertiles 1 and 3 for patient baseline
characteristics, and differences in observed rates of in-hospital clinical
events, in-hospital mortality and re-admission to hospital and death.
As this is an exploratory analysis, no adjustment to alpha was made to
account for multiple testing. Odds ratios for an association between
hospital adherence tertiles 1 and 3 for in-hospital events, survival at hos-
pital discharge, survival at 6 months and readmission to hospital for ACS
at 6 months were determined using the generalized estimating equation
(GEE) to model tertile and their interaction with clustering on hospital;
and the GRACE risk score19 to adjust for a difference in presenting pa-
tient risk. Hospital data were complete for 75% of the cohort and 66.7%
of patients had complete follow-up data at 6 months.
Results
This analysis comprised CONCORDANCE registry data on 7444
patients with a definite ACS diagnosis of STEMI (n ¼ 2306) and
NSTEACS (5138) enrolled between February 2009 and March
2015 across 39 Australian hospitals. Hospital adherence tertile 1 in-
cluded 3016 ACS patients; hospital adherence tertile 2, 2527 ACS
patients and hospital adherence tertile 3, 1901 ACS patients. Data
were complete for 74.8% of patients in tertile 1; 77.1% in tertile
2; and 71.5% in tertile 3. The cumulative distribution function
(CDF) plot for the three tertiles showed very similar distributions
although tertile 3 hospitals had 3% of patients with completely miss-
ing data while tertile 1 hospitals had only 0.04% with completely
missing data. Six-month follow-up data were complete for 67.2%
and the tertile split is similar; tertile 1: 63.7% and tertile 3: 69.3%.
Variation in the hospital-specific
composite quality score
The mean of CPI adherence per hospital as the quality composite
score is presented in Figure 1. The mean adherence with the
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Mean of CPI adherence by patient and
hospital adherence tertile
Hospital Number of
patients
Mean SD Tertile
All hospitals combined 7444 68.29 21.99
1 67 37.64 21.45 3
2 26 39.28 30.93 3
3 63 47.63 25.43 3
4 68 53.41 25.98 3
5 38 58.74 24.86 3
6 113 60.57 18.84 3
7 225 62.10 22.09 3
8 290 62.27 23.59 3
9 260 62.55 20.59 3
10 111 62.85 24.03 3
11 549 64.59 25.85 3
12 91 64.94 18.84 3
13 209 65.63 25.32 2
14 185 65.92 21.55 2
15 388 66.11 21.35 2
16 164 66.32 23.85 2
17 69 68.14 19.75 2
18 93 69.36 24.35 2
19 511 69.52 18.70 2
20 401 69.54 22.29 2
21 23 69.57 26.72 2
22 111 69.63 19.40 2
23 114 69.86 19.88 2
24 137 72.01 19.74 2
25 122 72.23 19.92 2
26 408 72.56 17.58 1
27 427 72.60 20.86 1
28 175 72.87 17.23 1
29 53 74.29 18.21 1
30 141 75.62 17.37 1
31 311 76.88 18.87 1
32 280 76.94 18.28 1
33 86 77.49 19.87 1
34 343 78.93 18.16 1
35 342 80.41 16.42 1
36 129 80.48 16.03 1
37 167 81.76 15.66 1
38 53 81.87 12.91 1
39 101 90.17 10.84 1
Number of patients, mean and SD of adherencewith CPIs per hospital, and hospital
adherence tertile.
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composite of CPIs was 79% among tertile 1 hospitals; 69.8% among
tertile 2 hospitals and 56% among hospitals in tertile 3 (P, 0.0001).
In aggregate, the mean hospital composite adherence with CPIs in
this cohort was 68.3% (SD 21.7) with 10 of the 14 hospitals within
tertile 1 achieving greater than 75% adherence with the composite
of evidence-based CPIs (Figure 1).
Patient baseline characteristics and
hospital clinical services by CPI adherence
tertile
Patient admission characteristics
Patient admission characteristics by hospital adherence tertile are
presented in Table 2. Compared with patients treated in hospitals
in tertile 3, patients treated in tertile 1 hospitals were more likely
to be younger (P, 0.0001) males (P, 0.0001) with ST elevation
(P, 0.0001) or other ischaemic abnormalities on their admission
electrocardiograph (ECG) (P, 0.0001). Patients treated in tertile
3 hospitals were therefore older and were more likely to be female
with a prior history of heart disease including prior acute myocardial
infarction (AMI) (P, 0.0001) and/or prior congestive heart failure
(CHF) (P, 0.0001) and were more likely to have undergone previ-
ous revascularization including PCI (P, 0.0050) and/or coronary
artery bypass grafts (CABG) (P, 0.0001). Patients in tertile 3 hos-
pitals were also more likely to be frail (P, 0.0001) with a greater
burden of risk factors for heart disease including hypertension
(P, 0.0018), dyslipidaemia (P, 0.0010), diabetes (P, 0.0001),
and renal impairment (P, 0.0001) and had a higher admission
GRACE risk score19 (P, 0.0200).
Hospital clinical services
Characteristics of the hospital clinical services captured by the regis-
try are shown in Figure 2. All hospitals in tertile 1 had a cardiac cath-
eter lab with a primary PCI (PPCI) services (P, 0.0012). Most of
these hospitals had systems of care such as single call activation of
the cardiac catheter lab, cardiac catheter lab activation enroute to
hospital by ambulance and the expedient arrival of the cardiac
catheter lab team to hospital within 30 min of notification. Only
one-third of tertile 3 hospitals were able to provide these clinical
services, and only 50% of hospitals in adherence tertile 3 had a
process for the rapid transfer of STEMI patients from the emergency
department to a PCI-capable hospital for PPCI or rescue PCI.
Importantly, the majority of hospitals in either hospital adherence
tertile 1 or tertile 3 had an arrangement with the ambulance service
to divert STEMI patients directly to a PCI-capable hospital within
their area health service or local health district.
Except for the presence of coronary angiography services and
consequently PCI, access to specialist cardiology services was equit-
able in both hospital adherence tertiles 1 and 3 and there was
no significant difference in the availability of exercise stress test,
echocardiography and stress-echocardiography. Similarly, there
was no difference in access to in-hospital secondary prevention; ob-
jective risk assessment; outpatient exercise programmes, outpatient
heart failure programmes or the presence of a full-time or part-time
secondary prevention coordinator. Nonetheless, hospitals in adher-
ence tertile 1 were significantly more likely to refer patients to
secondary prevention programmes (P, 0.0001).
Adherence with evidence-based CPIs
by hospital adherence tertile
The evidence-based CPIs are presented in Table 3. Comparisons
between hospital adherence tertiles 1 and 3 revealed significant vari-
ation in adherence with all CPIs (P, 0.0001) except risk stratifica-
tion of NSTEACS on hospital admission which occurred ,15% of
the time overall. Hospitals in tertile 1 were found to provide greater
access to reperfusion for STEMI (P, 0.0001), and more frequently
provided access to coronary angiography within 48 h (P, 0.0001)
and coronary angiography at any time during hospital admission
(P, 0.0001). Tertile 1 hospitals also provided left ventricular as-
sessment more frequently (P, 0.0001) and were significantly
more likely to prescribe evidence-based medical therapies including
clopidogrel, prasugrel or ticagrelor in-hospital (P, 0.0001) and
at hospital discharge (P, 0.0001), together with beta-blockers
(P, 0.0001); statins (P, 0.0001) and ACE-inhibitor or angiotensin
receptor blockers (ARB) or both at discharge (P, 0.0001). Overall,
there was a 15.9% difference between tertiles 1 and 3 hospitals for
the prescription of four or more recommended therapies (including
of aspirin, clopidogrel, prasugrel or ticagrelor; statin; beta-blocker
and either ACE or ARB or both) (P, 0.0001).
Observed (unadjusted) outcomes
Observed outcomes reveal more than 92.2% of patients admitted to
hospital with an ACS survive to hospital discharge. There were few-
er in-hospital deaths due to an ACS recorded in tertile 1 hospitals;
2.5% (3141/3222) compared with 7.8% (2074/2250) in tertile 3 hos-
pitals (P, 0.0001). Overall, patients admitted to tertile 1 hospitals
were less likely to experience an adverse event in-hospital; 18.9%
(608/3222) compared with 32.6% (734/2250) in tertile 3 hospitals
(P, 0.0001). Of those patients surviving to hospital discharge,
97% (1792/1843) of patients admitted to tertile 1 hospitals were
alive at 6 months following their index admission compared with
92% (1270/1375) of patients in tertile 3 hospitals (P, 0.0001). Like-
wise, fewer patients treated in tertile 1 hospitals required readmis-
sion to hospital for an ACS within 6 months, 17.6% (323/1835)
compared with 21% (290/1374) of patients treated in tertile 3 hos-
pitals (P, 0.0125).
Figure 1 Composite measure of hospital adherence with CPIs.
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Table 2 Patient admission characteristics and comparison for a difference between by hospital adherence tertiles
1 and 3
Patient characteristics Tertile 1, n5 3016,
n (%)
Tertile 2, n5 2527,
n (%)
Tertile 3, n 5 1901,
n (%)
% Diff Tert
1 2 Tert 3
P Value
Gender
Female 777 (25.8) 796 (31.5) 598 (31.5) 25.7 ,0.0001
Male 2239 (74.2) 1731 (68.5) 1303 (68.5) 5.7
Age (years) 64.0 (13.27) 64.0 (13.90) 68.0 (13.83) 24.0 ,0.0001
Past history
Prior AMI 729/2991 (24.4) 799/2509 (31.8) 704/1889 (37.3) 212.9 ,0.0001
Angina 589/2988 (19.7) 649/2509 (25.9) 513/1888 (27.2) 27.5 ,0.0001
Prior CHF 148/2987 (5.0) 241/2508 (9.6) 210/1888 (11.1) 26.1 ,0.0001
Prior positive stress test 172/2987 (5.8) 150/2508 (6.0) 135/1885 (7.2) 21.4 0.0496
Prior positive coronary angiography 890/2996 (29.7) 996/2508 (39.7) 720/1887 (38.2) 28.5 ,0.0001
Prior PCI 582/3015 (19.3) 528/2509 (21.0) 427/1888 (22.6) 23.3 0.0052
Prior CABG 247/2988 (8.3) 340/2506 (13.6) 270/1887 (14.3) 26.0 ,0.0001
Hypertension 1813/3003 (60.4) 1573/2506 (62.8) 1222/1885 (64.8) 24.4 0.0018
Dyslipidaemia 1647/3002 (54.9) 1418/2506 (56.6) 1124/1885 (59.6) 24.7 0.0011
Diabetes (Type I/II) 712/2992 (23.8) 703/2506 (28.1) 596/1888 (31.6) 27.8 ,0.0001
Renal impairment 159/2984 (5.3) 277/2509 (11.0) 207/1888 (11.0) 25.7 ,0.0001
Smoker 2028/3016 (67.2) 1700/2527 (67.3) 1122/1901 (59.0) 8.2 ,0.0001
Prior TIA/Stroke 172/2973 (5.8) 198/2497 (7.9) 173/1881 (9.2) 23.4 ,0.0001
Peripheral arterial disease 184/2983 (6.2) 151/2342 (6.5) 153/1883 (8.1) 21.9 0.0088
Atrial fibrillation 238/2991 (8.0) 283/2507 (11.3) 237/1887 (12.6) 24.6 ,0.0001
Major Bleeding 63/2986 (2.1) 56/2508 (2.2) 46/1887 (2.4) 20.3 0.4509
Frailtya 550/3016 (18.2) 571/2527 (22.6) 549/1901 (28.9) 210.7 ,0.0001
Clinical signs
Heart rate 75.0 (19.67) 76.0 (20.20) 80.0 (21.51) 25.0 ,0.0001
Systolic BP 140.0 (27.46) 138.0 (27.21) 139.0 (28.11) 1.0 0.1889
Diastolic BP 80.0 (16.86) 79.0 (16.37) 79.5 (18.12) 0.5 0.0710
Cardiac arrest on admission 137/3014 (4.5) 94/2508 (3.7) 72/1884 (3.8) 0.7 0.2227
Abnormal for ischaemia 1947/3012 (64.6) 1423/2506 (56.8) 964/1885 (51.1) 13.5 ,0.0001
ST elevation 1144/1851 (61.8) 715/1397 (51.2) 501/927 (54.0) 7.8 ,0.0001
New LBBB 76/1656 (4.6) 51/1379 (3.7) 45/889 (5.1) 20.5 0.5933
ST depression 703/1739 (40.4) 481/1391 (34.6) 405/917 (44.2) 23.8 0.0631
T wave inversion 635/1735 (36.6) 576/1392 (41.4) 383/917 (41.8) 25.2 0.0093
Elevated biomarkers 2412/2736 (88.2) 1741/2268 (76.8) 1139/1473 (77.3) 10.9 ,0.0001
Serum creatinine (mean, SD) 91.0 (46.9) 91.0 (56.4) 97.0 (64.3) 26.0 ,0.0001
Total cholesterol (mean, SD) 4.5 (1.6) 4.5 (1.5) 4.5 (2.2) 0.0 0.4643
HDL (mean, SD) 1.0 (0.4) 1.0 (0.4) 1.1 (0.6) 20.1 ,0.0001
LDL (mean, SD) 2.6 (1.7) 2.6 (1.1) 2.4 (1.7) 0.2 0.1873
Killip Class 1 2744 (91.1) 2165 (86.4) 1621 (86.2) ,0.0001
Killip Class 2 203 (6.7) 272 (10.9) 191 (10.2)
Killip Class 3 43 (1.4) 53 (2.1) 51 (2.7)
Killip Class 4 21 (0.7) 16 (0.6) 18 (1.0)
GRACE risk score (mean, SD) 128.0 (38) 125.0 (40) 132.0 (43) 24.0 ,0.0001
ACUITY score (mean, SD) 16.0 (7.1) 16.0 (7.2) 18.0 (7.8) 22.0 ,0.0001
Probability for a difference between hospital tertile 1 and hospital tertile 3 determined by x2 squared (a ¼ 0.05).
GRACE risk score.19
ACUITY/HORIZONSAMI bleeding risk score.20
aComponents of frailty include a past history of dementia, impaired mobility, incontinence, liver disease, lung disease and/or cancer limiting life expectancy.
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Risk-adjusted outcomes
Risk-adjusted analyses confirmed a significant association between
hospitals in tertile 1 and reduced in-hospital adverse events 20.9%
(592/2838) compared with 27.1% (453/1669) in tertile 3 hospitals
(OR: 0.84; CI: 0.71–0.99). The proportion of patients discharged
alive from tertile 1 hospitals was 97.4% (2764/2838) compared
with 95.6% (1595/1669) of patients in tertile 3 (OR 0.47; CI:
0.28–0.77). Furthermore, 97.8% (1711/1749) of patients from
tertile 1 hospitals were alive at 6 months compared with 96.7%
(1032/1067) of ACS patients discharged from hospitals in tertile 3
(OR 0.48 CI: 0.20–1.16) and 18% (306/1703) of patients from tertile
1 hospitals were re-admitted for ACS at 6 months compared with
24.2% (258/1065) of patients in tertile 3 (OR 0.79; CI: 0.60–1.05)
although this latter difference was not significant (Figure 3).
Figure 2 Comparison of hospital clinical services between hospital adherence tertiles 1 and 3.
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Table 3 Mean hospital adherence with CPIs and comparison for a difference between hospital adherence tertiles 1 and 3
Clinical process indicator Tertile 1 Tertile 2 Tertile 3 % Diff tert
12 tert 3
P value
Patients
received care/
eligible for care
Mean hospital
adherence
score (%)
Patients
received care/
eligible for care
Mean hospital
adherence
score (%)
Patients
received care/
eligible for care
Mean hospital
adherence
score (%)
1. STEMI patients arriving within 12 h of symptom onset
receiving either thrombolysis or primary PCI or both.a
946/1135 83.3 507/702 72.2 326/467 69.8 13.5 ,0.0001
2. Left ventricular function assessed.a 2761/3016 91.5 2317/2527 91.7 1644/1901 86.5 5 ,0.0001
3. ACS patients undergoing coronary angiography
during admission.a
2583/2788 92.6 1756/2180 80.6 1163/1623 71.7 20.9 ,0.0001
4. ACS patients undergoing coronary angiography
within 48 h.a
1797/2578 69.7 1080/1738 62.1 688/1149 59.9 9.8 ,0.0001
5. Non-high-risk ACS patients undergoing functional
testing, angiography or both.a
176/228 77.2 144/347 41.5 147/278 52.9 24.3 ,0.0001
6. ACS patients receiving in-hospital clopidogrel,
coplavix, prasugrel, or ticagrelor.a
2617/2788 93.9 1954/2180 89.6 1341/1623 82.6 11.3 ,0.0001
7. ACS patients discharged alive on aspirin or coplavix.a 2763/2928 94.4 2224/2430 91.5 1549/1732 89.4 5 ,0.0001
8. ACS patients discharged alive on clopidogrel or
coplavix, or prasugrel or ticagrelor.a
2144/2705 79.3 1535/2088 73.5 1029/1466 70.2 9.1 ,0.0001
9. ACS patients discharged alive on beta-blocker.a 2434/2928 83.1 1914/2431 78.7 1270/1732 73.3 9.8 ,0.0001
10. ACS patients discharged alive on statin.a 2741/2928 93.6 2201/2430 90.6 1515/1732 87.5 6.1 ,0.0001
11. ACS patients discharged alive on ACE-inhibitor or
angiotensin receptor blocker or both.a
2292/2871 79.8 1789/2415 74.1 1193/1723 69.2 10.6 ,0.0001
12. ACS patients discharged on appropriate medical
therapy; that is all four of one or more of aspirin or
clopidogrel or coplavix or prasugrel or ticagrelor and
statin, beta-blocker and ACE or ARB or both.a
1827/2928 62.4 1353/2431 55.7 805/1732 46.5 15.9 ,0.0001
13. ACS patients discharged alive referred to secondary
prevention.
2304/2928 78.7 1441/2431 59.3 855/1732 49.4 29.3 ,0.0001
14. Risk profile of NSTEACS determined as either high-,
intermediate- or low-risk ACS on admission to
hospital.
287/3016 9.5 352/2527 13.9 185/1901 9.7 20.2 0.8025
Probability for a difference between hospital tertile 1 and hospital tertile 3 was determined using x2-test (a ¼ 0.05).
aPatients with a contraindication to the treatment are excluded.
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Discussion
In this Australian ACS cohort, the composite quality score reveals
variation in hospital adherence with evidence-based care. With
risk adjustment, there was an association between greater adher-
ence with the composite of CPIs, reduced in-hospital adverse events
and improved survival at hospital discharge.
Proportionally, more clinical services specific to the treatment
of an acute ACS event such as STEMI were located in tertile 1 hos-
pitals. There were fewer cardiac catheter labs in tertile 3 hospitals
and consequently less angiography. Overall, tertile 1 hospitals
were more likely than tertile 3 hospitals to complete coronary
angiography within 48 h of patient presentation, provide left
ventricular assessment, prescribe evidence-based therapies in-
hospital and at discharge and refer patients to secondary preven-
tion services.
Despite echocardiography being available across all hospitals,
patients attending hospitals in tertile 3 were less likely to receive
left ventricular assessment that suggests perhaps either a system
failure or insufficient resources to facilitate routine echocardiog-
raphy. System failure may also be the likely factor impacting the
coordination of care by tertile 3 hospitals to facilitate access to acute
services including angiography within 48 h and possibly the prescrip-
tion of evidence-based medical therapy and patient referral to
secondary prevention. This is important as a high proportion of
patients attending tertile 3 hospitals had elevated biomarkers and/
or an abnormal ECG on admission to hospital.
The generation a composite score using this methodology17 de-
monstrates the utility of the all-or-none approach in the calculation
of a composite quality score which is feasible for use by clinicians
and hospital administrators to measure and benchmark their per-
formance. The CPIs included in this composite score are derived
from guideline recommendations, which, in some instances, are re-
flective of expert consensus views, and a perception that adherence
to these measures is likely to improve outcomes.21,22 Indeed, our
data would support this. Previously, it has been shown that model-
ling for coronary artery catheterization did not change the associ-
ation between an opportunity-based composite score (OBCS)
and clinical outcomes,12 consequently we did not adjust for the rela-
tive benefits of individual therapies or interventions in the calcula-
tion of this composite score. Similarly, the rationale for counting
each of the medical therapies individually, and the relative value of
including the group of four or more is that we provide a more accur-
ate picture of the impact of prescription of all evidence-based ther-
apies on being discharged alive and survival at 6 months. Reporting
both the prescription of individual therapies and four or more med-
ical therapies provided another opportunity for the hospital to per-
form. In this observational registry cohort, data were normally
distributed across each tertile. There were a large number of man-
datory variables built into the database. In addition, where data were
incomplete, efforts were made to contact sites and the data ac-
quired. Data elements that remained unavailable after this process
was left as missing, as is usually applied in the analysis of observation-
al cohorts.18 The nature of clinician-driven quality improvement is
clearly dynamic. In this analysis, there is a likely cumulative influence
of the presence of acute care services and strategies such as the
rapid identification of STEMI on adherence with other clinical pro-
cesses, for instance the prescription of evidence-based therapies.
While we recognize that reasons for non-adherence with evidence-
based care are difficult to capture in a clinical registry, this compos-
ite quality score has the potential to provide guidance on which
failures of care can be detected and acted upon quickly by clinicians
and health service providers to improve the quality of hospital-
based care for ACS.
Figure 3 Risk-adjusted in-hospital outcomes and outcomes at 6 months.
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Our findings suggest that expanding the performance framework
to include a composite measure of adherence with evidence-based
clinical processes is a valuable quality instrument that can be applied
periodically in addition to reporting health outcomes alone.
Furthermore, the provision of a continuous and comprehensive
cycle of data collection is feasible outside health service research,
using health technologies such as the electronic medical record as
the vehicle for capturing and reporting patient level clinical pro-
cesses and patient outcomes.
This is particularly salient as there are few datasets available by
which to report performance as a continuous cycle of data collec-
tion and audit or to provide feedback to hospitals benchmarked
with peer comparisons as an ongoing resource for quality improve-
ment purposes. Reporting quality measures to health service provi-
ders is problematic when there is limited capacity to report more
broadly on adherence with evidence-based care, dissimilar hospital
infrastructure for data collection and variable access to health infor-
mation technology between hospitals.23
In the current Australian environment of activity-based funding
(ABF) to determine how and where clinical services are provided,
there is potential to expand the performance framework to include
process measures of effective healthcare delivery into routine
health service performance reporting.24 Additionally, the method
for calculating the quality composite score could be generated at
the local hospital level by clinicians, health administrators and by
health administrative data collection agencies to inform hospital per-
formance reporting. The calculation of a composite quality score to
measure hospital performance relies only on high-quality data cap-
ture and provides a tool that is interpretable by all stakeholders of
ACS care to identify areas of health service provision for system im-
provement. Reporting quality measures of hospital performance has
the potential to engage clinicians in self-assessment and professional
bodies in ongoing education to co-operatively monitor patient
outcomes and health service delivery and inform health policy
development.14,25
Limitations
These data, although collected systematically, are observational and
other factors not investigated here may also impact hospital per-
formance. Mortality rates reported by the registry were small over-
all, and several hospitals contributed comparatively fewer patients,
impacting our ability to determine a stronger association between
hospital adherence tertiles and mortality at 6 months. The broader
influences of patient risk and clinical services have previously been
evaluated,26 and it is clear from this analysis that patient character-
istics and clinical services including greater availability of coronary
angiography differ between hospitals. These issues and others
such as changes in medical/nursing workforce and the impact of
clinical leadership on clinician-driven implementation of evidence-
based care are beyond the scope of this study.
Conclusion
In this Australian ACS cohort, the composite measure of adherence
to evidence-based CPIs reveals variation between hospitals in the
quality of care for ACS. Risk-adjusted analyses confirmed an
association between higher hospital adherence with evidence-based
CPIs and lower in-hospital clinical events, demonstrating the utility
of a composite quality score to measure and report hospital per-
formance in the management of ACS. A hospital performance
framework that includes patient level evidence-based process mea-
sures would better inform the quality improvement process and
provide greater scope for engaging clinicians and hospital adminis-
trators in evidence-based quality improvement initiatives.8,25
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8 An integrated discussion of the 
three units of analysis  
Cardiovascular disease (coronary artery disease and consequent acute coronary 
syndromes) remains the leading cause of death in Australia. Thirteen per cent of all 
hospitalisations are related to cardiovascular disease and more than 33,054 deaths were 
related to myocardial infarction in 2012–210332. Unwarranted variation in healthcare 
provision for acute coronary syndromes has been attributed to a lack of data and 
knowledge regarding variation in care, the absence of feedback to clinicians about how 
the care they deliver affects these patients, a lack of time to engage in the quality review 
process, limited decision-support tools and poorly aligned directions for heath-service 
delivery (Krumholz 2008b). Clinical registries are effective for capturing patient-level 
data to report variation and to inform the planning and implementation of quality 
improvement initiatives33. 
A discussion of the case-study findings from the three units of analysis is provided in 
this chapter together with the stakeholder report prototype in Appendix 1. This case-
study demonstrates the contribution of observational registries in ACS in the analysis of 
temporal trends of adherence to evidence-based care and further, the contribution made 
by both patient and hospital characteristics to CER initiatives reporting quality of care. 
Secondly, the calculation of multiple clinical process measures as a single quality 
composite score provides an accurate measure of hospital performance that is 
reproducible and deliverable in a stakeholder report for interpretation by clinicians, 
hospital administrators and policy advocates alike.  
 
 
                                                 
 
32 Australian Institute of Health and Welfare 
33 Commission on Safety and Quality in Healthcare (ACSQHC) Atlas 2017 
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This case study tested the following propositions as three units of analysis to confirm 
the case-study findings:  
P1) Measuring temporal changes in the delivery of guideline-recommended care 
longitudinally provides valuable insights into the management of ACS over time; 
P2) Evidence-based clinical process indicators can be used to construct a quality 
composite score and a hierarchy of hospital performance.  
These propositions were developed from the case-study theories outlined in Chapter 2 
which were to demonstrate that clinical process measures captured within a quality 
comparative effectiveness (CER) research framework enhanced hospital performance 
reporting on the management of ACS.  
The methodologies used to examine the propositions were tested in each unit of 
analysis. Empirically testing these propositions and reporting both observed and risk-
adjusted outcomes was consistent with the positivist case-study approach (Yin 2014) 
that is, undertaking deductive analyses to support the findings of each unit of analysis 
that were applicable to quality reporting across the wider ACS population.  
The analysis undertaken in Chapter 4 included both NSTEACS and STEMI patient 
groups enrolled in the Australian and New Zealand cohort of the GRACE registry and 
underpinned the longitudinal analysis on the management and outcomes of patients in 
the most acute ACS cohort (STEMI patients) who were enrolled in the combined 
GRACE and CONCORDANCE registries as reported in Chapter 6. This first unit of 
analysis (Chapter 4) provided the initial insights into in-hospital management, in-
hospital clinical events and events at six months of 5615 patients recruited across 11 
hospitals in Australian and New Zealand between 2000 and 2017. Descriptive analysis 
and observed outcomes determined the association between temporal trends in 
adherence to evidence-based care and mortality and hospital readmission at six months 
and demonstrated substantial changes in the uptake of evidence-based medical therapies 
and interventions over an eight-year period 2000–2007. Important findings included a 
15% (p<0.01) increase in the uptake of primary PCI and a reduction of 26% (p<0.01) in 
the administration of fibrinolysis for acute STEMI. In the published results it was 
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postulated there may have been insufficient time to determine the impact of additional 
access to primary PCI on the absolute increase in primary PCI rates and the 
corresponding decline in the use of fibrinolysis during the study period. We were able to 
continue to review this trend in the STEMI cohort in the subsequent analysis 
(Chapter 6) and found a continuing increase in the provision of access to primary PCI, 
so throughout the 17-year study period 65% of STEMI patients received access to 
primary PCI and rates of fibrinolysis significantly declined during the period so that by 
2015–16, 38% of STEMI received fibrinolysis (p<0.01). 
This second unit of analysis (Chapter Six) included 4110 STEMI patients enrolled into 
either the GRACE (n=1279) or CONCORDANCE (n=2832) registries between 
February 1999 and August 2016 across 46 Australian hospitals. Patient demographic 
and clinical characteristics and in-hospital management including time from symptom 
onset to presentation were stratified by year of enrolment and the merged registry 
datasets were divided into six time periods. Descriptive statistics and multiple logistic 
regression analysis determined the association between the admission period and 
outcomes including in-hospital mortality, (re)MI, heart failure, and mortality to six 
months and unscheduled readmission within six months. Data were complete for 96% 
of critical data items, that is, those items required to calculate the CPIs in both datasets 
relating to pre-hospital and in-hospital and outcomes. This level of data quality was 
achieved through strong registry coordination where a supportive relationship with all 
participating hospitals was considered a priority for the success of the registry program. 
While site audits were undertaken with rigour, they were also regarded as an 
opportunity to educate site staff on the registry protocol, the interpretation of site reports 
as well as processes for participant screening and recruitment.  
 
Overall, we found there was significant uptake in the use of medical therapies inclusive 
of statins, antiplatelet agents (thienopyridines, predominantly clopidogrel), angiotensin 
converting enzyme inhibitors (ACE) and/or angiotensin receptor inhibitors (ARB) in 
both the first unit of analysis (Chapter 4) and in the second unit of analysis (Chapter 6), 
where the increase in the prescription of evidence-based therapies was sustained in-
hospital, and at hospital discharge for the prescription of statins, antiplatelets and beta-
blockers.  
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Observed outcomes reported in the first unit of analysis (Chapter 4) revealed a 
significant 3.9% decrease (p=0.04) in observed mortality across all groups STEMI and 
NSTEACS in-hospital, without a decline in mortality at six months follow-up. 
Declining rates of in-hospital congestive heart failure (8.2%, p=0.003), (Aliprandi-Costa 
et al. 2011) and rates of hospital readmission at six months (p<0.011) were assumed to 
be related to improved heart failure medical management and improved 
revascularisation during this period. In contrast to the first unit of analysis (Chapter 4) 
findings presented in Chapter 6 revealed access to primary PCI increased over the 
17-year period from 1999 and although the median door-to-balloon time decreased by 
11 minutes (p<0.01), approximately 35% of STEMI patients undergoing primary PCI 
exceeded the evidence-based threshold of the 90-minute door-to-balloon time.  
This is an important finding because the delivery of timely reperfusion is directly 
associated with reduced mortality. However, it is a costly 24-hour service for health 
administrators to provide. For example, medical, nursing and technical staff are rostered 
on-call and are paid accordingly; cardiac catheterisation laboratories entail both costly 
equipment and communication processes – the key prerequisites that create every 
opportunity for restoring blood flow through a coronary occlusion within 90 minutes of 
symptom onset. For such an investment, it is striking that over one-third of patients do 
not have coronary perfusion restored within 90 minutes and this may have directly 
impacted our ability to observe a reduction in mortality in-hospital and at six months 
over the 17-year period. We further postulated that other factors could be at play such as 
the nature of Australia’s geography and the availability of primary PCI services. That is, 
not all hospitals with PCI capability provide a 24-hour emergency primary PCI service. 
The foundation of the CONCORDANCE registry (Chapter 5) leveraged this body of 
evidence to align the CER framework design of the registry with the CER framework 
promoted by the Institute of Medicine priorities for CER when first promulgated in 
2009 (Iglehart 2009; Medicine 2009) and subsequent recommendations from the ‘Future 
Directions for Cardiovascular Disease Comparative Effectiveness Research’ workshop 
published in 2012 (Hlatky et al. 2012).  
 
Engaging clinicians in evidence generation and the quality review process was the 
rationale underpinning the design of the CONCORDANCE registry and was a unique 
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approach to the design of a clinical registry at that time. We fully expected the 
provisioning of calculated, benchmarked data as a real-time resource to participating 
clinicians would lead to local practice improvement. It was interesting then that we 
observed no reduction in the gap between our highest and lowest performing hospitals 
after several years of generating and providing these data. Our intention was to use the 
registry data to inform health service provision reporting and develop a resource for 
underperforming hospitals which would include the protocols and processes applied 
routinely by higher performing hospitals. Consistent with our research methodology, in 
the first instance we needed to provide evidence to participating clinicians that 
adherence to each measure was important in the delivery of overall care for ACS. This 
was achieved in our third unit of analysis (Chapter 7) which presented data on 7444 
ACS registry patients from 39 Australian hospitals to derive a hospital-specific quality 
composite score by calculating mean adherence to 15 evidence-based CPIs. Using 
hierarchical logistic regression analysis we accounted for both patient risk and 
clustering of patients within hospitals, the association between the hospital-specific 
composite quality score and in-hospital major adverse events, in-hospital mortality and 
mortality, and readmission for ACS at six months. In this analysis both clinical process 
measures and short- and medium-term outcome measures were included, together with 
hospital and workforce characteristics to describe those Australian hospitals that deliver 
high quality care for ACS.  
 
The inclusion of hospital and workforce characteristics was critical in the design of this 
analysis. For example, we were able to describe those hospital services, such as 
secondary prevention services, that were offered effectively.  For example, we observed 
that patients admitted to hospitals in the lowest performing tertile hospitals were more 
likely to have a previous history of hypertension, dyslipidaemia, renal impairment and 
diabetes. In this analysis (Chapter 7) we found no difference in the availability of 
secondary prevention services between hospitals in the highest performing tertile and 
the lowest performing tertile, yet hospitals in the lowest performing tertile were 
significantly less likely to refer patients to secondary prevention services (p<0.01) 
(Aliprandi-Costa, 2016). This highlights an important area of focus for improvement in 
the delivery of secondary prevention programs in these underperforming hospitals.  
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This case-study moved beyond the current recommended approach of using an ACS 
clinical registry to describe current-practice patterns and variation in care, to providing a 
reporting resource for stakeholders inclusive of hospital administrators, health 
departments and patients (Appendix 1). Communication and feedback strategies are 
recognised as an important impetus for change (Glasziou et al. 2012; Torchiana et al. 
2013) in a wider stakeholder group particularly when contemporary evidence-based 
composite measures are used to assess individual hospital performance and compare 
benchmarked performance across similar hospital settings (Eijkenaar et al. 2013) as 
provided in this report.   
Consistent with the requirement for the quality measures to be evidence-based and 
appropriate to be reported as measures of quality of care, the data presented in this 
report includes both clinical process and outcome measures which are realistic and 
accessible via hospital data sets and via direct patient contact (Scott, Poole, and 
Jayathissa 2008; Scott, Thomson, and Narasimhan 2008). In this report the method for 
aggregating clinical data in the CONCORDANCE clinical quality registry is provided, 
together with the calculated clinical process indicators and composite measures of 
hospital performance in plain language for ease of stakeholder interpretation and to 
facilitate the stakeholder engagement process. The mean performance of 39 Australian 
hospitals is provided with an executive statement on how data can be used to report 
hospital performance for several hospitals within a local health district (LHD) compared 
with hospitals in New South Wales (NSW) and hospitals in other Australian states and 
territories.  
Delivering quality care is not a ‘first world’ problem. In Australia the cost for hospital-
based care currently is fast exceeding the growth of the economy as measured by the 
gross domestic product (GDP).34 Therefore more effective provision of these acute care 
services may reduce the cost of acute care interventions. Importantly, registries that 
report on how clinicians apply the evidence from clinical trials into daily clinical 
practice offer significant value.  
                                                 
 
34 Australian Institute of Health and Welfare. Cardiovascular disease, diabetes and chronic kidney disease – Australian facts: 
morbidity – hospital care. Canberra: AIHW; 2014 
Chapter 8: An integrated discussion of the three units of analysis 
103 
 
From 2009 this CER initiative (CONCORDANCE registry) has provided a platform for 
a practical clinical trial (Chew et al 2015) and a bi-national ACS audit (Chew et al 
2013). It has delivered a quality reporting resource and generated important insights into 
current practice patterns. The next steps of this research would be to undertake a 
stakeholder evaluation of the developed report (Appendix 1). Following a detailed 
stakeholder analysis, the identified key stakeholders could then be invited to participate 
in an evaluation of this report. The final report format would be the maturity exemplar 
of a customised hospital-performance report of agreed measures of performance in the 
management of ACS. This report also provides a mechanism to share resources and 
protocols with underperforming hospitals for practice improvement and, although this 
report is currently de-identified, it is not inconceivable that such a report could be 
identified in the future.  Section 8.1 outlines the research implications and future 
directions for this research to progress this CER initiative to a platform for ongoing 
health service provision reporting.  
8.1 Research implications and future directions 
The implications of findings from this thesis are both theoretical and practical. 
Theoretical contributions 
The CONCORDANCE registry was uniquely designed with a focus on quality 
reporting, and was the largest Australian ACS registry with hospital representation in 
every state and territory. CONCORDANCE was specifically designed to include the 
attributes of a clinical-quality registry to facilitate comparisons within the ACS 
population, to demonstrate the association of adherence to evidence-based care and 
patient outcomes. These comparisons determined that both the design of the 
CONCORDANCE registry within a CER framework and the collected data were 
sufficiently robust and complete to facilitate reporting temporal trends. My report on the 
management of ST-elevation acute myocardial infarction (STEMI) in Australia is the 
most extensive Australian report on this high-risk cohort to date.  
The second theoretical contribution was the development and testing of a quality 
composite measure of hospital performance. The development of the quality composite 
score enabled us to measure and report on hospital performance in the management of 
Chapter 8: An integrated discussion of the three units of analysis 
104 
 
ACS and to demonstrate the association between greater hospital adherence with the 
quality composite score and improved patient outcomes. 
The exploration of a quality CER framework within a clinical registry has not 
previously been undertaken in the Australian context and makes an original contribution 
to hospital performance reporting on the management of ACS in Australia. 
Practical implications 
The practical implication of this research is underpinned by our finding that reporting 
quality measures to participating investigator clinicians alone does not lead to 
meaningful practice change in underperforming hospitals35.  From 2009 the registry 
generated evidence-based clinical process indicators as a real-time, web-based resource 
to participating clinicians. This thesis identifies that providing this feedback alone was 
insufficient in minimising performance differences between the highest and poorest 
performing hospitals in this cohort.  
Currently there are no valid aggregate measures of excellence in the delivery of 
hospital-based care for ACS. Quality outcomes data are being collected solely for 
research purposes and siloed within research collaboratives and/or at the local hospital 
level by clinician researchers, which limits the practical value of these data for hospital 
administrators, health departments and their agencies. The enormous effort and cost put 
into collecting clinical outcomes data is wasted without these data being more widely 
shared. Performance measures are still underutilised in the planning and delivery of 
costly acute care services for ACS and there remains widespread heterogeneity in 
patterns of care, in reporting systems and IT platforms across LHDs in Australia.  
As recently as 2016 the final report from an inquiry under Section 122 of the Health 
Services Act36 into ‘Off-protocol prescribing of chemotherapy for head and neck 
cancers’ was released37. The inquiry team needed the re-abstraction of data from 
hospital clinical systems and other databases to undertake the review. However, it was 
                                                 
 
35 B. Aliprandi-Costa et al. Real-time reporting of clinical process measures reveals improved performance, yet differences persist 
between hospitals in the Australian Cooperative National Registry of Acute Coronary Care, Guideline Adherence and Clinical 
Events (CONCORDANCE). American College of Cardiology May 2014 
36 Health Services Act 1997 No 154 https://legislation.nsw.gov.au/inforce/59d71b18-59e1-693c-e068-b6c6de1d2851/1997-154.pdf 
37 http://www.health.nsw.gov.au/patients/cancertreatment/Documents/section-122-final-report.pdf 
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noted that while there were Medical Oncology Information Systems (MOSAIC) in place 
in some hospitals, other hospitals and some local health districts did not have this 
technology available to report routinely on prescribing practices, nor processes for these 
data to be reviewed and communicated. We know from our research that clinicians vary 
their practice based on clinical guidelines, their experience in delivering particular 
treatments and the management of adverse events related to treatment delivery. For 
example, in Chapter Four (Aliprandi-Costa, 2011) we found the use of Glycoprotein 
(GP) IIb/IIIa receptor antagonists increased by 6% between 2000 and 2005 on the 
background of clinical guidelines38 supporting their use, yet rates of use had declined by 
2007 to similar rates of use in 2000 in the NSTEACS group. In the discussion of these 
published findings we postulated this decline was related to cost constraints and 
concerns that the potential for increased bleeding outweighed the benefits of improved 
cardiovascular-related outcomes, particularly when these patients also received dual 
antiplatelet therapy. It is striking then that, despite the availability of comprehensive 
health-service provision policies and clinical guidelines, there are no uniform solutions 
for the routine abstraction and presentation of data from readily available hospital 
systems on clinical care and prescribing practices to clinicians, hospital administrators 
and health departments. 
This thesis is noteworthy for three reasons. Firstly, it offers a measure of hospital 
performance in the management of ACS which is easy to interpret and makes it possible 
to report the care provided to the patient informed by risk-adjusted outcomes. Secondly, 
it demonstrates that important insights can be gained from longitudinal reporting on 
current practice patterns and practice variation in the management of the ACS cohort 
and STEMI sub-group within this cohort, which would not have been possible outside a 
quality registry framework. Thirdly, it highlights the limitation of providing calculated 
clinical-process measures with real-time feedback data to participating clinicians alone. 
To address this limitation a report prototype has been developed which offers a 
mechanism to communicate performance to a wider stakeholder group beyond clinician 
researchers.  
                                                 
 
38 https://www.mja.com.au/journal/2006/184/8/guidelines-management-acute-coronary-syndromes-2006 
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The Second Australian Atlas of Healthcare Variation 2017 of the Australian 
Commission on Safety and Quality in Health Care (ACSQHC) recommended the 
‘development of a national (ACS) quality registry that leveraged the electronic medical 
record in the acute hospital setting to report variation and provide a feedback 
mechanism to clinicians’39, our research suggests that performance improvement is 
more likely to  be achieved when data are provisioned more broadly to patient 
representatives, hospital clinicians and administrators, local health district 
administrators and government to review and improve care delivery (Krumholz 2013). 
Measures of adherence with evidence-based care have been undertaken in other clinical 
areas including the management of sepsis, where compliance with sepsis bundles of 
care were correlated with improved patient outcomes.   
Organisations such as the American College of Cardiology40 provide a platform for 
practitioners and health administrators alike to monitor performance and participate in 
quality improvement initiatives, so it is not inconceivable that this model could advance 
a more innovative and agile platform being developed to inform a local, state and 
territory and national reporting strategy. A recent Gratten Institute report41 
acknowledged the contribution of clinical registries to evidence generation and 
recommended that in order to make data useful, registry data should be linked to 
hospital and health-system databases for routine reporting.  
This progresses the concept from that of a static registry, as presented in this thesis, to a 
more nuanced model for routine data capture – in fact, a ‘distributed registry’ approach 
using the in-patient medical record on the management of ACS to specifically assess 
ACS. Further, with the advance in information technologies such as machine learning, 
routinely collected hospital information becomes both accessible and useable for this 
purpose. These technologies use collaborative data-driven logic to leverage existing 
data applications (electronic medical, pathology and administration databases) and 
incorporate methods of machine learning and dynamic reporting to generate insights 
                                                 
 
39 Commission on Safety and Quality in Healthcare (ACSQHC) Atlas (2017) 
40 https://cvquality.acc.org/NCDR-Home 
41 https://grattan.edu.au/report/strengthening-safety-statistics 
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and data solutions to meet the needs of all stakeholders42. These technologies advance 
the current state of database infrastructure for health service research including clinical 
registry databases to cut across the disparate hospital technology infrastructure. Data 
validation methodologies would ensure the attributes of quality data capture in defined 
patient groups (ACS) are preserved, and the data captured would include patient 
comorbidities, adverse events and outcome measures.   
This strategy would require investment by hospitals in information technology (IT) 
infrastructure. There are opportunities for such investments to be incentivised within 
government funding agreements and by hospital accreditation bodies for locally 
developed IT solutions. Such leverage would minimise hospital attrition from 
participation in quality improvement initiatives. Information technology solutions for 
health data and reporting are advancing rapidly and the momentum should be in this 
space – enhancing outcomes reporting and the design of clinical registries using 
routinely captured hospital data. The utility of the electronic medical record (eMR) can 
be further harnessed to generate real-time data extraction on quality processes of care 
across all clinical areas. Agencies such as NSW E-Health have the capability to 
facilitate quality reporting at the local hospital and local health district level, and 
between jurisdictions (where the eMR has the same provider) on agreed quality 
measures of performance. This concept could then be expanded to compare with 
evidence-based international benchmarks on publicly available reporting platforms. 
Potential barriers to system-wide performance reporting transformation include 
heterogenous IT infrastructure and opposing views on public hospital performance 
reporting. However, not-for-profit organisations such as the Health Round Table or 
agencies such as the Australian Commission on Safety and Quality in Healthcare could 
play a valuable role in undertaking stakeholder engagement activities on comparative 
hospital performance reporting to inform the development of health policy. 
These strategies provide an accessible resource and circumvent the barrier of disparate 
information technology infrastructure within and between local health districts to use 
existing data sources to report to clinicians, hospital administrators and government on 
                                                 
 
42 IBM Analytics data sheet March 2017.  IBM Corporation, New Orchard Road Armonk NY 10504 
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the quality of health service delivery. It should not be impossible to imagine one 
nationwide warehouse of health outcomes data abstracted from routinely collected 
hospital information systems.  
 
8.2 Conclusion  
 
In Australia43, 44 and internationally45 quality frameworks are being described to guide 
the management of ACS. Yet, in Australia, the provision of a comparative effectiveness 
research framework together with access to an ACS clinical registry and methods of 
data collection, analysis and quality reporting, are not available outside investigator-
initiated research endeavours and clinical trials. In this case study, the contribution of a 
comparative effectiveness research framework to bridge the quality-reporting gap on 
effective health service delivery for ACS was explored to provide a strategy for 
engaging a wider stakeholder group in the monitoring and review of unwarranted 
variation in care. Data from the Australian and New Zealand cohort of the GRACE 
registry were used to describe longitudinal change in the management of ACS and the 
association with in-hospital adverse clinical events and mortality, and hospital 
readmission and mortality at six months. The design of the CONCORDANCE registry 
within a comparative effectiveness research framework, which formed the constructs of 
the thesis conceptual framework, is described, and then, patient-level data from the two 
aligned ACS clinical registries (GRACE and CONCORDANCE) were used to report 
temporal trends in the management of ST-elevation acute myocardial infarction over a 
17-year period and the association with in-hospital clinical events and mortality, and 
hospital readmission and mortality at six months.  
 
In aggregate, these findings and the registry design facilitated the development and 
testing of a quality composite measure of hospital performance. Hospitals with high 
adherence to the composite score had lower in-hospital clinical events and mortality, 
                                                 
 
43 Heart Foundation of Australia; Australian acute coronary syndromes capability framework. 2015 
44 Australian Commission for Safety and Quality in Health care; Acute coronary syndromes clinical care standard.2014 
45 https://www.gov.uk/government/publications/quality-standards-for-coronary-heart-disease-care 
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lower hospital readmission and lower mortality at six months. Analysis established the 
contribution of a quality composite measure of hospital performance in the management 
of ACS and facilitated the development of a reporting strategy using clinical process 
data in a stakeholder report prototype. This report has the potential to communicate 
hospital performance directly to clinicians and administrators, and would support an 
inexpensive, foundational engagement strategy with a technology solution for future 
practice improvement for disease states associated with high rates of mortality and high 
costs for health-service provision. While this work is based around the management of 
ACS all the methodologies lend themselves to exploring outcomes and quality health 
service provision in a variety of clinical settings. Health service provision and patient 
outcomes reporting using clinical process indicators to report performance with peer 
comparisons has the potential to realise the successful translation of research outcomes 
to a much wider and potentially more effective audience. 
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Quality measures of health service provision are currently 
restricted to broad measures of effectiveness such as surgical wait 
times, time to treatment in the emergency department, and rates 
of all-cause mortality. However, there is a growing appreciation 
that measuring and reporting hospital performance is more 
complex.  
We have demonstrated that assessing adherence to evidence 
based clinical processes is a valid measure of hospital performance 
and can be used to refine policy and health service planning for 
acute coronary syndromes (ACS).1
There is also growing awareness that the method of collating and 
reporting performance metrics within a comparative effectiveness 
framework in collaboration with key stakeholders (clinicians, health 
administrators and government health agencies), may be more 
effective than just reporting to clinicians, for improving health 
service provision for disease states which are associated with high 
cost for health service provision, such as ACS.
The cost of health care for acute coronary syndromes 
is high.
Overall, Australian health care expenditure in 2013-14 was $155 
billion. Of this, $59 billion was spent on in-patient costs for both 
public and private hospitals.  Approximately 11% ($ 5 billion) 
was spent on cardiovascular disease (CVD) and despite intense 
focus on primary and secondary prevention strategies for CVD, 
there were more than 120,000 hospitalisations for ACS costing 
the healthcare system more than $1.8 billion annually.2 With 
these costs in mind, there are substantial gains for stakeholders in 
understanding variation in clinical care and how we might improve 
quality reporting in this context.
Using this report to 
understand local health 
district and NSW 
performance in the 
management of acute 
coronary syndromes
1 Aliprandi-Costa B et al; European Heart Journal-Quality of Care and Clinical Outcomes. 2016;3:37-16.
2 Australian Institute of Health and Welfare, 2014. Cardiovascular disease and chronic kidney disease –Australian facts. Prevalence and incidence.
3 Heart Foundation of Australia, 2015. Australian acute coronary syndromes capability framework. 
4 Australian Commission for Safety and Quality in Health care, 2014. Acute coronary syndromes clinical care standard.
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Measuring performance
There are standards and clinical frameworks 
for the management of ACS,3,4 but no 
reliable way to capture compliance with 
these guidelines. Nor is there an easy way 
for clinicians, health administrators and 
government health agencies to compare 
compliance across diverse clinical settings.
Australian Hospitals deliver high quality 
care to people admitted to hospital with an 
ACS but there are few avenues by which to 
communicate and evaluate success.
This report can be used by all stakeholders 
to review compliance with evidence based 
care by hospitals located within an LHD 
in comparison with hospitals in NSW and 
hospital in other states and territories.
How does NSW perform? 
The timely provision of reperfusion for patients admitted to hospital 
with acute ST elevation acute myocardial infarction (STEMI)
The provision of access to coronary angiography 
during hospital admission for patients with 
high-risk ACS.
Left ventricular functional assessment for high risk ACS 
patients during hospital admission. 
NSW is below the national benchmark across three measures:
This report is an example of 
what might be provided
 to a stakeholder outside 
this research project.
 
A report such as this could 
also be web-based and 
provide partially identified 
stakeholder specific 
information that would 
facilitate direct comparison 
of the performance of a 
hospital and/or LHD with 
hospitals nationally.
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INTRODUCTION
Process for 
monitoring variation 
and improving health 
service provision
Develop processes for routine data extraction
 
From the patient medical record to measure adherence with 
evidence based processes of care.
Identify unwarranted clinical variation and begin 
strategic planning to meet short-term targets (clinical 
areas requiring immediate practice improvement) and 
identify long term targets. 
For example, based on the data provided the following targets could 
be achieved through quality improvement initiatives:
Implement 
improvement 
initiatives
Re-evaluate 
to determine 
future focus 
areas for quality 
improvement
4. 3. 
1. 
2. 
Greater than 
80% 
of high risk ACS hospitals will 
receive inpatient coronary 
angiography and left ventricular 
functional assessment 
during hospital admission
Greater than 
75%
of hospitals will provide 
timely reperfusion 
for STEMI 
(ST elevation 
myocardial infarction)
Provide hospital administrators and 
clinicians with protocols to assist with 
the implementation of practice change, 
clinical support and a time frame for 
completion of improvement initiatives.
Routine calculation of the composite 
measure of performance for comparison 
and to communicate outcomes. 
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Develop and monitor 
processes for routine 
data capture Identify hospitals 
and/or LHDs operating 
below the benchmark
Strategic planning 
of long term 
targets
Strategic planning 
of short-term 
targets
Implementation 
of practice change 
initiatives
Communicate 
and re-evaluate 
performance
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Observational data captured through clinical quality registries have 
become vehicles for generating evidence on the effectiveness of 
therapeutic strategies to treat cardiovascular diseases in subgroups 
of patients and poorly resourced environments that are not well 
represented in clinical trials. Clinical registries have evolved from 
our awareness of the ‘gap’ between the generation of evidence 
through clinical trials and the translation of evidence into clinical 
care and have facilitated analyses on variation in clinical practice 
compared to best practice recommendations.1,2
Cardiovascular disease registries have had a presence in the 
Australian health landscape since 1999 and have provided 
the opportunity to document and understand the drivers for 
suboptimal care and patient outcomes.3,4 There are well described 
clinical processes for evaluating care provision along the ACS care 
pathway which demonstrate adherence to evidence based care. 
Captured rigorously, these measures are reliable and relevant to 
all ACS patients and provide readily identifiable targets for quality 
improvement initiatives.  In adopting a comparative effectiveness 
research framework (CER) these data enable associations between 
logistics of care, access to services and provision of evidence 
based care and patient outcomes to be described.
The Cooperative National Registry of Acute Coronary care, 
Guideline Adherence and Clinical Events (CONCORDANCE) 
Registry is a clinician-driven initiative providing measures of 
clinical care for ACS patients admitted to participating Australian 
hospitals. The clinical process data reported here have been 
aggregated via the CONCORDANCE Registry for the purpose of 
generating this report.  
Australia and New Zealand Clinical Trial Registration (ANZCTR): 
CONCORDANCE Registry- ACTRN1261400088767
Using clinical 
registry data 
to document 
variation in care
ACS    acute coronary   
    syndromes 
CER     comparative   
    effectiveness   
    research
 
LHD    local health district
LOE    Levels of evidence 
NSTEMI    Non-ST Elevation  
    myocardial infarction
NSTEACS Non-ST elevation  
    acute coronary   
    syndrome (includes  
    NSTEMI and UAP)
PCI    Percutaneous   
    coronary intervention
PPCI    Primary   
    percutaneous    
    coronary intervention
STEMI    ST elevation   
    myocardial infarction
UA    Unstable angina
1 Evans, S.M., et al., Development of clinical-quality registries in Australia: the way forward. Med J Aust, 2011. 194(7): p. 360-3.
2 McNeil, J.J., et al., Clinical-quality registries: their role in quality improvement. Med J Aust, 2010. 192(5): p. 244-5.
3 Grace Investigators 2001 Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients 
hospitalised with acute coronary syndromes Am Heart J Vol 141; Issue 2; pages 190-9
4 Aliprandi-Costa, B., et al., Management and outcomes of patients with acute coronary syndromes in Australia and New Zealand, 2000-2007. Med J 
Aust, 2011. 195(3): p. 116-21.
Abbreviations
CER Report ACS 2009 - 2017  B. Aliprandi-Costa98
The CONCORDANCE registry5 was designed within a CER framework to report on the 
management and outcomes of patients admitted to hospital with an ACS. The registry has 
provided data on adherence to evidence based care and patient outcomes to the hospital based 
clinician investigators since 2009. 
Participating hospitals are located in geographically diverse regions of Australia and represent the 
range of cardiology clinical services provided in these locations. A purposive sampling strategy 
was adopted to ensure the inclusion of a broad distribution of hospitals with percutaneous 
interventional (PCI) capabilities and non PCI capabilities. Each month, the first 10 consecutive 
patients admitted to hospital with a provisional diagnosis of ACS are enrolled through an opt-out 
consent process.  Information including pre-hospital care, patient demographics, past medical 
history, presenting characteristics, in-hospital management and outcomes at six months and two 
years are entered into a web-based database using an electronic clinical record form (eCRF). 
The CONCORDANCE registry uses standardised definitions and data are abstracted by trained 
hospital staff and audited to ensure accuracy and consistency with the registry protocol.
Description of the Registry
Alfred Health (Vic)
Nambour General Hospital
Coffs Harbour Hospital
Lyell McEwin Hospital
Royal Hobart Hospital
Alice Springs Hospital
Concord Hospital
Bairnsdale Regional 
Royal Perth Hospital
Dubbo Hospital
Royal Prince Alfred
Monash Heart
Austin Hospital
Flinders Medical Centre
Nepean Hospital
Sir Charles Gairdner Hospital 
Bankstown Hospital
Geelong Hospital
Northern Hospital
St Vincent’s Hospital (Victoria)
Bathurst Hospital
Gold Coast Hospital
Orange Base Hospital
The Queen Elizabeth Hospital
Box Hill Hospital
John Hunter Hospital
Port Macquarie Hospital
Toowoomba Hospital
Campbelltown Hospital
Launceston General
Prince Charles Hospital
Townsville Hospital
Canberra Hospital
Lismore Base Hospital
Royal Brisbane Hospital
Westmead Hospital 
Liverpool Hospital
Royal Darwin Hospital
Wollongong Hospital
5 B Aliprandi-Costa DB, I Ranasinghe, A Patel. The Australian Cooperative National Registry 
of Acute Coronary care, Guideline Adherence and Clinical Events (CONCORDANCE)
Note: Participating hospitals 
are not individually identified 
in the report. 
Participating hospitals
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ACS POPULATION
0
10
20
30
40
50
LHD NSW1 NSW AOH
19.4
25.625.924.8
44.9
43.544.1
41.5
30
24.423.4
27.3
LHD = sample of 3 hospitals inclusive of one hospital with on-site cardiac surgery; one hospital with a cardiac catheter laboratory and onsite PPCI and one metropolitan 
hospital with no cardiac catheter lab or on-site surgery (n=3)
NSW1 = All NSW hospitals (n=12) except for those hospitals included in LHD
NSW= All NSW hospitals inclusive of hospitals in LHD (n=15)
All other hospitals (AOH) = Aggregate of other participating hospitals exclusive of hospitals in NSW and the LHD.
REPORTING GROUP
STEMI
(n(%)
NSTEMI
n(%)
UA
n(%)
LHD 237(27.3) 304(41.5) 168(24.8)
NSW1 633(23.4) 1147(44.1) 607(25.9)
NSW 870(24.4) 1451(43.5) 775(25.6)
AOH 1421(30) 2091(44.9) 837(19.4)
39 
Australian
hospitals 
STEMI
(n= 2306)  
UA
(n= 1612)  
NSTEMI
(n= 3542)  
7,490
patients recruited 
between 
February 2009 and 
November 2016
ACS population treated by a local health district 
(LHD), NSW and aggregate of all other participating 
hospitals (AOH)
1110
Composite measures 
of performance
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COMPOSITE MEASURES OF PERFORMANCE
The purpose of calculating a composite 
measure of performance is to characterise 
overall adherence to a range of evidence 
based clinical processes. The method for 
calculating the composite score has been 
described previously.1 
Adherence to guideline recommended care is 
determined for each patient by the proportion 
of care processes delivered to eligible patients 
based on their diagnosis at discharge. 
Only hospitals with more than ten patients 
in either cohort (NSTEMI or STEMI) are 
included in the calculation of the composite 
performance score. 
The presentation of the composite 
scores in this report has been aligned 
with the presentation of these data by 
American College of Cardiology’s National 
Cardiovascular Data Registry (NCDR)2
Calculating the 
composite measure 
of adherence to 
evidence based care
^ Note: Only ST elevation MI patients are included in adherence 
measures for primary percutaneous intervention (PPCI) or 
thrombolysis and only patients who survived the admission process 
were included in the CPIs for acute treatment. Patients surviving to 
hospital discharge were included in measures for access to discharge 
therapies and referral to secondary prevention.
^^Note: Patients transferred through more than one hospital are 
included in this analysis to reflect all care provided during the index 
admission). 
Those patients who 
received all possible care 
processes (numerator) 
against the number of 
patients eligible for care 
(denominator) were 
included in the aggregate 
patient adherence score.^ 
Adherence with CPIs were 
summated for each patient 
and then averaged within 
each hospital. 
The composite adherence 
score, as an aggregate 
measure of hospital 
performance was then 
calculated - the higher 
value representing greater 
compliance with clinical 
procedures.
The means for each 
centre were then 
ordered from highest 
to lowest to determine 
hospital performance 
tertiles.^^
1 Aliprandi-Costa, B., et al., The Contribution of the Composite of Clinical Process Indicators as a 
Measure of Hospital Performance in the Management of Acute Coronary Syndromes-insights from 
the CONCORDANCE Registry.2016  European Heart Journal-Quality of Care and Clinical Outcomes
2 American College of Cardiology National Cardiovascular Data Registry (NCDR https://cvquality.acc.
org/NCDR-Home.aspx)
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Clinical processes included in the composite measure calculation for the management of STEMI:
• Reperfusion therapy (either PCI or thrombolysis for STEMI only) 
Thrombolysis </= 30mins
PPCI </= 90mins
• Assessment of LV systolic function
• Antiplatelets in-hospital
• Antiplatelets at discharge
• Beta Blocker at discharge
• ACE-I or ARB at discharge
• Statin at discharge
• Referral to secondary prevention 
Composite measure of performance in the 
management of STEMI 
Hospi ta l S tate STEMI  cases  (n )
Mean compliance for 
STEMI cases
Tertile based on 
STEMI compliance
Hospital 1 SA 17 56.47 Bottom
Hospital 2 NSW 29 58.28 Bottom
Hospital 3 NSW 199 58.44 Bottom
Hospital 4 QLD 29 58.62 Bottom
Hospital 5 NSW 39 59.97 Bottom
Hospital 6 NSW 99 60.4 Bottom
Hospital 7 NSW 27 62.22 Bottom
Hospital 8 NSW 11 62.73 Bottom
Hospital 9 QLD 77 62.86 Bottom
Hospital 10 NSW 65 63.69 Bottom
Hospital 11 VIC 54 64.44 Bottom
Hospital 12 NSW 70 64.86 Bottom
Hospital 13 TAS 39 64.87 Middle
Hospital 14 NSW 11 65.45 Middle
Hospital 15 NT 27 65.56 Middle
Hospital 16 VIC 33 65.76 Middle
Hospital 17 SA 20 66 Middle
Hospital 18 NT 121 66.03 Middle
Hospital 19 NSW 102 66.76 Middle
Hospital 20 VIC 53 67.36 Middle
Hospital 21 NSW 43 67.44 Middle
Hospital 22 NSW 130 67.83 Middle
Hospital 23 QLD 106 68.21 Middle
Hospital 24 VIC 165 68.97 Top
Hospital 25 SA 100 69 Top
Hospital 26 NSW 145 69.45 Top
Hospital 27 QLD 11 70 Top
Hospital 28 WA 57 70.35 Top
Hospital 29 QLD 27 70.37 Top
Hospital 30 ACT 66 70.61 Top
Hospital 31 WA 131 70.84 Top
Hospital 32 VIC 49 71.63 Top
Hospital 33 TAS 27 72.22 Top
Hospital 34 NSW 38 73.16 Top
Hospital 35 VIC 66 73.33 Top
Note: only hospitals with 10pts in either cohort are included
COMPOSITE MEASURES OF PERFORMANCE - STEMI
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COMPOSITE MEASURES OF PERFORMANCE - STEMI
60
62
64
66
68
70
72
ACT NSW NT QLD SA VIC WA
70.59
68.58
63.82
66.0165.7
64.26
70.61
Mean compliance with the composite of clinical 
processes for STEMI by state and territory
Mean compliance with composite of clinical 
processes for STEMI by LHD, NSW and the 
national aggregate of participating hospitals
60
62
64
66
68
LHD NSW NSW1 AOH
67.14
64
64.63
63.37
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Composite measure of performance 
in-patient clinical events and patient 
reported outcomes at 6 months
STEMI clinical events in-hospital and at 6 months 
by top and bottom hospital performance tertile
STEMI Outcomes in-hospital and at 6 months from the index admission
Event
Tertile based 
on STEMI 
compliance
Number of 
events (Y)
Number of 
possible 
cases
Percent of 
Events
Chi-square 
Probability
Odds 
ratio
Lower 95% 
CL
Upper 95% 
CL
Congestive heart failure Top 84 866 9.7 . . . .
Congestive heart failure Bottom 96 712 13.48 0.0186 1.4508 1.0627 1.9806
Cardiogenic shock Top 49 866 5.658 . . . .
Cardiogenic shock Bottom 68 713 9.537 0.0034 1.7578 1.2003 2.5743
Acute renal failure Top 69 871 7.922 . . . .
Acute renal failure Bottom 66 710 9.296 0.3309 1.1912 0.8369 1.6955
Recurrent ischaemia Top 34 845 4.024 . . . .
Recurrent ischaemia Bottom 88 714 12.32 <.0001 3.3531 2.2269 5.0489
Myocardial infarct Top 34 867 3.922 . . . .
Myocardial infarct Bottom 26 709 3.667 0.7929 0.9327 0.5542 1.5696
Cardiac arrest Top 61 873 6.987 . . . .
Cardiac arrest Bottom 69 716 9.637 0.0552 1.4196 0.9908 2.034
Stroke Top 7 872 0.803 . . . .
Stroke Bottom 14 712 1.966 0.044 2.4785 0.9949 6.1744
Death Top 29 884 3.281 . . . .
Death Bottom 93 723 12.86 <.0001 0.2298 0.1496 0.353
Any in-hospital event Top 195 855 22.81 . . . .
Any in-hospital event Bottom 247 712 34.69 <.0001 1.7978 1.4398 2.245
Alive at 6 months Top 514 526 97.72 . . . .
Alive at 6 months Bottom 389 415 93.73 0.0021 0.3493 0.1741 0.701
Admission for cardiac causes Top 104 522 19.92 . . . .
Admission for cardiac causes Bottom 92 414 22.22 0.3906 1.1484 0.8373 1.575
STEMI patients in top performing hospials had: 
•	 less congestive heart failure in-hospital
•	 less cardiogenic shock in-hospital
•	 less recurrent ischaemia in-hospital
•	 fewer in-hospital deaths
•	 and were more likely to be alive at 6 months
COMPOSITE MEASURES OF PERFORMANCE - STEMI
Chi-squared analysis determined the probability for differences in in-hospital and 6 month outcomes.
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COMPOSITE MEASURES OF PERFORMANCE - NSTEMI
Hospita l State NSTEMI cases (n ) Mean compliance for NSTEMI cases Tertile based on NSTEMI compliance
Hospital 1 NSW 34 45.22 Bottom
Hospital 2 SA 25 49 Bottom
Hospital 3 SA 24 52.6 Bottom
Hospital 4 NSW 15 54.17 Bottom
Hospital 5 QLD 64 59.38 Bottom
Hospital 6 NSW 214 60.69 Bottom
Hospital 7 NSW 27 61.11 Bottom
Hospital 8 NSW 62 62.7 Bottom
Hospital 9 NSW 165 63.18 Bottom
Hospital 10 NSW 137 63.41 Bottom
Hospital 11 NSW 56 63.62 Bottom
Hospital 12 NT 98 64.54 Bottom
Hospital 13 NSW 86 64.68 Bottom
Hospital 14 NSW 96 64.97 Middle
Hospital 15 ACT 62 65.52 Middle
Hospital 16 NSW 28 66.07 Middle
Hospital 17 VIC 83 67.02 Middle
Hospital 18 QLD 49 67.35 Middle
Hospital 19 TAS 53 67.45 Middle
Hospital 20 NSW 35 67.5 Middle
Hospital 21 VIC 110 67.5 Middle
Hospital 22 NSW 37 67.52 Middle
Hospital 23 QLD 182 68.27 Middle
Hospital 24 NT 227 69.71 Middle
Hospital 25 NSW 219 70.38 Middle
Hospital 26 VIC 125 70.59 Top
Hospital 27 QLD 197 71.3 Top
Hospital 28 VIC 49 72.45 Top
Hospital 29 NSW 121 72.83 Top
Hospital 30 QLD 35 73.57 Top
Hospital 31 TAS 22 75 Top
Hospital 32 WA 188 75.27 Top
Hospital 33 WA 83 75.45 Top
Hospital 34 NSW 193 75.52 Top
Hospital 35 NSW 71 75.53 Top
Hospital 36 SA 143 76.84 Top
Hospital 37 VIC 78 77.24 Top
Hospital 38 VIC 33 81.06 Top
Composite measure of performance in the 
management of NSTEMI
Clinical processes included in the composite measure calculation for the management of NSTEMI:
1. Angiography within </= 48 hours
2. Assessment of LV systolic function 
3. Antiplatelets in-hospital
4. Antiplatelets at discharge
5. Beta Blocker at discharge
6. ACE-I or ARB at discharge
7. Statin at discharge
8. Referral to secondary prevention
NSTEMI hospital performance tertile
Note: 38 out of 39 hospitals are listed as only hospitals with 10pts in either cohort are included
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COMPOSITE MEASURES OF PERFORMANCE - NSTEMI
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PATIENT OUTCOMES IN-HOSPITAL AND AT 6 MONTHS - NSTEMI
NSTEMI outcomes in-hospital and at 6 months
Event
Tertile based 
on NSTEMI 
compliance
Number of 
events (Y)
Number of 
possible 
cases
Percent of 
Events
Chi-square 
Probability
Odds 
ratio
Lower 95% 
CL
Upper 95% 
CL
Congestive heart failure Top 100 1041 9.606 . . . .
Congestive heart failure Bottom 80 490 16.33 0.0001 1.8361 1.3386 2.5186
Cardiogenic shock Top 57 1040 5.481 . . . .
Cardiogenic shock Bottom 53 489 10.84 0.0002 2.0964 1.4185 3.0983
Acute renal failure Top 76 1045 7.273 . . . .
Acute renal failure Bottom 47 488 9.631 0.1133 1.3588 0.9286 1.9885
Recurrent ischaemia Top 40 942 4.246 . . . .
Recurrent ischaemia Bottom 63 491 12.83 <.0001 3.3193 2.1971 5.0146
Myocardial infarct Top 36 1039 3.465 . . . .
Myocardial infarct Bottom 23 487 4.723 0.2348 1.381 0.8091 2.3572
Cardiac arrest Top 78 1047 7.45 . . . .
Cardiac arrest Bottom 47 491 9.572 0.1556 1.3151 0.9003 1.921
Stroke Top 8 1037 0.771 . . . .
Stroke Bottom 10 489 2.045 0.0315 2.6853 1.0532 6.8468
Death Top 34 1059 3.211 . . . .
Death Bottom 69 497 13.88 <.0001 0.2058 0.1344 0.315
Any in-hospital event Top 236 958 24.63 . . . .
Any in-hospital event Bottom 175 490 35.71 <.0001 1.6996 1.3422 2.1522
Alive at 6 months Top 598 617 96.92 . . . .
Alive at 6 months Bottom 284 303 93.73 0.0223 0.4749 0.2476 0.911
Admission for cardiac causes Top 123 612 20.1 . . . .
Admission for cardiac causes Bottom 66 303 21.78 0.5537 1.1071 0.7905 1.5506
NSTEMI clinical events in-hospital and at 6 months 
by top and bottom hospital performance tertile
NSTEMI patients treated in top performing tertile hospitals had:
•	 less congestive cardiac failure
•	 less cardiogenic shock
•	 less recurrent ischaemia
•	 fewer in-hospital deaths
•	 were more likely to be alive at 6 months
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NSTEMI outcomes in-hospital and at 6 months
Event
Tertile based 
on NSTEMI 
compliance
Number of 
events (Y)
Number of 
possible 
cases
Percent of 
Events
Chi-square 
Probability
Odds 
ratio
Lower 95% 
CL
Upper 95% 
CL
Congestive heart failure Top 100 1041 9.606 . . . .
Congestive heart failure Bottom 80 490 16.33 0.0001 1.8361 1.3386 2.5186
Cardiogenic shock Top 57 1040 5.481 . . . .
Cardiogenic shock Bottom 53 489 10.84 0.0002 2.0964 1.4185 3.0983
Acute renal failure Top 76 1045 7.273 . . . .
Acute renal failure Bottom 47 488 9.631 0.1133 1.3588 0.9286 1.9885
Recurrent ischaemia Top 40 942 4.246 . . . .
Recurrent ischaemia Bottom 63 491 12.83 <.0001 3.3193 2.1971 5.0146
Myocardial infarct Top 36 1039 3.465 . . . .
Myocardial infarct Bottom 23 487 4.723 0.2348 1.381 0.8091 2.3572
Cardiac arrest Top 78 1047 7.45 . . . .
Cardiac arrest Bottom 47 491 9.572 0.1556 1.3151 0.9003 1.921
Stroke Top 8 1037 0.771 . . . .
Stroke Bottom 10 489 2.045 0.0315 2.6853 1.0532 6.8468
Death Top 34 1059 3.211 . . . .
Death Bottom 69 497 13.88 <.0001 0.2058 0.1344 0.315
Any in-hospital event Top 236 958 24.63 . . . .
Any in-hospital event Bottom 175 490 35.71 <.0001 1.6996 1.3422 2.1522
Alive at 6 months Top 598 617 96.92 . . . .
Alive at 6 months Bottom 284 303 93.73 0.0223 0.4749 0.2476 0.911
Admission for cardiac causes Top 123 612 20.1 . . . .
Admission for cardiac causes Bottom 66 303 21.78 0.5537 1.1071 0.7905 1.5506
Clinical Process 
Indicators
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CLINICAL PROCESS INDICATORS
0
22.5
45
67.5
90
STEMI LHD STEMI NSW1 STEMI NSW STEMI AOH
83.6
71.3
24.7
46.7
 First medical contact to PPCI, Thrombolysis or both LHD(n=237)
NSW1
(n=633)
NSW
(n=870)
AOH
(n=1436)
STEMI patients n(%) 110 (46.7) 186 (29.4) 620 (71.3) 1200 (83.6)
Access to urgent reperfusion could be improved 
in the LHD and across NSW. 
The proportion of STEMI patients arriving to 
hospital within 12 hours of symptom onset who 
received thrombolysis or Primary PCI (PPCI) or both
LHD = sample of 3 hospitals inclusive of one hospital with on-site cardiac surgery; one hospital with a cardiac catheter laboratory and onsite PPCI and one metropolitan hospital 
with no cardiac catheter lab or on-site surgery (n=3)
NSW1 = All NSW hospitals (n=12) except for those hospitals included in LHD
NSW= All NSW hospitals inclusive of hospitals in LHD (n=15)
All other hospitals (AOH) = Aggregate of other participating hospitals exclusive of hospitals in NSW and the LHD.
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CLINICAL PROCESS INDICATORS
The door-to-needle time for STEMI patients 
arriving within 12 hours of symptom onset and 
undergoing thrombolysis
LHD
NSW1
NSW
AOH
0 10 20 30 40 50 60
60
51
51
50
Door-to-needle time
STEMI
LHD NSW1 NSW AOH
STEMI patients (n) 53 183 104 224
Median Time (minutes) 50 51 51 60
LHD = sample of 3 hospitals inclusive of one hospital with on-site cardiac surgery; one hospital with a cardiac catheter laboratory and onsite PPCI and one metropolitan hospital with 
no cardiac catheter lab or on-site surgery (n=3)
NSW1 = All NSW hospitals (n=12) except for those hospitals included in LHD
NSW= All NSW hospitals inclusive of hospitals in LHD (n=15)
All other hospitals (AOH) = Aggregate of other participating hospitals exclusive of hospitals in NSW and the LHD.
All participating hospitals exceed the target for 
the provision of thrombolysis </= 30 mins
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CLINICAL PROCESS INDICATORS
Door-to-balloon time for STEMI patients arriving 
within 12 hours of symptom onset undergoing 
primary PCI (PPCI)
LHD
NSW1
NSW
AOH
0 30 60 90 120
95
105
100
83
Door-to-balloon time
STEMI
LHD NSW1 NSW AOH
STEMI patients (n) 100 210 310 500
Median Time (minutes) 83 100 105 95
LHD = sample of 3 hospitals inclusive of one hospital with on-site cardiac surgery; one hospital with a cardiac catheter laboratory and onsite PPCI and one metropolitan hospital 
with no cardiac catheter lab or on-site surgery (n=3)
NSW1 = All NSW hospitals (n=12) except for those hospitals included in LHD
NSW= All NSW hospitals inclusive of hospitals in LHD (n=15)
All other hospitals (AOH) = Aggregate of other participating hospitals exclusive of hospitals in NSW and the LHD.
Hospitals in the LHD had a median door-to-balloon time 
of less than 90mins.
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CLINICAL PROCESS INDICATORS
The proportion of high risk ACS patients 
undergoing coronary angiography in-hospital
0
25
50
75
100
LHD NSW1 NSW AOH
5049.4
6.7
42.7
54.7
49.2
17.2
32.1
89.789.1
30.6
58.5
STEMI NSTEMI UA
LHD
237
NSW 1
633
NSW
870
AOH
1436
LHD
304
NSW 1
1147
NSW
1451
AOH
2091
LHD
168
NSW 1
607
NSW
775
AOH
837
Proportion of high 
risk ACS undergoing 
Angio </= 48 hrs n(%)
138
(58.5)
193
(30.6)
775
(89.1)
1288
(89.7)
97
(32.1)
197
(17.2)
713
(49.2)
1143
(54.7)
72
(42.7)
41
(6.7)
383
(49.4)
419
(50)
LHD = sample of 3 hospitals inclusive of one hospital with on-site cardiac surgery; one hospital with a cardiac catheter laboratory and onsite PPCI and one metropolitan 
hospital with no cardiac catheter lab or on-site surgery (n=3)
NSW1 = All NSW hospitals (n=12) except for those hospitals included in LHD
NSW= All NSW hospitals inclusive of hospitals in LHD (n=15)
All other hospitals (AOH) = Aggregate of other participating hospitals exclusive of hospitals in NSW and the LHD.
Access to in-hospital angiography is provisioned 
predominately to patients with STEMI. 
Less than 55% of all other high-risk ACS patients undergo 
angiography in-hospital in NSW and nationally. 
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CLINICAL PROCESS INDICATORS
The proportion of high risk ACS receiving left 
ventricular systolic assessment in-hospital
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High risk ACS LV 
function assessed n(%)
136
(57.3)
152
(24)
707
(81.3)
1120
(78)
147
(48.5)
265
(23.1)
1037
(71.5)
1257
(60.1)
74
(44.4)
80
(13.2)
447
(57.6)
299
(35.7)
LHD = sample of 3 hospitals inclusive of one hospital with on-site cardiac surgery; one hospital with a cardiac catheter laboratory and onsite PPCI and one metropolitan hospital 
with no cardiac catheter lab or on-site surgery (n=3)
NSW1 = All NSW hospitals (n=12) except for those hospitals included in LHD
NSW= All NSW hospitals inclusive of hospitals in LHD (n=15)
All other hospitals (AOH) = Aggregate of other participating hospitals exclusive of hospitals in NSW and the LHD.
Left ventricular systolic assessment is provided in less than 
60% of  patients with STEMI and less frequently in all other 
high risk ACS patients.
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CLINICAL PROCESS INDICATORS
Proportion of high risk ACS patients 
receiving PCI and in-hospital antiplatelets
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Receipt of PCI and 
in-hospital antiplatelet 
n(%)
140
(59)
185
(29.3)
768
(88.3)
1306
(91)
183
(50.4)
379
(33)
1210
(83.4)
1804
(86.3)
96
(57.3)
109
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584
(75.3)
481
(57.5)
LHD = sample of 3 hospitals inclusive of one hospital with on-site cardiac surgery; one hospital with a cardiac catheter laboratory and onsite PPCI and one metropolitan hospital 
with no cardiac catheter lab or on-site surgery (n=3)
NSW1 = All NSW hospitals (n=12) except for those hospitals included in LHD
NSW= All NSW hospitals inclusive of hospitals in LHD (n=15)
All other hospitals (AOH) = Aggregate of other participating hospitals exclusive of hospitals in NSW and the LHD.
Antiplatelets = Clopidogrel, Coplavix, Prasugrel or Ticagrelor
Proportionally fewer high risk ACS patients in the LHD are 
prescribed antiplatelets following PCI compared with NSW 
and all other hospitals. 
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CLINICAL PROCESS INDICATORS
Proportion of high risk patients discharged alive on 
antiplatelets
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Discharged alive on 
antiplatelet n(%)
47
(19.8)
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Hospitals within the LHD less frequently prescribed 
antiplatelets at discharge.
LHD = sample of 3 hospitals inclusive of one hospital with on-site cardiac surgery; one hospital with a cardiac catheter laboratory and onsite PPCI and one metropolitan hospital 
with no cardiac catheter lab or on-site surgery (n=3)
NSW1 = All NSW hospitals (n=12) except for those hospitals included in LHD
NSW= All NSW hospitals inclusive of hospitals in LHD (n=15)
All other hospitals (AOH) = Aggregate of other participating hospitals exclusive of hospitals in NSW and the LHD.
Antiplatelets = Clopidogrel, Coplavix, Prasugrel or Ticagrelor
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CLINICAL PROCESS INDICATORS
Proportion of patients discharged alive on 
a beta-blocker
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Discharged alive on 
beta-blockers n(%)
52
(21.9)
405
(64)
748
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Hospitals in the LHD less frequently prescribed 
beta blockers at hospital discharge.
LHD = sample of 3 hospitals inclusive of one hospital with on-site cardiac surgery; one hospital with a cardiac catheter laboratory and onsite PPCI and one metropolitan hospital 
with no cardiac catheter lab or on-site surgery (n=3)
NSW1 = All NSW hospitals (n=12) except for those hospitals included in LHD
NSW= All NSW hospitals inclusive of hospitals in LHD (n=15)
All other hospitals (AOH) = Aggregate of other participating hospitals exclusive of hospitals in NSW and the LHD.
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LHD = sample of 3 hospitals inclusive of one hospital with on-site cardiac surgery; one hospital with a cardiac catheter laboratory and onsite PPCI and one metropolitan hospital 
with no cardiac catheter lab or on-site surgery (n=3)
NSW1 = All NSW hospitals (n=12) except for those hospitals included in LHD
NSW= All NSW hospitals inclusive of hospitals in LHD (n=15)
All other hospitals (AOH) = Aggregate of other participating hospitals exclusive of hospitals in NSW and the LHD.
CLINICAL PROCESS INDICATORS
Proportion of patients discharged alive on statins
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Discharged alive on 
statins n(%)
57
(24)
455
(71.9)
834
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831
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Hospitals in the LHD less frequently prescribe statins 
at discharge.
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CLINICAL PROCESS INDICATORS
Proportion of patients discharged alive on 
ACE-inhibitor (ACE) or angiotensin receptor 
blocker (ARB)
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Discharged alive on 
ACE/ARB n(%)
49
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LHD = sample of 3 hospitals inclusive of one hospital with on-site cardiac surgery; one hospital with a cardiac catheter laboratory and onsite PPCI and one metropolitan hospital 
with no cardiac catheter lab or on-site surgery (n=3)
NSW1 = All NSW hospitals (n=12) except for those hospitals included in LHD
NSW= All NSW hospitals inclusive of hospitals in LHD (n=15)
All other hospitals (AOH) = Aggregate of other participating hospitals exclusive of hospitals in NSW and the LHD.
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LHD = sample of 3 hospitals inclusive of one hospital with on-site cardiac surgery; one hospital with a cardiac catheter laboratory and onsite PPCI and one metropolitan hospital 
with no cardiac catheter lab or on-site surgery (n=3)
NSW1 = All NSW hospitals (n=12) except for those hospitals included in LHD
NSW= All NSW hospitals inclusive of hospitals in LHD (n=15)
All other hospitals (AOH) = Aggregate of other participating hospitals exclusive of hospitals in NSW and the LHD.
CLINICAL PROCESS INDICATORS
Proportion of ACS patients referred to 
secondary prevention services
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patients referred to 
secondary prevention 
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Hospitals in the LHD less frequently refer patients to 
secondary prevention services.
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Appendix
A1 - PATIENT CHARACTERISTICS STEMI
A2 - PATIENT CHARACTERISTICS NSTEMI
A3 - PATIENT CHARACTERISTICS UA
A4 - CLINICAL PROCESS INDICATORS -    
  DESCRIPTION OF MEASURES
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APPENDIX
A1 ST-Elevation Myocardial Infarction (STEMI) 
patient characteristics
Ch
ar
ac
te
ris
tic
s 
of
 th
e 
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CS
 p
op
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at
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n 
STEMI LHD
n (%)
STEMI NSW1
n (%)
STEMI NSW
n (%)
STEMI AOH
n (%)
237 633 870 1436
Female 59 (24.9) 176 (27.8) 235 (27) 329 (22.9)
Male 178 (75.1) 457 (72.2) 635 (73) 1107 (77.1)
Age (years) Mean (SD) 64.5 (14.3) 63.1(13.1) 63.5 (13.4) 60.9 (13.9)
Past Medical History
Prior AMI 36(4.1) 95 (10.9) 131 (15.1) 209 (14.7)
Exertional angina 34(3.9 54 (6.2) 88 (10.1) 133 (9.3)
Prior CHF 18(2.1) 12 (1.4) 30 (3.4) 44 (3.1)
Prior positive stress test 7(0.8) 8 (0.9) 15 (1.7) 26 (1.8 )
Prior positive coronary angiography 33(3.8) 80 (9.2) 113 (13) 239 (16.8)
Prior PCI 14 (1.6) 60 (6.9) 74 (8.5) 160 (11.1)
Prior CABG 11 (1.3) 15 (1.7) 26 (3) 46 (3.2)
Hypertension 129 (14.9) 303 (34.9) 432 (49.8) 722 (50.5)
Dyslipidaemia 114 (13.1) 234 (27) 348 (40.1) 648 (45.3)
Diabetes (Type I/II) 62 (7.1) 120 (13.8) 182 (20.9) 283(19.8)
Renal impairment 14 (1.6) 25 (2.9) 39 (4.5) 67 (4.7)
Smoker 146 (16.8) 410 (47.1) 556 (63.9) 995 (69.3)
Prior TIA/Stroke 12 (1.4) 29 (3.3) 41(4.7) 73 (5.2)
Peripheral arterial disease 13 (1.5) 21 (2.4) 34 (3.9) 58 (4.1)
Atrial fibrillation 15 (1.7) 35 (4) 50 (3.9) 66 (4.6)
Major Bleeding 6 (0.7) 10 (1.1) 16 (1.8) 14 (1)
Frailty 60 (6.9) 108 (12.4) 168 (19.3) 229(16.1)
Dementia 10 (1.1) 15 (1.7) 25 (2.9) 25 (1.8)
Impaired mobility 27 (3.1) 35 (4) 62 (7.1) 69 (4.9)
Incontinence 11 (1.3) 17 (2) 28 (3.2) 23 (1.6)
Liver disease 4 (0.5) 7 (0.8) 11 (1.3) 33 (1.6)
Lung disease 26 (3.8) 49 (7.2) 75 (11) 100 (1.6)
Cancer 4 (0.5) 17 (2.2) 21 (2.7) 32 (2.3)
Documented not for resuscitation 20 (2.3) 24 (2.8) 44 (5.1) 44 (3.1)
Clinical Characteristics on admission
Heart rate (BPM) 85.4(22.2) 78.7 (21.2) 80.5 (21.6) 78.4 (19.7)
Systolic BP (mmHg) 134.1 (28.8) 133.8 (28.1) 133.9 (28.2) 137.8 (28.4)
Diastolic BP (mmHg) 81.7 (18.3) 80.6 (17.8) 80.9(17.9) 82.3 (18.2)
Cardiac arrest on admission 27 (3.1) 55 (6.3) 82 (9.4) 130 (9.1)
Abnormal for ischaemia 228 (26.2) 589 (67.7) 817 (93.9) 1376 (95.)
ST elevation 211 (25.9) 550 (67.5) 761(93.4) 1266 (93.2)
New LBBB 12 (1.6) 24 (3.1) 36 (4.7) 49 (4.2)
T wave inversion 51 (6.6) 112 (14.5) 163 (21) 239 (20)
ST depression 95 (12) 217 (27.4) 312 (39.4) 375 (30.6)
Elevated biomarkers 207(28.8) 467 (65) 674 (93.7) 1310 (97.3)
Serum Creatinine Mean (SD) 118.7 (67.4) 104.8 (48.8) 108.5 (54.8) 102.5 (48.1)
Total Cholesterol Mean (SD) 4.9 (1.4) 4.7 (1.2) 4.7 (1.2) 4.7 (1.6)
HDL 1.2 (0.37) 1.1 (0.4) 1.1 (0.3) 1.1 (0.4)
LDL 3.1 (2.2) 3.0 (3.5) 3.0 (3.2) 2.9 (1.1)
Killip Class 1 197 (83.1) 572 (90.4) 769 (88.4) 1282 (89.3)
Killip Class 2 23 (9.7) 43 (6.8) 66 (7.6) 110 (7.7)
Killip Class 3 6 (2.5) 13 (2.1) 19 (2.2) 25 (1.7)
Killip Class 4 11 (4.6) 5 (0.8) 16 (1.8) 19 (1.3)
GRACE Risk Score Mean(SD) 160.9 (45.2) 146.9 (40.0) 150.8 (40.5) 144.6 (38.3)
ACUITY Score Mean (SD) 21.5 (8.6) 20.4 (7.2) 20.7 (7.6) 19.7 (6.9)
LHD = sample of 3 hospitals inclusive of one hospital with on-site cardiac surgery; one hospital with a cardiac catheter laboratory and onsite PPCI and one metropolitan hospital 
with no cardiac catheter lab or on-site surgery (n=3)
NSW1 = All NSW hospitals (n=12) except for those hospitals included in LHD
NSW= All NSW hospitals inclusive of hospitals in LHD (n=15)
All other hospitals (AOH) = Aggregate of other participating hospitals exclusive of hospitals in NSW and the LHD.
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NSTEMI LHD
n (%)
NSTEMI NSW1
n (%)
NSTEMI NSW
n (%)
NSTEMI AOH
n (%)
304 1147 1451 2091
Female 99 (32.6) 383 (33.4) 482 (33.2) 631 (30.1)
Male 205 (67.4) 764 (66.6) 969 (66.8) 1462 (69.9)
Age (years) Mean (SD) 304 (71.164) 1147 (67.478) 1451 (68.25) 2091 (64.206)
Past Medical History
Prior AMI 124 (8.6) 355 (24.5) 479(33) 629 (30.2)
Exertional angina 114 (7.9) 268 (18.5) 382 (26.4) 445 (21.4)
Prior CHF 48 (3.3) 118 (8.1) 166 (11.5) 202 (9.7)
Prior positive stress test 27 (1.9) 66 (4.6) 93 (6.4) 112 (5.4)
Prior positive coronary angiography 124 (8.6) 399 (27.5) 523 (36.1) 690 (33.1)
Prior PCI 50 (3.4) 227 (15.6) 277 (19.1) 390 (18.6)
Prior CABG 54 (3.7) 166(11.5) 220 (15.2) 232 (11.2)
Hypertension 214 (14.8) 764 (52.7) 978 (67.5) 1304 (62.4)
Dyslipidaemia 190 (13.1) 660 (45.5) 850 (58.7) 1192 (57)
Diabetes (Type I/II) 109 (7.5) 337 (23.3) 446 (30.8) 602 (28.9)
Renal impairment 443 125 (8.6) 169 (11.7) 217 (10.4)
Smoker 17412 695 (47.9) 869 (59.9) 1426 (68.1)
Prior TIA/Stroke 473.3 106 (7.3) 153 (10.6) 136 (6.6)
Peripheral arterial disease 443 92 (6.3) 136 (9.4) 153 (7.3)
Atrial fibrillation 563.9 149 (10.3) 205 (14.1) 211 (10.1)
Major Bleeding 15 (1) 37 (2.6) 52 (3.6) 39 (1.9)
Frailty 112 (7.7) 284(19.6) 396 (27.3) 422 (20.2)
Dementia 20 (1.4) 51 (3.5) 71 (4.9) 61 (2.9)
Impaired mobility 60 (4.1) 131(9) 191 (4.9) 179 (8.6)
Incontinence 19 (1.3) 54(3.7) 73 (5) 36 (1.7)
Liver disease 11 (0.8) 24(1.7) 35 (2.4) 47 (2.3)
Lung disease 51 (4.3) 120 (10) 171(14.3) 199 (12.4)
Cancer 15 (1.2) 30(2.5) 45 (3.7) 31 (1.6)
Documented not for resuscitation 37 (2.6) 38 (2.6) 75 (5.2) 80 (3.8)
 Clinical Characteristics on Admission
Heart rate (BPM) 83.5 (21.9) 83.5 (21.9) 84.3 (22.3) 79.33 (20)
Systolic BP (mmHg) 142.9 (27.7) 142.9 (27.7) 142.34 (27.8) 141.7 (27.4)
Diastolic BP (mmHg) 82.1 (16.6) 82.075 (16.6) 81.5 (17) 79.9 (16.8)
Cardiac arrest on admission 5 (0.3) 19 (1.3) 24 (1.7) 42 (2)
Abnormal for ischaemia 168 (11.6) 475 (32.8) 643 (44.3) 1031 (49.4)
ST elevation 21 (3.4) 66(10.7) 87 (14.2) 177 (18.7)
New LBBB 6 (1) 11 (1.8) 17 (2.8) 48 (5.1)
T wave inversion 82 (13) 239(38) 321 (51) 585 (58.9)
ST depression 92 (14.6) 246 (39.1) 338 (53.7) 422 (43.8)
Elevated biomarkers 276 (23) 848(70.7) 1124 (93.7) 1908 (94.9)
Serum Creatinine Mean (SD) 111.6 (56.5) 111.6 (56.5) 115.7 (60.5) 107.2 (58.7)
Total Cholesterol Mean (SD) 4.6 (1.9) 4.6 (1.9) 4.6 (1.8) 4.6 (1.5)
HDL 1.1 (0.4) 1.1 (0.42) 1.1 (0.4) 1.1 (0.5)
LDL 2.6 (1.6) 2.6 (1.6) 2.6 (1.5) 2.7 (1.07)
Killip Class 1 221 (73) 1017(88.7) 1238 (85.4) 1813 (87)
Killip Class 2 63 (21) 99 (8.6) 162 (11.2) 215 (10.3)
Killip Class 3 17 (5.6) 282.4(2.4) 45 (3.1) 48 (2.3)
Killip Class 4 2 (0.7) 20.2 (0.2) 40.3 (0.3) 9 (0.4)
GRACE Risk Score Mean (SD) 1147 (129.9) 129.8 (38.4) 134  (40.8) 126.3 (38.1)
ACUITY Score Mean (SD) 1147 (17.5) 17.5 (7.1) 18  (7.5) 16.2 (7.1)
A2 Non ST Elevation Myocardial Infarction (NSTEMI) 
patient characteristics
LHD = sample of 3 hospitals inclusive of one hospital with on-site cardiac surgery; one hospital with a cardiac catheter laboratory and onsite PPCI and one metropolitan hospital 
with no cardiac catheter lab or on-site surgery (n=3)
NSW1 = All NSW hospitals (n=12) except for those hospitals included in LHD
NSW= All NSW hospitals inclusive of hospitals in LHD (n=15)
All other hospitals (AOH) = Aggregate of other participating hospitals exclusive of hospitals in NSW and the LHD.
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A3 Unstable Angina (UA) patient characteristics
UA LHD
n (%)
UA NSW1
n (%)
UA NSW
n (%)
UA AOH
n (%)
168 607 775 837
Female 46 (27.4) 176 (29) 222 (28.6) 279 (33.3)
Male 122 (72.6) 43 (171) 553 (71.4) 558 (66.7)
Age (years) Mean (SD) 70.9 (11.6) 67.2 (12.3) 68 (12.3) 64.5 (12.8)
Past Medical History        
Prior AMI 113 (15.1) 263 (35.1) 376 (50.1) 414 (50)
Exertional angina 101 (13.5) 228 (30.4) 329 (43.9) 382 (46.1)
Prior CHF 20 (2.7) 45 (6) 65 (8.7) 94 (11.4)
Prior positive stress test 27 (3.6) 61 (8.2) 88 (11.8) 125 (15.1)
Prior positive coronary angiography 129 (17.2) 355 (47.3) 484 (64.5) 565 (68.1)
Prior PCI 75 (10) 235 (31.3) 310 (41.3) 330 (39.8)
Prior CABG 46 (6.1) 126 (16.8) 172 (22.9) 167 (20.2)
Hypertension 133 (17.8) 426 (57) 559 (74.7) 623 (75.2)
Dyslipidaemia 130 (17.5) 419 (56.3) 549 (73.8) 613 (73.9)
Diabetes (Type I/II) 63 (8.4) 171 (22.8) 234 (31.2) 274 (33.1)
Renal impairment 19 (2.5) 48 (6.4) 67 (8.9) 87 (10.5)
Smoker 95 (12.3) 362 (46.7) 457 (59) 555 (66.3)
Prior TIA/Stroke 15 (2) 56 (7.5) 71 (9.5) 70 (8.5)
Peripheral arterial disease 16 (2.1) 30 (4) 46 (6.1) 64 (7.7)
Atrial fibrillation 20 (2.7) 88 (11.7) 108 (14.4) 121 (14.6)
Major Bleeding 12 (1.6) 13 (1.7) 25 (3.3) 21 (2.5)
Frailty 51 (6.8) 113 (15.1) 164 (21.9) 201 (24.3)
Dementia 9 (1.2) 18 (2.4) 27 (3.6) 18 (2.2)
Impaired mobility 23 (3.1) 44 (5.9) 67 (8.9) 72 (8.7)
Incontinence 4 (0.5) 20 (2.7) 24 (3.2) 15 (1.8)
Liver disease 3 (0.4) 5 (0.7) 8 (1.1) 18 (2.2)
Lung disease 15 (2.4) 59 (9.5) 74 (11.9) 110 (15.8)
Cancer 4 (0.7) 6 (1) 10 (1.7) 13 (1.7)
Documented not for resuscitation 5 (0.7) 7 (0.9) 12 (1.6) 19 (2.3)
Clinical Characteristics on Admission
Heart rate (BPM) 73.8 (17.1) 78.3 (18.7) 77.3 (18.5) 74.1 (17.4)
Systolic BP (mmHg) 141.4 (28.1) 139.6 (25.5) 140 (26.1) 140.6 (25.3)
Diastolic BP (mmHg) 74.4 (19.1) 78.9 (13.9) 77.9 (15.3) 77  (15.3)
Cardiac arrest on admission 5 (0.7) 11 (1.5) 16 (2.1) 9 (1.1)
Abnormal for ischaemia 65 (8.7) 156 (20.9) 221 (29.6) 254 (30.6)
ST elevation 8 (3.8) 26 (12.3) 34 (16.1) 38 (16.1)
New LBBB 6 (2.9) 8 (3.8) 14 (6.7) 8 (3.5)
T wave inversion 46 (20.9) 85 (38.6) 131 (59.5) 160 (66.1)
ST depression 21 (9.9) 58 (27.4) 7 (37.4) 67 (28.8)
Elevated biomarkers 63 (12.4) 92 (18.1) 155 (30.5) 133 (18.8)
Serum Creatinine Mean (SD) 114.2 (63.5) 97.6  (44.6) 101.23 (49.8) 98.6 (50.8)
Total Cholesterol Mean (SD) 4.6 (1.3) 4.5 (2.7) 4.8 (2.6) 4.3 (2.1)
HDL 1.2 (0.3) 1.2 (0.5) 1.2 (0.5) 1.1 (0.5)
LDL 2.7 (1.1) 2.3 (1) 2.3 (1) 2.3 (1)
Killip Class 1 148 (88.1) 540 (93.4) 688 (92.2) 756 (91.1)
Killip Class 2 16 (9.5) 30 (5.2) 46 (6.2) 68 (8.2)
Killip Class 3 1 (0.6) 5 (0.9) 60 (0.8) 4 (0.5)
Killip Class 4 3 (1.8) 3 (0.5) 61 (0.8) 2 (0.2)
GRACE Risk Score Mean (SD) 127.24 (38.9) 115.8 (33.8) 118.2 (35.2) 108.2 (32.1)
ACUITY Score Mean (SD) 17.5 (7.2) 15.5 (6.1) 15.9 (6.4) 15.2 (6.4)
APPENDIX
LHD = sample of 3 hospitals inclusive of one hospital with on-site cardiac surgery; one hospital with a cardiac catheter laboratory and onsite PPCI and one metropolitan hospital 
with no cardiac catheter lab or on-site surgery (n=3)
NSW1 = All NSW hospitals (n=12) except for those hospitals included in LHD
NSW= All NSW hospitals inclusive of hospitals in LHD (n=15)
All other hospitals (AOH) = Aggregate of other participating hospitals exclusive of hospitals in NSW and the LHD.
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Performance Measure PROPORTION OF STEMI PATIENTS ARRIVING WITHIN 12 HOURS OF SYMPTOM ONSET WHO RECEIVED THROMBOLYSIS OR PRIMARY PCI OR BOTH.
Description of the measure ST-elevation acute myocardial infarction patients with onset of symptoms less than 12 
hours from hospital presentation and receiving primary PCI or thrombolysis. 
Clinical recommendation10 Class 1 Level of Evidence A
Period of care Acute care for index event
Numerator All STEMI patients arriving to hospital within 12hrs of symptom onset. STEMI is defined 
as ST elevation acute myocardial infarction or left bundle branch block (LBBB) on the 
admission electrocardiograph (ECG).
Denominator All patients with a diagnosis of ST-elevation acute myocardial infarction or LBBB on 
admission without a contraindication to fibrinolysis and who received either PPCI or 
fibrinolysis. 
Data sources Hospital medical record
Methods of reporting Aggregated CONCORDANCE Registry data calculated as a count and presented as a 
proportion.
Performance Measure DOOR TO NEEDLE TIME FOR STEMI PATIENTS ARRIVING WITHIN 12 HOURS OF SYMPTOM ONSET AND RECEIVING THROMBOLYSIS
Description of the measure Fibrinolysis should be given to patients with a diagnosis of STEMI diagnosis admission 
to hospital </= 30mins of first medical contact and onset of symptoms less than 12 
hours and PCI cannot be performed within 120mins of first medical contact. STEMI is 
defined as ST elevation acute myocardial infarction or left bundle branch block (LBBB) 
on the admission electrocardiograph (ECG).
Clinical recommendation10 Class 1; Level of Evidence A
Period of care Acute care for index event
Numerator All patients with a diagnosis of STEMI on admission without a contraindication to 
fibrinolysis and who did not receive PPCI 
Denominator All STEMI patients arriving to hospital within 12hrs of symptom onset
Data sources Hospital medical record
Methods of reporting Aggregated CONCORDANCE Registry data calculated as a count and presented as a 
proportion.
Performance Measure
DOOR-TO-BALLOON TIME FOR STEMI PATIENTS ARRIVING WITHIN 12 HOURS 
OF SYMPTOM ONSET UNDERGOING PRIMARY PCI (PPCI) BY DISCHARGE 
DIAGNOSIS.
Description of the measure All STEMI patients should have access to timely reperfusion with PPCI if immediately 
available. STEMI is defined as ST elevation acute myocardial infarction or left bundle 
branch block (LBBB) on the admission electrocardiograph (ECG).
Clinical recommendation10 Class 1; Level of Evidence A
Period of care Acute care for index event
Numerator All patients with a diagnosis of STEMI on admission arriving to hospital within 12hrs of 
symptom onset
Denominator All patients with a diagnosis of STEMI on admission without a contraindication to 
fibrinolysis and who did not receive PPCI 
Data sources Hospital medical record
Methods of reporting Aggregated CONCORDANCE Registry data calculated as a count and presented as a 
proportion.
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Performance Measure PROPORTION OF HIGH RISK ACS UNDERGOING CORONARY ANGIOGRAPHY DURING ADMISSION
Description of the measure High risk ACS should undergoing coronary angiography during admission.
Clinical recommendation10 Class IIa Level of Evidence B
Period of care Acute care for index event
Numerator All high risk ACS enrolled in the CONCORDANCE Registry
Denominator All High Risk ACS enrolled in the registry and alive within 48hrs of hospital 
presentation. 
High risk ACS is defined as: 
1) final diagnosis is ST-elevation MI or non ST-elevation MI
OR 
2) final diagnosis is Unstable angina, and either one of these: [1] index ECG indicating 
ischaemia; [2] Killip class is greater than 1; [3] LV function grade determined (either 
mild, moderate or severe impairment); [4] Diabetes treated (2), (either insulin, oral 
hypoglycaemic med); [5] Serum creatinine is measured (value on admission is greater 
than upper limit of normal); [6] Recurrent ischaemia in admission; [7] previous PCI < 
6mths before presentation &/or previous CABG  > 5 years before presentation
Data sources Hospital medical record
Methods of reporting Aggregated CONCORDANCE Registry data calculated as a count and presented as a 
proportion.
Performance Measure HIGH RISK ACS RECEIVING LEFT VENTRICULAR (LV) SYSTOLIC  ASSESSMENT
Description of the measure High risk ACS with documented assessment of LV systolic function during 
hospitalisation. 
Clinical recommendation10 STEMI: Class I Level of Evidence A 
Definite ACS: Class I Level of Evidence B 
Period of care Acute care for index event
Numerator High Risk ACS with a recorded assessment of  LV systolic function during 
hospitalisation
Denominator All High Risk ACS enrolled in the registry defined as: 
final diagnosis is ST-elevation MI or non ST-elevation MI OR 
2) final diagnosis is Unstable angina, and either one of these [1] index ECG indicating 
ischaemia; [2] Killip class is greater than 1; [3] LV function grade determined (either 
mild, moderate or severe impairment); [4] Diabetes treated (2), (either insulin, oral 
hypoglycaemic med); [5] Serum creatinine is measured (value on admission is greater 
than upper limit of normal); [6] Recurrent ischaemia in admission; [7] previous PCI < 
6mths before presentation &/or previous CABG  > 5 years before presentation
Data sources Hospital medical record
Methods of reporting Aggregated CONCORDANCE Registry data as a count and presented as a proportion.
APPENDIX
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Performance Measure PROPORTION OF PATIENTS DISCHARGED ALIVE ON A BETA-BLOCKER
Description of the measure Proportion of high risk patients discharged alive on a Beta-Blocker without a 
contraindication to the therapy. 
Clinical recommendation10 Class I Level of Evidence: B
Period of care Acute care for index event 
Numerator All high risk ACS enrolled in the CONCORDANCE Registry alive at discharge
Denominator All high-risk patients alive at discharge and without a contraindication to the therapy 
and prescribed a Beta-Blocker at discharge. High risk ACS is defined as; 
1) final diagnosis is ST-elevation MI or non ST-elevation MI
OR 
2) final diagnosis is Unstable angina, and either one of these [1] index ECG indicating 
ischaemia; [2] Killip class is greater than 1; [3] LV function grade determined (either 
mild, moderate or severe impairment); [4] Diabetes treated (2), (either insulin, oral 
hypoglycaemic med); [5] Serum creatinine is measured (value on admission is greater 
than upper limit of normal); [6] Recurrent ischaemia in admission; [7] previous PCI < 
6mths before presentation &/or previous CABG  > 5 years before presentation
Data sources Hospital medical record
Methods of reporting Aggregated CONCORDANCE Registry data as a count and presented as a proportion.
Performance Measure PROPORTION OF HIGH RISK PATIENTS DISCHARGED ALIVE ON EITHER 
CLOPIDOGREL ,COPLAVIX,  PRASUGREL OR TICAGRELOR
Description of the measure
Proportion of high risk patients discharged alive on either Clopidogrel, Coplavix, 
Prasugrel or Ticagrelor without a contraindication to the therapy. 
Clinical recommendation10 Class I Level of Evidence: B
Period of care Acute care for index event 
Numerator All high risk ACS enrolled in the CONCORDANCE Registry 
Denominator
All high-risk patients alive at discharge and without a contraindication to either therapy 
and were prescribed either/or Clopidogrel, Coplavix, prasugrel, ticagrelor. High risk 
ACS is defined as: 
1) final diagnosis is ST-elevation MI or non ST-elevation MI
OR 
2) final diagnosis is Unstable angina, and either one of these: [1] index ECG indicating 
ischaemia; [2] Killip class is greater than 1; [3] LV function grade determined (either 
mild, moderate or severe impairment); [4] Diabetes treated (2), (either insulin, oral 
hypoglycaemic med); [5] Serum creatinine is measured (value on admission is greater 
than upper limit of normal) [6] Recurrent ischaemia in admission [7] previous PCI < 
6mths before presentation &/or previous CABG  > 5 years before presentation
Data sources Hospital medical record
Methods of reporting Aggregated CONCORDANCE Registry data as a count and presented as a proportion.
APPENDIX
Performance Measure THE PROPORTION OF HIGH RISK ACS PATIENTS RECEIVING PCI AND IN-HOSPITAL CLOPIDOGREL, COPLAVIX, PRASUGREL OR TICAGRELOR
Description of the measure High risk ACS receiving PCI and in-hospital clopidogrel, coplavix, prasugrel or ticagrelor 
in-hospital.
Clinical recommendation10 Class I Level of Evidence: C
Period of care Acute care for index event
Numerator All high risk ACS enrolled in the CONCORDANCE Registry 
Denominator All High Risk ACS enrolled without a contraindication to clopidogrel, coplavix, prasugrel 
or ticagrelor. High Risk ACS is defined as: 
1) final diagnosis is ST-elevation MI or non ST-elevation MI OR 
2) final diagnosis is Unstable angina, and either one of these [1] index ECG indicating 
ischaemia; [2] Killip class is greater than 1; [3] LV function grade determined (either 
mild, moderate or severe impairment); [4] Diabetes treated (2), (either insulin, oral 
hypoglycaemic med); [5] Serum creatinine is measured (value on admission is greater 
than upper limit of normal) [6] Recurrent ischaemia in admission [7] previous PCI < 
6mths before presentation &/or previous CABG  > 5 years before presentation
Data sources Hospital medical record
Methods of reporting Aggregated CONCORDANCE Registry data as a count and presented as a proportion.
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Performance Measure PROPORTION OF PATIENTS DISCHARGED ALIVE ON STATIN
Description of the measure Proportion of high risk patients discharged alive on Statin without a contraindication to 
the therapy. 
Clinical recommendation10 Class I Level of Evidence: A
Period of care Acute care for index event 
Numerator All high risk ACS enrolled in the CONCORDANCE Registry on either therapy
Denominator All high-risk patients alive at discharge and prescribed a Statin excluding those patients 
who refused therapy or a contraindicated was noted.
High Risk ACS is defined as;  
1) final diagnosis is ST-elevation MI or non ST-elevation MI
OR 
2) final diagnosis is Unstable angina, and either one of these: [1] index ECG indicating 
ischaemia; [2] Killip class is greater than 1; [3] LV function grade determined (either 
mild, moderate or severe impairment); [4] Diabetes treated (2), (either insulin, oral 
hypoglycaemic med); [5] Serum creatinine is measured (value on admission is greater 
than upper limit of normal); [6] Recurrent ischaemia in admission; [7] previous PCI < 
6mths before presentation &/or previous CABG  > 5 years before presentation
Data sources Hospital medical record
Methods of reporting Aggregated CONCORDANCE Registry data as a count and reported as a proportion 
Performance Measure Proportion of high risk patients discharged alive on ACE or ARB  
Description of the measure Proportion of high risk patients discharged alive on a ACE and/or ARB without a 
contraindication to the therapy. 
Clinical recommendation10 Class I Level of Evidence: A
Period of care Acute care for index event 
Numerator All high risk ACS enrolled in the CONCORDANCE Registry.
Denominator All high-risk patients on either therapy and alive at discharge and prescribed ACE or 
ARB excluding those patients with a contraindication noted.
High Risk ACS is defined as;  
1) final diagnosis is ST-elevation MI or non ST-elevation MI
OR 
2) final diagnosis is Unstable angina, and either one of these [1] index ECG indicating 
ischaemia; [2] Killip class is greater than 1; [3] LV function grade determined (either 
mild, moderate or severe impairment); [4] Diabetes treated (2), (either insulin, oral 
hypoglycaemic med); [5] Serum creatinine is measured (value on admission is greater 
than upper limit of normal); [6] Recurrent ischaemia in admission; [7] previous PCI < 
6mths before presentation &/or previous CABG  > 5 years before presentation
Data sources Hospital medical record
Methods of reporting Aggregated CONCORDANCE Registry data as a count and reported as a proportion 
Performance Measure PROPORTION OF PATIENTS DISCHARGED ALIVE AND REFERRED TO SECONDARY PREVENTION SERVICES
Description of the measure Proportion of patients discharged alive and referred to secondary prevention services 
and the referral is documented. Secondary prevention attendance can include face-to-
face sessions, exercise training or on-line education. 
Clinical recommendation10 STEMI: Class I, Level of Evidence: A
NSTEACS: Class I, Level of Evidence B
Period of care Acute care for index event
Numerator All ACS patients enrolled in the CONCORDANCE Registry 
Denominator All ACS patients alive at discharge and without a medical or patient related reason for 
non-referral. 
Data sources Hospital medical record
Methods of reporting Aggregated CONCORDANCE Registry data as a count and reported as a proportion 
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